Note: Descriptions are shown in the official language in which they were submitted.
TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY
10
FIELD OF THE INVENTION
This invention is in the area of improved compounds, compositions and methods
of
transiently protecting healthy cells, and in particular hematopoietic stem and
progenitor cells
(HSPC) as well as renal cells, from damage associated with DNA damaging
chemotherapeutic
agents. In one aspect, improved protection of healthy cells is disclosed using
disclosed
compounds that act as highly selective and short, transiently-acting cyclin-
dependent kinase 4/6
(CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging
chemotherapeutic regimens for the treatment of proliferative disorders.
BACKGROUND
Chemotherapy refers to the use of cytotoxic (typically DNA damaging) drugs to
treat a
range of proliferative disorders, including cancer, tumors, psoriasis,
arthritis, lupus and multiple
sclerosis, among others. Chemotherapeutic compounds tend to be non-specific
and, particularly
at high doses, toxic to normal, rapidly dividing cells. This often leads to a
variety of side effects
in patients undergoing chemotherapy.
Bone marrow suppression, a severe reduction of blood cell production in bone
marrow, is
one such side effect. It is characterized by both myelosuppression (anemia,
neutropenia,
agranulocytosis, and thrombocytopenia) and lymphopenia. Neutropenia is
characterized by a
1
Date Recue/Date Received 2021-06-02
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
selective decrease in the number of circulating neutrophils and an enhanced
susceptibility to
bacterial infections. Anemia, a reduction in the number of red blood cells or
erythrocytes, the
quantity of hemoglobin, or the volume of packed red blood cells (characterized
by a
determination of the hematocrit) affects approximately 67% of cancer patients
undergoing
chemotherapy in the United States. Sec BioWorld Today, page 4, Jul. 23,
2002.
Thrombocytopenia is a reduction in platelet number with increased
susceptibility to bleeding.
Lymphopenia is a common side-effect of chemotherapy characterized by a
reduction in the
number of circulating lymphocytes (also called T- and B-cells). Lymphopenic
patients are
predisposed to a number of types of infections.
Myelosuppression continues to represent the major dose-limiting toxicity of
cancer
chemotherapy, resulting in considerable morbidity along with the potential
need to require a
reduction in chemotherapy dose intensity, which may compromise disease control
and survival.
Considerable evidence from prospective and retrospective randomized clinical
trials clearly
shows that chemotherapy-induced myelosuppression compromises long-term disease
control and
survival (Lyman, G.H., Chemotherapy dose intensity and quality cancer care
(Oncology
(Williston Park), 2006. 20(14 Suppl 9): p. 16-25)). Furthermore, treatment
regimens for, for
example, lung, breast, and colorectal cancer recommended in the National
Comprehensive
Cancer Network guidelines are increasingly associated with significant
myelosuppression yet are
increasingly recommended for treating early-stage disease as well as advanced-
stage or
metastatic disease (Smith, R.E., Trends in recommendations for
myelosuppressive chemotherapy
for the treatment of solid tumors. J Natl Compr Cane Netw, 2006. 4(7): p. 649-
58). This trend
toward more intensive treatment of patients with cancer creates demand for
improved measures
to minimize the risk of myelosuppression and complications while optimizing
the relative dose-
intensity.
In addition to bone marrow suppression, chemotherapeutic agents can adversely
affect
other healthy cells such as renal epithelial cells, resulting potentially in
the development of acute
kidney injury due to the death of the tubular epithelia. Acute kidney injury
can lead to chronic
kidney disease, multi-organ failure, sepsis, and death.
One mechanism to minimize myelosuppression, nephrotoxicity, and other
chemotherapeutic cytotoxicities is to reduce the planned dose intensity of
chemotherapies. Dose
2
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
reductions or cycle delays, however, diminish the effectiveness and ultimately
compromise long-
term disease control and survival.
Small molecules have been used to reduce some of the side effects of certain
chemotherapeutic compounds. For example, lcukovorin has been used to mitigate
the effects of
methotrexate on bone marrow cells and on gastrointestinal mucosa cells.
Amifostine has been
used to reduce the incidence of neutropenia-related fever and mucositis in
patients receiving
alkylating or platinum-containing chemotherapeutics. Also, dexrazoxane has
been used to
provide cardioprotection from anthracycline anti-cancer compounds.
Unfortunately, there is
concern that many chemoprotectants, such as dexrazoxane and amifostine, can
decrease the
efficacy of chemotherapy given concomitantly.
Additional chemoprotectant therapies, particularly with chemotherapy
associated anemia
and neutropenia, include the use of growth factors. Hematopoietic growth
factors are available
on the market as recombinant proteins. These proteins include granulocyte
colony stimulating
factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF)
and their
derivatives for the treatment of neutropenia, and erythropoietin (EPO) and its
derivatives for the
treatment of anemia. However, these recombinant proteins are expensive.
Moreover, EPO has
significant toxicity in cancer patients, leading to increased thrombosis,
relapse and death in
several large randomized trials. G-CSF and GM-CSF may increase the late (>2
years post-
therapy) risk of secondary bone marrow disorders such as leukemia and
myelodysplasia.
Consequently, their use is restricted and not readily available any more to
all patients in need.
Further, while growth factors can hasten recovery of some blood cell lineages,
no therapy exists
to treat suppression of platelets, macrophages, T-cells or B-cells.
Roberts et al in 2012 reported that Pfizer compound PD-0332991 induced a
transient cell
cycle arrest in CDK4/6 dependent subsets of healthy cells such as HSPCs (see
Roberts et al.
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy.
JNCI
2012;104(6):476-487). This compound is currently being tested by Pfizer in
clinical trials as an
anti-neoplastic agent against estrogen-positive, HER2-negative breast cancer.
Hematopoietic stem cells give rise to progenitor cells which in turn give rise
to all the
differentiated components of blood as shown in Figure 1 (e.g., lymphocytes,
erythrocytes,
platelets, granulocytes, monocytes). HSPCs require the activity of CDK4/6 for
proliferation (see
Roberts et al. Multiple Roles of Cyelin-Dependent Kinase 4/6 Inhibitors in
Cancer Therapy.
3
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
JNCI 2012;104(6):476-487). In healthy kidneys, the renal epithelium
infrequently enters the cell
cycle (about 1% of epithelial cells). After a renal insult, however, a robust
increase in epithelial
proliferation occurs (see Humphreys, B.D. et al. Intrinsic epithelial cells
repair the kidney after
injury. Cell Stem Cell 2, 284-91 (2008)). Importantly, following renal injury,
surviving renal
epithelial cells replicate to repair damage to the kidney tubular epithelium
(sec Humphreys, B.D.
et al. Repair of injured proximal tubule does not involve specialized
progenitors. Proc Natl Acad
Sci U S A 108, 9226-31(2011)). See also WO 2010132725 filed by Sharpless et
al.
A number of CDK 4/6 inhibitors have been identified, including specific
pyrido[2,3-
d]pyrimidines, 2-anilinopyrimidines, diaryl ureas, benzoy1-2,4-
diaminothiazoles, indolo[6,7-
a]pyrrolo[3,4-c]carbazoles, and oxindoles (see P.S. Sharma, R. Sharma, R.
Tyagi, Curr. Cancer
Drug Targets 8 (2008) 53-75). WO 03/062236 identifies a series of 2-(pyridin-2-
ylamino-
pyrido[2,3]pyrimidin-7-ones for the treatment of Rb positive cancers that show
selectivity for
CDK4/6, including 6-acety1-8-cyclopenty1-5-methyl-2-(5-piperazin-1-yl-pyridin-
2-ylammino)-
8H-pyrido-[2,3-4pyrimidin-7-one (PD0332991). The clinical trial studies have
reported rates
of Grade 3/4 neutropenia and leukopenia with the use of PD0332991, resulting
in 71% of
patients requiring a dose interruption and 35% requiring a dose reduction; and
adverse events
leading to 10% of the discontinuations (see Finn, Abstract S1-6, SABCS 2012).
VanderWel et al. describe an iodine-containing pyrido[2,3-d]pyrimidine-7-one
(CKIA) as
a potent and selective CDK4 inhibitor (see VanderWel et al., J. Med. Chem. 48
(2005) 2371-
2387).
WO 99/15500 filed by Glaxo Group Ltd discloses protein kinase and
serine/threonine
kinase inhibitors.
WO 2010/020675 filed by Novartis AG describes pyrrolopyrimidine compounds as
CDK
inhibitors. WO 2011/101409 also filed by Novartis describes pyrrolopyrimidines
with CDK 4/6
inhibitory activity.
WO 2005/052147 filed by Novartis and WO 2006/074985 filed by Janssen Pharma
disclose addition CDK4 inhibitors.
US 2007/0179118 filed by Barvian et al. teaches the use of CDK4 inhibitors to
treat
inflammation.
4
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
WO 2012/061156 filed by Tavares and assigned to G1 Therapeutics describes CDK
inhibitors. WO 2013/148748 filed by Tavares and assigned to G1 Therapeutics
describes Lactam
Kinase inhibitors.
U.S. Patent Publication 2011/0224227 to Sharpless et al. describes the use of
certain
CDK4/6 inhibitors, such as F'D0332991 and 2BrIC (sec Zhu, et al., J. Med.
Chem., 46 (11) 2027-
2030 (2003); PCT/US2009/059281) to reduce or prevent the effects of cytotoxic
compounds on
HSPCs in a subject undergoing chemotherapeutic treatments. See also U.S.
Patent Publication
2012/0100100.
Stone, et at., Cancer Research 56, 3199-3202 (July 1,1996) describes
reversible, p16-
mediated cell cycle arrest as protection from chemotherapy.
Accordingly, it is an object of the present invention to provide new
compounds,
compositions and methods to treat patients during chemotherapy.
SUMMARY OF THE INVENTION
In one embodiment, improved compounds, methods, and compositions are provided
to
minimize the effect of chemotherapeutic agent toxicity on CDK4/6 replication
dependent healthy
cells, such as hematopoietic stem cells and hematopoietic progenitor cells
(together referred to as
HSPCs), and/or renal epithelial cells, in subjects, typically humans, that
will be, are being, or
have been exposed to the chemotherapeutic agent (typically a DNA-damaging
agent).
Specifically, the invention includes administering an effective amount of a
selected
compound of Formula I, II, III, IV, or V, as described herein, a
pharmaceutically acceptable
composition, salt, isotopic analog, or prodrug thereof, which provides an
optimal transient G1 -
arrest of healthy cells, for example HSPCs and/or renal epithelial cells, in a
subject during or
following the subject's exposure to a chemotherapeutic agent, such as a DNA-
damaging
chemotherapeutic agent:
5
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
R2
R11
R8
N
R6 N (R)y
0
Z-N
R
R2
X"( R11
R8
R6 N
N (R1)y
0
Z -N
R
R2
r ¨x
g\
R11
R8
N
R6 N (R)y
0
Z-N
R
R11 R8
R2
N \ (R1 )y 0
I\
R6 N
Z N
R w, or
6
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
R8
N \ (R1)Y 0
Rio
N
Z
R V.
In one non-limiting example, a compound can be selected from the compounds of
Table 1 below,
or a pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
non-limiting example, a compound can be selected from compounds T, Q, GG, U,
or AAAA,
described below, or a pharmaceutically acceptable composition, salt, isotopic
analog or prodrug
thereof.
The described compounds provide improved protection of CDK-replication
dependent
healthy cells during chemotherapeutic agent treatment due in part because they
(i) exhibit a
short, transient G1 -arresting effect and (ii) display a rapid, synchronous
reentry into the cell
cycle by the cells following the cessation of the chemotherapeutic damaging
effect. The use of
these CDK4/6 specific, short, transient Gl-arresting compounds as
chemoprotectants allows for,
for example, an accelerated cell lineage recovery, reduced cytotoxicity risk
due to replication
delay, and/or a minimization of chemotherapeutic agent induced cell death.
Despite reports using known CDK4/6 inhibitors such as 2BrIC and PD0332991 to
demonstrate chemoprotection, it has been discovered that these inhibitors may
not be the most
ideal compounds for use in pharmacological quiescence (PQ) strategies. For
example, the use of
2BrIC in vivo is limited by its restricted bioavailability, and despite the
relative selectivity for
CDK4/6 exhibited by PD0332991, the compound has a relatively long-acting intra-
cellular effect
(see Roberts et al. Multiple Roles of Cyclin-Dependent Kinasc 4/6 Inhibitors
in Cancer Therapy.
JCNI 2012;104(6):476-487 (Fig. 2A)), extending the transiency of G1 arrest
beyond what may
be necessary for sufficient protection from chemotherapeutic treatments. Such
a long acting
effect delays, for example, the proliferation of HSPC cell lineages necessary
to reconstitute the
hematological cell lines that are adversely affected by chemotherapeutic
agents or are cycled out
during their natural life-cycle. The long-acting G1 arrest provided by
PD0332991 may limit its
use as a potential chemoprotectant in subjects whose chemotherapeutic
treatment regimen
requires a rapid reentry into the cell cycle by HSPCs in order to reconstitute
the erythroid,
7
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
platelet, and myeloid cells (monocyte and granulocyte) adversely effected by
chemotherapeutic
agents or acute HSPC Gl-arrest in order to limit myelosuppressive or
hematologic toxicity
effects. Furthermore, PD0332991 may be limited in its use as a chemoprotectant
in subjects
exposed to chemotherapeutic agents at regular and repeated intervals, for
example, on regimens
.. that are repeated every several days, as it may limit the ability of these
subjects' HSPCs to
reenter the cell-cycle quickly before it would be necessary to arrest them
again prior to the
subject's next chemotherapeutic cycle. With respect to other affected tissues,
for example renal
cells, the timely resumption of proliferation is critical to tissue repair,
for example renal tubular
epithelium repair, due to nephrotoxic agents, and therefore, an overly long
period of PQ is
.. undesirable.
Thus in an alternative embodiment, the invention includes administering a
compound
described herein in an effective amount to a host in need thereof, such
compound displaying one
or any combination of the following factors which provide an improved
therapeutic effect (either
alone or in any combination thereof, each of which is considered specifically
and independently
described): i) wherein a substantial portion of the CDK4/6-replication
dependent healthy cells
(e.g. at least 80% or greater) return to or approach pre-treatment baseline
cell cycle activity (i.e.,
reenter the cell-cycle) in less than 24 hours, 30 hours or 36 hours from the
last administration of
the active compound in humans or for example, using a protocol described in
the Examples
below; ii) wherein a substantial portion of the healthy cells reenter the cell-
cycle synchronously
.. in less than 24 hours, 30 hours or 36 hours from the last administration of
the active compound;
(iii) wherein the dissipation of the active compound's CDK4/6 inhibitory
effect occurs in less
than 24 hours, 30 hours, or 36 hours from the administration of the inhibitor;
(iv) wherein the
active compound has an IC50 for CDK4 and/or CDK6 inhibition that is more than
1500 times
less than its IC50 concentration for CDK2 inhibition; (v) wherein a
substantial portion of the
.. healthy cells return to or approach pre-treatment baseline cell cycle
activity (i.e., reenter the cell-
cycle) in less than 24 hours, 30 hours, or 36 hours from the dissipation of
the active compound's
CDK4/6 inhibitory effect; (vi) wherein the pre-treatment baseline cell cycle
activity (i.e. reenter
the cell-cycle) within less than about 24 hours, about 30 hours, or about 36
hours from the point
in which the CDK4/6 inhibitor's concentration level in the subject's blood
drops below a
.. therapeutic effective concentration; or (vii) wherein a substantial portion
of the healthy cells
8
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
reenter the cell-cycle synchronously in less than 24 hours, 30 hours, or 36
hours from the last
administration of the chemotherapeutic agent.
The compounds described herein can be administered to the subject prior to
treatment
with a chemotherapeutic agent, during treatment with a chemotherapeutic agent,
after exposure
to a chemotherapeutic agent, or a combination thereof. The compound described
herein is
typically administered in a manner that allows the drug facile access to the
blood stream, for
example via intravenous injection or sublingual, intraaortal, or other
efficient blood-stream
accessing route; however, oral, topical, transdermal, intranasal,
intramuscular, or by inhalation
such as by a solution, suspension, or emulsion, or other desired
administrative routes can be
used. In one embodiment, the compound is administered to the subject less than
about 24 hours,
hours, 16 hours, 12 hours, 8 hours, or 4 hours, 2.5 hours, 2 hours, 1 hour,
1/2 hour or less prior
to treatment with the chemotherapeutic agent. Typically, the active compound
described herein
is administered to the subject prior to treatment with the chemotherapeutic
agent such that the
compound reaches peak serum levels before or during treatment with the
chemotherapeutic
15 agent. In one embodiment, the active compound is administered
concomitantly, or closely
thereto, with the chemotherapeutic agent exposure. If desired, the active
compound can be
administered multiple times during the chemotherapeutic agent treatment to
maximize inhibition,
especially when the chemotherapeutic drug is administered over a long period
or has a long half-
life. The active compound described herein can be administered following
exposure to the
20 chemotherapeutic agent if desired to mitigate healthy cell damage
associated with
chemotherapeutic agent exposure. In certain embodiments, the active compound
is administered
up to about 1/2 hour, up to about 1 hour, up to about 2 hours, up to about 4
hours, up to about 8
hours, up to about 10 hours, up to about 12 hours, up to about 14 hours, up to
about 16 hours, or
up to about 20 hours or greater following the chemotherapeutic agent exposure.
In a particular
embodiment, the active compound is administered up to between about 12 hours
and 20 hours
following exposure to the chemotherapeutic agent.
The CDK4/6 inhibitors described herein show a marked selectivity for the
inhibition of
CDK4 and/or CDK6 in comparison to other CKD, for example CDK2. For example,
CDK4/6
inhibitors described in the present invention provide for a dose-dependent Gl-
arresting effect on
a subject's CDK4/6-replication dependent healthy cells, for example HSPCs or
renal epithelial
cells, and the methods provided for herein are sufficient to afford
chemoprotection to targeted
9
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CDk4/6-replication dependent healthy cells during chemotherapeutic agent
exposure, for
example, during the time period that a DNA-damaging chemotherapeutic agent is
capable of
DNA-damaging effects on CDK4/6-replication dependent healthy cells in the
subject, while
allowing for the synchronous and rapid reentry into the cell-cycle by these
cells shortly after the
chemotherapeutic agent dissipates due to the time-limited CDK4/6 inhibitory
effect provided by
the compounds described herein compared to, for example, PD0332991. Likewise,
CDK4/6
inhibitors useful in the present invention provide for a dose-dependent
mitigating effect on
CDK4/6-replication dependent healthy cells that have been exposed to toxic
levels of
chemotherapeutic agents, for example an accidental overdose, allowing for
repair of DNA
damage associated with chemotherapeutic agent exposure and synchronous, rapid
reentry into
the cell-cycle following dissipation of the CDK4/6 inhibitory effect compared
to, for example,
PD0332991. In one embodiment, the use of a CDK4/6 inhibitor described herein
results in the
Gl-arresting effect on the subject's CDK4/6-replication dependent healthy
cells dissipating
following administration of the CDK4/6 inhibitor so that the subject's healthy
cells return to or
approach their pre-administration baseline cell-cycle activity within less
than about 24 hours, 30
hours, 36 hours, or 40 hours, of administration. In one embodiment, the Gl-
arresting effect
dissipates such that the subject's CDK4/6-replication dependent healthy cells
return to their pre-
administration baseline cell-cycle activity within less than about 24 hours,
30 hours, 36 hours, or
40 hours.
In one embodiment, the use of a CDK4/6 inhibitor described herein results in
the Gl-
arresting effect dissipating such that the subject's CDk4/6-dependent healthy
cells return to or
approach their pre-administration baseline cell-cycle activity within less
than about 24 hours, 30
hours, 36 hours, or 40 hours of the chemotherapeutic agent effect. In one
embodiment, the Gl-
arresting effect dissipates such that the subject's CDK4/6-replication
dependent cells return to
their pre-administration baseline cell-cycle activity within less than about
24 hours, 30 hours, 36
hours, or 40 hours, or within about 48 hours of the cessation of the
chemotherapeutic agent
administration. In one embodiment, the CDK4/6-replication dependent healthy
cells are HSPCs.
In one embodiment, the CDK4/6-dependent healthy cells are renal epithelial
cells.
In one embodiment, the use of a CDK4/6 inhibitor described herein results in
the Gl-
arresting effect dissipating so that the subject's CDK4/6-replication
dependent healthy cells
return to or approach their pre-administration baseline cell-cycle activity
within less than about
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
24 hours, 30 hours, 36 hours, 40 hours, or within less than about 48 hours
from the point in
which the CDK4/6 inhibitor's concentration level in the subject's blood drops
below a
therapeutic effective concentration.
In one embodiment, the CDK4/6 inhibitors described herein are used to protect
renal
epithelium cells during exposure to a chemotherapeutic agent, for example, a
DNA damaging
chemotherapeutic agent, wherein the renal epithelial cells are transiently
prevented from entering
S-phase in response to chemotherapeutic agent induced renal tubular epithelium
damage for no
more than about 24 hours, about 30 hours, about 36 hours, about 40 hours, or
about 48 hours
from the point in which the CDK4/6 inhibitor's concentration level in the
subject's blood drops
below a therapeutic effective concentration, from the cessation of the
chemotherapeutic agent
effect, or from administration of the CDK4/6 administration.
CDK4/6 inhibitors useful in the described methods may be synchronous in their
off-
effect, that is, upon dissipation of the G1 arresting effect, CDK4/6-
replication dependent healthy
cells exposed to a CDK4/6 inhibitor described herein reenter the cell-cycle in
a similarly timed
fashion. CDK4/6-replication dependent healthy cells that reenter the cell-
cycle do so such that
the normal proportion of cells in G1 and S are reestablished quickly and
efficiently, within less
than about 24 hours, 30 hours, 36 hours, 40 hours, or within about 48 hours of
the from the point
in which the CDK4/6 inhibitor's concentration level in the subject's blood
drops below a
therapeutic effective concentration.
This advantageously allows for a larger number of healthy cells to begin
replicating upon
dissipation of the G1 arrest compared with asynchronous CDK4/6 inhibitors such
as PD0332991.
In addition, synchronous cell-cycle reentry following G1 arrest using a CDK4/6
inhibitor
described herein provides for the ability to time the administration of
hematopoietic growth
factors to assist in the reconstitution of hematopoietic cell lines to
maximize the growth factor
effect. As such, in one embodiment, the use of the compounds or methods
described herein is
combined with the use of hematopoietic growth factors including, but not
limited to, granulocyte
colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating
factor (GM-
CSF), thrombopoietin, interleukin (IL)-12, steel factor, and erythropoietin
(EPO), or their
derivatives. In one embodiment, the CDK4/6 inhibitor is administered prior to
administration of
the hematopoietic growth factor. In one embodiment, the hematopoietic growth
factor
administration is timed so that the CDK4/6 inhibitor's effect on HSPCs has
dissipated.
11
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In one aspect, the use of a CDK4/6-inhibitor described herein allows for a
chemo-
protective regimen for use during standard chemotherapeutic dosing schedules
or regimens
common in many anti-cancer treatments. For example, the CDK4/6-inhibitor can
be
administered so that CDK4/6-replication dependent healthy cells arc GI
arrested during
chemotherapeutic agent exposure wherein, due to the rapid dissipation of the
G1 -arresting effect
of the compounds, a significant number of healthy cells reenter the cell-cycle
and are capable of
replicating shortly after chemotherapeutic agent exposure, for example, within
less than about
24, 30, 40, or 48 hours, and continue to replicate until administration of the
CDK4/6-inhibitor in
anticipation of the next chemotherapeutic treatment. In one embodiment, the
CDK4/6-inhibitor
is administered to allow for the cycling of the CDK4/6-replication dependent
healthy cells
between Gl-arrest and reentry into the cell-cycle to accommodate a repeated-
dosing
chemotherapeutic treatment regimen, for example including but not limited to a
treatment
regimen wherein the chemotherapeutic agent is administered: on day 1-3 every
21 days; on days
1-3 every 28 days; on day 1 every 3 weeks; on day 1, day 8, and day 15 every
28 days, on day 1
and day 8 every 28 days; on days 1 and 8 every 21 days; on days 1-5 every 21
days; 1 day a
week for 6-8 weeks; on days 1, 22, and 43; days 1 and 2 weekly; days 1-4 and
22-25; 1-4; 22-25,
and 43-46; and similar type-regimens, wherein the CDK4/6-replication dependent
cells are 61
arrested during chemotherapeutic agent exposure and a significant portion of
the cells reenter the
cell-cycle between chemotherapeutic agent exposure. In one embodiment, the
CDK4/6-inhibitor
.. can be administered so that the subject's CDK4/6-replication dependent
cells are Gl-arrested
during daily chemotherapeutic agent exposure, for example a contiguous multi-
day
chemotherapeutic regimen, but a significant portion of CDK4/6-replication
dependent cells
reenter the cell-cycle and replicate between daily treatment. In one
embodiment, the CDK4/6-
inhibitors can be administered so that the subject's CDK4/6-replication
dependent cells are G1 -
arrested during chemotherapeutic agent exposure, for example a contiguous
multi-day regimen,
but a significant portion of healthy cells reenter the cell-cycle and
replicate during the off periods
before the next chemotherapeutic agent exposure. In one embodiment, the CDK4/6
inhibitor is
administered so that a subject's CDK4/6-replication dependent cells' 61-arrest
is provided
during a daily chemotherapeutic agent treatment regimen, for example, a
contiguous multi-day
treatment regimen, and the arrested cells are capable of reentering the cell-
cycle shortly after the
multi-day regimen ends. In one embodiment, the cancer is small cell lung
cancer and the
12
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CDK4/6 inhibitor is administered on days 1, 2, and 3 during a 21-day treatment
cycle wherein
the administered DNA damaging agent is selected from the group consisting of
carboplatin,
cisplatin, and etoposide, or a combination thereof.
The subject treated according to the present invention may be undergoing
therapeutic
chemotherapy for the treatment of a proliferative disorder or disease such as
cancer. The cancer
can be characterized by one or a combination of increased activity of cyclin-
dependent kinase 1
(CDK1), increased activity of cyclin-dependent kinase 2 (CDK2), loss,
deficiency, or absence of
retinoblastoma tumor suppressor protein (Rb)(Rb-null), high levels of MYC
expression,
increased cyclin El, E2, and increased cyclin A. The cancer may be
characterized by reduced
expression of the retinoblastoma tumor suppressor protein or a retinoblastoma
family member
protein or proteins (such as, but not limited to p107 and p130). In one
embodiment, the subject
is undergoing chemotherapeutic treatment for the treatment of an Rb-null or Rb-
deficient cancer,
including but not limited to small cell lung cancer, triple-negative breast
cancer, HPV-positive
head and neck cancer, retinoblastoma, Rb-negative bladder cancer, Rb negative
prostate cancer,
osteo sarcoma, or cervical cancer. In one embodiment, the cancer is a CDK4/6-
independent
cancer. Administration of the inhibitor compound may allow for a higher dose
of a
chemotherapeutic agent to be used to treat the disease than the standard dose
that would be safely
used in the absence of administration of the CDK4/6 inhibitor compound.
The host or subject, including a human, may be undergoing chemotherapeutic
treatment
of a non-malignant proliferative disorder, or other abnormal cellular
proliferation, such as a
tumor, multiple sclerosis, lupus, or arthritis.
The protected HSPCs include hematopoietic stem cells, such as long term
hematopoietic
stem cells (LT-HSCs) and short term hematopoietic stem cells (ST-HSCs), and
hematopoietic
progenitor cells, including multipotent progenitors (MPPs), common myeloid
progenitors
(CMPs), common lymphoid progenitors (CLPs), granulocyte-monocyte progenitors
(GMPs) and
megakaryocyte-erythroid progenitors (MEPs). Administration of the inhibitor
compound
provides temporary, transient pharmacologic quiescence of hematopoietic stem
and/or
hematopoietic progenitor cells in the subject.
Administration of a CDK4/6 inhibitor as described herein can result in reduced
anemia,
reduced lymphopenia, reduced thrombocytopenia, or reduced neutropenia compared
to that
typically expected after, common after, or associated with treatment with
chemotherapeutic
13
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
agents in the absence of administration of the CDK4/6 inhibitor. The use of
the CDK4/6
inhibitor as described herein results in a faster recovery from bone marrow
suppression
associated with long-term use of CDK4/6 inhibitors, such as myelosuppression,
anemia,
lymphopenia, thrombocytopenia, or neutropenia, following the cessation of use
of the CDK4/6
inhibitor. In some embodiments, the use of a CDK4/6 inhibitor as described
herein results in
reduced or limited bone marrow suppression associated with long-term use of
CDK4/6
inhibitors, such as myelosuppression, anemia, lymphopenia, thrombocytopenia,
or neutropenia.
In an alternative aspect, a CDK4/6 inhibitor described herein can be used for
its anti-
cancer, anti-tumor, or anti-proliferative effect in combination with a
chemotherapeutic agent to
treat an Rb-negative cancer or other Rb-negative abnormal proliferation. In
one embodiment,
the CDK4/6 inhibitor described herein provides an additive effect to or
synergistic effect with the
anti-cancer or anti-proliferative activity of the chemotherapeutic.
Chemotherapeutics that can be
combined with the CDK4/6 inhibitors described herein are any chemotherapeutics
effective or
useful to treat RB-null cancers or abnormal cellular proliferation. In one
particular embodiment,
the use of a compound described herein is combined in a therapeutic regime
with at least one
other chemotherapeutic agent, and can be one that does not rely on
proliferation or advancement
through the cell-cycle for anti-proliferative activity. Such agent may
include, but is not limited
to, tamoxifen, midazolam, letrozole, bortezomib, anastrozole, goserelin, an
mTOR inhibitor, a
PI3 kinase inhibitors, dual mTOR-PI3K inhibitors, MEK inhibitors, RAS
inhibitors, ALK
inhibitors, HSP inhibitors (for example, HSP70 and HSP 90 inhibitors, or a
combination
thereof), BCL-2 inhibitors, apopototic inducing compounds, AKT inhibitors, PD-
1 inhibitors, or
FLT-3 inhibitors, or combinations thereof Examples of mTOR inhibitors include
but are not
limited to rapamycin and its analogs, everolimus (Afinitor), temsirolimus,
ridaforolimus,
sirolimus, and deforolimus. Examples of P13 kinase inhibitors include but are
not limited to
Wortmannin, demethoxyviridin, perifosine, idelalisib, PX-866, IPI-145
(Infinity), BAY 80-6946,
BEZ235, RP6503, TGR 1202 (RP5264), MLN1117 (INK1117), Pictilisib, Buparlisib,
SAR245408 (XL147), SAR245409 (XL765), Palomid 529, ZSTK474, PWT33597, RP6530,
CUDC-907, and AEZS-136.. Examples of MEK inhibitors include but are not
limited to
Tametinib, Selumetinib, MEK162, GDC-0973 (XL518), and PD0325901. Examples of
RAS
inhibitors include but are not limited to Reolysin and siG12D LODER. Examples
of ALK
inhibitors include but are not limited to Crizotinib, AP26113, and LDK378. HSP
inhibitors
14
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
include but are not limited to Geldanamycin or 17-N-Allylamino-17-
demethoxygeldanamycin
(17AAG), and Radicicol. The CDK4/6 inhibitor combined with the
chemotherapeutic is selected
from the group consisting of a compound or composition comprising Formula I,
Formula II,
Formula III, Formula IV, or Formula V described above, or a pharmaceutically
acceptable
composition, salt, isotopic analog or prodrug thereof. In one embodiment, the
compound is
selected from the compounds provided for in Table 1, or a pharmaceutically
acceptable
composition, salt, isotopic analog or prodrug thereof In one embodiment, the
compound is
selected from compounds T, Q, GG, U, or AAAA, or a pharmaceutically acceptable
composition, salt, isotopic analog or prodrug thereof
In certain embodiments, a compound described herein is administered to the
subject prior
to treatment with another chemotherapeutic agent, during treatment with
another
chemotherapeutic agent, after administration of another chemotherapeutic
agent, or a
combination thereof In one embodiment, the CDK4/6 inhibitor is selected from a
compound
described in Table 1. In one embodiment, the compound is selected from
compounds T, Q, GG,
U, or AAAA.
In some embodiments, the subject or host is a mammal, including a human.
In summary, the present invention includes the following features:
A. Compounds of Formula I, II, III, IV, and V as described herein, and
pharmaceutically acceptable compositions, salts, isotopic analogs, or prodrugs
thereof, for use in
the chemoprotection of CDK4/6-replication dependent healthy cells, for example
HSPCs and/or
renal epithelial cells, during a chemotherapeutic agent exposure. In one
embodiment, the
compound is selected from the compounds described in Table 1 or a
pharmaceutically acceptable
composition, salt, isotopic analog or prodrug thereof. In one embodiment, the
compound is
selected from compounds T, Q, GG, U, or AAAA, or a pharmaceutically acceptable
composition, salt, isotopic analog or prodrug thereof
B. Compounds of Formula I, II, III, IV, and V as described herein, and
pharmaceutically acceptable compositions, salts, isotopic analogs, and
prodrugs thereof, for use
in the chemoprotection of CDK4/6-replication dependent healthy cells, for
example HSPCs
and/or renal epithelial cells, during a chemotherapeutic regimen for the
treatment of a
proliferative disorder. In one embodiment, the compound is selected from the
compounds
described in Table 1 or a pharmaceutically acceptable composition, salt,
isotopic analog or
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
prodrug thereof. In one embodiment, the compound is selected from compounds T,
Q, GG, U, or
AAAA, or a pharmaceutically acceptable composition, salt, isotopic analog or
prodrug thereof
C. Compounds of Formula I, II, III, IV, and V as described herein, and
pharmaceutically acceptable compositions, salts, isotopic analogs, and
prodrugs thereof, for use
in the chemoprotection of CDK4/6-replication dependent healthy cells, for
example HSPCs
and/or renal epithelial cells, during a chemotherapeutic regimen for the
treatment of a cancer. In
one embodiment, the compound is selected from the compounds described in Table
1, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
embodiment, the compound is selected from compounds T, Q, GG, U, or AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof;
D. Compounds of Formula I, II, III, IV, and V as described herein, and
pharmaceutically acceptable compositions, salts, isotopic analogs, and
prodrugs thereof, for use
in combination with hematopoietic growth factors in a subject that will be, is
being, or has been
exposed to chemotherapeutic agents. In one embodiment, the compound is
selected from the
compounds described in Table 1 or a pharmaceutically acceptable composition,
salt, isotopic
analog or prodrug thereof. In one embodiment, the compound is selected from
compounds T, Q,
GG, U, or AAAA, or a pharmaceutically acceptable composition, salt, isotopic
analog or prodrug
thereof;
E. Use of compounds of Formula I, II, III, IV, and V as described herein, and
pharmaceutically acceptable compositions, salts, isotopic analogs, and
prodrugs thereof, in the
manufacture of a medicament for use in the chemoprotection of CDK4/6-
replication dependent
healthy cells, for example HSPCs and/or renal epithelial cells. In one
embodiment, the
compound is selected from the compounds described in Table 1 or a
pharmaceutically acceptable
composition, salt, isotopic analog or prodrug thereof. In one embodiment, the
compound is
selected from compounds T, Q, GG, U, or AAAA, or a pharmaceutically acceptable
composition, salt, isotopic analog or prodrug thereof
F. Use of compounds of Formula I, II, 111, IV, and V as described herein,
and
pharmaceutically acceptable compositions, salts, isotopic analogs, and
prodrugs thereof, in the
manufacture of a medicament for use in the mitigation of DNA damage of CDK4/6-
replication
dependent healthy cells, for example HSPCs and/or renal epithelial cells, that
have been exposed
to chemotherapeutic agent exposure. In one embodiment, the compound is
selected from the
16
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
compounds described in Table 1 or a pharmaceutically acceptable composition,
salt, isotopic
analog or prodrug thereof. In one embodiment, the compound is selected from
compounds T, Q,
GG, U, or AAAA, or a pharmaceutically acceptable composition, salt, isotopic
analog or prodrug
thereof;
G. A
pharmaceutical formulation comprising an effective subject-treating amount of
compounds of Formula I, II, III, IV, and V as described herein, or
pharmaceutically acceptable
compositions, salts, and prodrugs thereof for use in chemoprotection of
healthy cells. In one
embodiment, the compound is selected from the compounds described in Table 1
or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
embodiment, the compound is selected from compounds T, Q, GG, U, or AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof;
H. A processes for the preparation of therapeutic products that contain an
effective
amount of compounds of Formula I, IT, III, IV, and V as described herein. In
one embodiment,
the compound is selected from the compounds described in Table 1 or a
pharmaceutically
acceptable composition, salt, isotopic analog or prodrug thereof. In one
embodiment, the
compound is selected from compounds T, Q, GG, U, or AAAA, or a
pharmaceutically
acceptable composition, salt, isotopic analog or prodrug thereof;
I. A method for manufacturing a medicament of Formula 1, II, III, IV, and V
intended for therapeutic use in the chemoprotection of CDK4/6-replication
dependent healthy
cells, for example HSPCs and/or renal epithelial cells. In one embodiment, the
medicament is
selected from the compounds described in Table 1 or a pharmaceutically
acceptable composition,
salt, isotopic analog or prodrug thereof. In one embodiment, the medicament is
selected from
compounds T, Q, GG, U, or AAAA, or a pharmaceutically acceptable composition,
salt, isotopic
analog or prodrug thereof;
J. A method
for manufacturing a medicament of Formula I, II, III, IV, and V
intended for therapeutic use in the mitigation of DNA damage of CDK4/6-
replication dependent
healthy cells, for example HSPCs and/or renal epithelial cells, that have been
exposed to
chemotherapeutic agents. In one embodiment, the medicament is selected from
the compounds
described in Table 1 or a pharmaceutically acceptable composition, salt,
isotopic analog or
prodrug thereof. In one embodiment, the medicament is selected from Compounds
T, Q, GG, U,
17
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
or AAAA, or a pharmaceutically acceptable composition, salt, isotopic analog
or prodrug
thereof;
K.
A method of inhibiting the growth of an Rb-negative cancer or proliferative
condition by administering a compound of Formula I, II, III, IV, or V, or
pharmaceutically
acceptable composition, salt, isotopic analog or prodrug thereof; in
combination with a
chemotherapeutic to provide an additive to or synergistic effect with a
chemotherapeutic. In one
embodiment, the compound is selected from the compounds described in Table 1
or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
embodiment, the compound is selected from Compounds T, Q, GG, U, or AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
embodiment, the CDK4/6 inhibitors are combined with a chemotherapeutic
selected from the
group consisting of MEK inhibitors, PI3 kinase delta inhibitors, BCL-2
inhibitors, AKT
inhibitors, apoptotic inducing compounds, AKT inhibitors, PD-1 inhibitors, FLT-
3 inhibitors,
HSP90 inhibitors, or mTOR inhibitors, or combinations thereof
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic drawing of hematopoiesis showing the hierarchical
proliferation of
healthy hematopoietic stem cells (HSC) and healthy hematopoietic progenitor
cells with
increasing differentiation upon proliferation.
FIG. 2A is a graph of the percentage of cells in G2-M phase (open circles), S
phase
(triangles), GO-GI phase (squares), <2N (diamonds) vs. variable concentration
(nM) of
Compound T in tHS68 cells. The Cdk4/6-dependent cell line (tHS68) was treated
with the
indicated concentrations of Compound T for 24 hours. Following treatment of
Compound T,
cells were harvested and analyzed for cell cycle distribution. As described in
Example 152,
tHS68 cells show a clean GI arrest accompanied by a corresponding decrease in
the number of
cells in S-phase. FIG. 2B is a graph of the number of tHS68 cells (CDK4/6-
dependent cell line)
vs. the DNA content of the cells (as measured by propidium iodide). Cells were
treated with
DMSO for 24 hours, harvested, and analyzed for cell cycle distribution. FIG.
2C is a graph of
the number of WM2664 cells (CDK4/6-dependent cell line) vs. the DNA content of
the cells (as
measured by propidium iodide). Cells were treated with DMSO for 24 hours,
harvested, and
analyzed for cell cycle distribution. FIG. 2D is a graph of the number of
A2058 cells (CDK4/6-
18
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
independent cell line) vs. the DNA content of the cells (as measured by
propidium iodide). Cells
were treated with DMSO for 24 hours, harvested, and analyzed for cell cycle
distribution. FIG.
2E is a graph of the number of tHS68 cells (CDK4/6-dependent cell line) vs.
the DNA content of
the cells (as measured by propidium iodide) after treatment with Compound T.
Cells were
treated with Compound T (300 nA/1) for 24 hours, harvested, and analyzed for
cell cycle
distribution. As described in Example 152, treatment of tHS68 cells with
Compound T causes a
loss of the S-phase peak (indicated by arrow). FIG. 2F is a graph of the
number of WM2664 cells
(CDK4/6-dependent cell line) vs. the DNA content of the cells (as measured by
propidium
iodide) after treatment with Compound T. Cells were treated with Compound T
(300 nM) for 24
hours, harvested, and analyzed for cell cycle distribution. As described in
Example 152,
treatment of WM2664 cells with Compound T causes a loss of the S-phase peak
(indicated by
arrow). FIG. 2G is a graph of the number of A2058 cells (CDK4/6-independent
cell line) vs. the
DNA content of the cells (as measured by propidium iodide) after treatment
with Compound T.
Cells were treated with Compound T (300 nM) for 24 hours, harvested, and
analyzed for cell
cycle distribution. As described in Example 152, treatment of A2058 cells with
Compound T
does not cause a loss of the S-phase peak (indicated by arrow).
FIG. 3 is a Western blot showing the phosphorylation levels of Rb at
Ser807/811 and
Ser780 after treatment with Compound T. Cdk4/6-dependent (tHS68 or WM2664) and
Cdk4/6-
independent cell lines (A2058) were treated with Compound T (300 nM) for the
indicated times
(0, 4, 8, 16, and 24 hours). MAPK levels are shown as a control for protein
levels. Following
treatment, cells were harvested and analyzed for Rb-phosphorylation by western
blot analysis.
As described in Example 153, Compound T treatment resulted in reduced Rb-
phosphorylation
after treatment in Cdk4/6-dependent cell lines (tHS68 and WM2664), but not in
the Cdk4/6-
independent cell line (A2058).
FIG. 4A is a graph of the percentage of cells in S phase in an Rb-positive
cell line
(W11V12664) or in the Rb-negative small cell lung cancer cell lines (H345,
H69, H209, SHP-77,
NC1417, or H82) after treatment with DMSO (dark bars) or F'D0332991 (light
bars). Cells were
treated with PD0332991 (300 nM) or DMSO control for 24 hours. Cell
proliferation was
measured by EdU incorporation and flow cytometry. Data represents 100,000 cell
events for
each cell treatment. As described in Example 154, the RB-null SCLC cell line
was resistant to
19
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Cdk4/6 inhibition, as no changes in the percent of cells in S-phase were seen
upon treatment with
PD0332991.
FIG. 4B is a graph of the percentage of cells in S phase in an Rb-positive
cell line
(tHS68) or in the Rb-negative small cell lung cancer cell lines (H345, H69,
SHP-77, or H82)
after treatment with DMSO (dark bars) or Compound GG (lighter bars). Cells
were treated with
Compound GG (300 nM or 1000 nM) or DMSO control for 24 hours. Cell
proliferation was
measured by EdU incorporation and flow cytometry. Data represents 100,000 cell
events for
each cell treatment. As described in Example 154, the RB-null SCLC cell line
was resistant to
Cdk4/6 inhibition, as no changes in the percent of cells in S-phase were seen
upon treatment with
Compound GG.
FIG. 4C is a graph of the percentage of cells in S phase in an Rb-positive
cell line
(tHS68) or in the Rb-negative small cell lung cancer cell lines (H345, H209,
or SHP-77) after
treatment with DMSO (dark bars) or Compound T (lighter bars). Cells were
treated with
Compound T (300 nM or 1000 nM) or DMSO control for 24 hours. Cell
proliferation was
measured by EdU incorporation and flow cytometry. Data represents 100,000 cell
events for
each cell treatment. As described in Example 154, the RB-null SCLC cell line
was resistant to
Cdk4/6 inhibition, as no change in the percent of cells in S-phase were seen
upon treatment with
Compound T.
FIG. 5 is a graph of EdU incorporation vs. time after administration (hours)
of
PD0332991 to healthy mice HSPCs and healthy myeloid progenitor cells.
PD0332991
(150mg/kg) was administered by oral gavage to assess the temporal effect of
transient CDK4/6
inhibition on bone marrow arrest as reported in Roberts et al. Multiple Roles
of Cyclin-
Dependent Kinase 4/6 Inhibitors in Cancer Therapy. JCNI 2012;104(6):476-487
(FIG. 2A). As
described in Example 156, a single oral dose of PD0332991 results in a
sustained reduction in
HSPC EdU incorporation (circles; LKS+) and myeloid progenitor cells EdU
incorporation
(squares; LKS-) for greater than 36 hours.
FIG. 6A is a graph of the ratio of EdU incorporation into HSPCs (compared to
untreated
control mice) following oral gavage of Compounds T, Q, or GG at 150 mg/kg at
either 12 or 24
hours post administration. FIG. 6B is a graph of the percentage of EdU
positive HSPC cells for
mice treated with Compound T at either 12 or 24 hours. Mice were dosed with 50
mg/kg
(triangles), 100 mg/kg (squares), or 150 (upside down triangles) mg/kg by oral
gavage. FIG. 6C
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
is a graph of the percentage of EdU positive HSPC cells for mice treated with
compound T (150
mg/kg by oral gavage) at either 12, 24, 36 and 48 hours. As described in
Example 157,
Compound T and GG demonstrated a reduction in EdU incorporation at 12 hours,
and started to
return to normal levels of cell division by 24 hours.
FIG. 7 is a graph of the percentage of EdU positive HSPC cells for mice
treated with
either PD0332991 (triangles) or Compound T (upside down triangles) v. time
after
administration (hours) of the compound. Both compounds were administered at
150 mg/kg by
oral gavage and the percentage of EdU positive HSPC cells was measured at 12,
24, 36 or 48
hours. As described in Example 158, a single oral dose of PD0332991 results in
a sustained
reduction of HSPC proliferation for greater than 36 hours. In contrast, a
single oral dose of
Compound T results in an initial reduction of HSPC proliferation at 12 hours,
but proliferation of
HSPCs resumes by 24 hours after dosage of Compound T.
FIG. 8A is a graph of the percentage of cells in the GO-G1 phase of the cell
cycle vs. time
after washout of the compound (hours) in human fibroblast (Rb-positive) cells.
FIG. 8B is a
graph of the percentage of cells in the S phase of the cell cycle vs. time
after washout of the
compound (hours) in human fibroblast (Rb-positive) cells. FIG. 8C is a graph
of the percentage
of cells in the GO-G1 phase of the cell cycle vs. time after washout of the
compound (hours) in
human renal proximal tubule epithelial (Rb-positive) cells. FIG. 8D is a graph
of the percentage
of cells in the S phase of the cell cycle vs. time after washout of the
compound (hours) in human
renal proximal tubule epithelial (Rb-positive) cells. These cellular wash out
experiments
demonstrated that the inhibitor compounds of the present invention have a
short, transient G1 -
arresting effect in different cell types. The effect on the cell cycle
following washing out of the
compounds was determined at 24, 36, 40, and 48 hours. As described in Example
159, the
results show that cells treated with PD0332991 (circles) took significantly
longer to reach
baseline levels of cell division (see cells treated only with DMSO
(diamonds)), than cells treated
with Compound T (squares), Compound Q (triangles), Compound GG (X), or
Compound U (X
with cross).
FIG. 9A is a graph of plasma drug concentration (ng/ml) vs. time after
administration
(hours) of Compound T. FIG. 9B is a graph of plasma drug concentration (ng/ml)
vs. time after
administration (hours) of Compound Q. FIG. 9C is a graph of plasma drug
concentration
(ng/ml) vs. time after administration (hours) of compound GG. FIG. 9D is a
graph of plasma
21
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
drug concentration (ng/ml) vs. time after administration (hours) of Compound
U. Compounds
were dosed to mice at 30 mg/kg by oral gavage (diamonds) or 10 mg/kg by
intravenous injection
(squares). Blood samples were taken at 0, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0
hours post dosing and
the plasma concentrations were determined by HPLC.
FIG. 10 provides the half-life (minutes) of Compound T and PD0332991 in human
and
animal (monkey, dog, rat, and mouse) liver microsomes. As described in Example
158,
PD0332991 has a half-life greater than 60 minutes in each of the species
tested. Compound T
was determined to have a shorter half-life than PD0332991 in each of the
species tested.
FIG. 11A is a graph of cell survival of cells treated with 5uM etoposide vs.
treatment
with the indicated amount of Compound T. Surviving cells were determined at 24
hours post
treatment. As described in Example 162, shows that Compound T protects tHS68
cells from
chemotherapeutic induced cell death. FIG. 11B is a graph of cell survival of
cells treated with
100[LM carboplatin vs. treatment with the indicated amount of Compound T.
Surviving cells
were determined at 24 hours post treatment. As described in Example 162,
Compound T
protects tHS68 cells from chemotherapeutic induced cell death.
FIG. 12A is a graph of the relative H2AX activity vs. variable concentration
of
Compound T (nM) in HS68 cells treated with Compound T (100 nM, 300 nM, or 1000
nM) and
chemotherapy (etoposide, doxorubicin, carboplatin, paclitaxel, or
camptothecin). Cdk4/6-
dependent HS68 cells were treated with the indicated doses of Compound T and
chemotherapy.
H2AX foci formation was measured to evaluate chemotherapy-induced DNA damage.
As
described in Example 162, cells treated with Compound T and various
chemotherapeutic
compounds were protected from DNA damage induced by the chemotherapy.
FIG. 12B is a graph of the relative Caspase 3/7 activity vs. variable
concentration of
Compound T (nM) in HS68 cells treated with Compound T (100 nM, 300 nM, or 1000
nM) and
chemotherapy (etoposide, doxorubicin, carboplatin, paclitaxel, or
camptothecin). Cdk4/6-
dependent H568 cells were treated with the indicated doses of Compound T and
chemotherapy.
Caspasc 3/7 activity was measured to evaluate chemotherapy-induced apoptosis.
As described in
Example 162, cells treated with Compound T and various chemotherapeutic
compounds were
protected from caspase 3/7 activation induced by the chemotherapy.
22
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
FIG. 13 is a series of contour plots showing proliferation (as measured by EdU
incorporation after 12 hours) vs. cellular DNA content (as measured by DAPI
staining).
Representative contour plots show proliferation in WBM (whole bone marrow;
top) and HSPCs
(hematopoietic stem and progenitor cells; LSK; bottom), as measured by EdU
incorporation after
12 hours of no treatment, EdU treatment only, or EdU plus Compound T
treatment. As
described in Example 163, Compound T reduces proliferation of whole bone
marrow and
hematopoietic stem and/or progenitor cells.
FIG. 14A is a graph of the percentage of EdU-positive cells in whole bone
marrow
(WBM) and various hematopoietic stem and progenitor cells (Lin-, LSK, HSC,
MPP, or
CD28+LSK cell lineages) treated with Compound T (open bars) or untreated
(solid bars). As
described in Example 163, treatment with Compound T inhibits proliferation of
WBM and all
HSPC lineages tested. *P <0.05, **P <0.01.
FIG. 14B is a graph of the percentage of EdU-positive cells in whole bone
marrow
(WBM) and various lineage restricted progenitors (MP, GMP, MEP, CMP, or CLP
cell lineages)
treated with Compound T (open bars) or untreated (solid bars). As described in
Example 163,
treatment with Compound T inhibits proliferation of WBM and all lineage
restricted progenitors
tested. *P <0.05, **P <0.01.
FIG. 15A is a graph of the percentage of EdU-positive cells in T cell
populations (Total,
CD4+, CD8+, DP, DN, DN1, DN2, DN3, or DN4) treated with Compound T (open bars)
or
untreated (solid bars). As described in Example 164, treatment with Compound T
inhibits
proliferation of the CD4+, CD8+, DP, DN, DN1, DN2, DN3, or DN4 T cell
populations.
*P <0.05, **P <0.01.
FIG. 15B is a graph of the percentage of EdU-positive cells in B cell
populations (B220+,
B220+ sIgM+, Pre-pro-B sIgM-, Pro-B, Pre-B) treated with Compound T (open
bars) or
untreated (solid bars). As described in Example 164, treatment with Compound T
inhibits
proliferation of the various B cell populations (B220+, B220+ sIgM+, Pre-pro-B
sIgM-, Pro-B,
and Pre-B). *P <0.05, **P <0.01.
FIG. 15C is a graph of the percentage of EdU-positive cells in myeloid cell
populations
(Macl+Gr1+, Ter119+, or CD41+) treated with Compound T (open bars) or
untreated (solid
bars). As described in Example 164, treatment with Compound T inhibits
proliferation of the
Macl+Gr1+, Ter119+, or CD41+ myeloid cell populations. *P <0.05, **P <0.01.
23
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
FIG. 16 shows the pharmacodynamic assessment of Compound GG in the bone
marrow.
To assess the effect of transient CDK4/6 inhibition by Compound GG on
carboplatin-induced
cytotoxicity in the bone marrow, FVB/n mice (n=3 per group) were treated with
vehicle control,
90 mg/kg carboplatin by intraperitoneal injection, or 150 mg/kg Compound GG by
oral gavage
plus 90 mg/kg carboplatin by intraperitoneal injection. 24 hours after
treatment bone marrow
was harvested and the percent of cycling bone marrow progenitors was measured
by EdU
incorporation as explained earlier.
FIG. 17A is a graph of whole blood cell counts vs. time (days) after
administration of 5-
fluoruracil (5FU) (triangles), 5FU plus Compound T (squares), or untreated
control (circles).
FVB wild-type mice were treated with Compound T (150 mg/kg) or vehicle control
by oral
gavage thirty minutes prior to administration of 5-flurouracil (5FU) 150 mg/kg
by intraperitoneal
injection. Complete blood cell counts were measured every two days starting on
day six. As
described in Example 166, whole blood cells recover more rapidly from
chemotherapy (5FU)
when pretreated with Compound T. FIG. 17B is a graph of neutrophil cell counts
vs. time (days)
after administration of 5-fluoruracil (5FU) (triangles), 5FU plus Compound T
(squares), or
untreated control (circles). Experiments were conducted as described in Fig.
17A. As described
in Example 166, neutrophils recover more rapidly from chemotherapy (5FU) when
pretreated
with Compound T. FIG. 17C is a graph of lymphocyte cell counts vs. time (days)
after
administration of 5-fluontracil (5FU) (triangles), 5FU plus Compound T
(squares), or untreated
control (circles). Experiments were conducted as described in Fig. 17A. As
described in
Example 166, lymphocytes recover more rapidly from chemotherapy (5FU) when
pretreated
with Compound T. FIG. 17D is a graph of platelet cell counts vs. time (days)
after administration
of 5-fluoruracil (5FU) (triangles), 5FU plus Compound T (squares), or
untreated control
(circles). Experiments were conducted as described in Fig. 17A. As described
in Example 166,
platelets recover more rapidly from chemotherapy (5FU) when pretreated with
Compound T.
FIG. 17E is a graph of red blood cell counts vs. time (days) after
administration of 5-fluoruracil
(5FU) (triangles), 5FU plus Compound T (squares), or untreated control
(circles). Experiments
were conducted as described in Fig. 17A. As described in Example 166, red
blood cells recover
more rapidly from chemotherapy (5FU) when pretreated with Compound T. FIG. 17F
is a graph
of hematocrit (%) vs. time (days) after administration of 5-fluoruracil (5FU)
(triangles), 5FU
plus Compound T (squares), or untreated control (circles). Experiments were
conducted as
24
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
described in Fig. 17A. As described in Example 166, hematocrit percentage
recovers more
rapidly from chemotherapy (5FU) when pretreated with Compound T.
FIG 18A is a graph of whole blood cell counts 14 days after administration of
5-
fluoruracil (5FU), 5FU plus Compound T, or untreated control. FVB wild-type
mice were
treated with Compound T (150 mg/kg) or vehicle control by oral gavage thirty
minutes prior to
administration of 5-flurouracil (5FU) 150 mg/kg by intraperitoneal injection.
Complete blood
cell counts were measured on day 14. Boxes represent the 5%-95% distribution,
whiskers
represent minimum and maximum values, and the middle bar represents the
median. Student's t
test was done to calculate two-sided P values. As described in Example 166,
whole blood cells
recover more rapidly from chemotherapy (5FU) when pretreated with Compound T.
FIG 18B is
a graph of neutrophil cell counts 14 days after administration of 5-
fluoruracil (5FU), 5FU plus
Compound T, or untreated control. Experiments were conducted as described in
Figure 18A. As
described in Example 166, neutrophil cells recover more rapidly from
chemotherapy (5FU) when
pretreated with Compound T. FIG 18C is a graph of lymphocyte cell counts 14
days after
administration of 5-fluoruracil (5FU), 5FU plus Compound T, or untreated
control. Experiments
were conducted as described in Figure 18A. As described in Example 166,
lymphocyte cells
recover more rapidly from chemotherapy (5FU) when pretreated with Compound T.
FIG 18D is
a graph of red blood cell counts 14 days after administration of 5-fluoruracil
(5FU), 5FU plus
Compound T, or untreated control. Experiments were conducted as described in
Figure 18A. As
described in Example 166, red blood cells recover more rapidly from
chemotherapy (5FU) when
pretreated with Compound T. FIG 18E is a graph of platelet cell counts 14 days
after
administration of 5-fluoruracil (5FU), 5FU plus Compound T, or untreated
control. Experiments
were conducted as described in Figure 18A. As described in Example 166,
platelet cells recover
more rapidly from chemotherapy (5FU) when pretreated with Compound T.
FIG. 19A is a graph of whole blood cells (1000 cells/up in untreated mice
(circles), 5-
fluoruracil (5FU) plus Compound T treated mice (squares), or 5-FU treated mice
(triangles) at
Cycle 3, Day 10 (Day 52). FVB wild-type mice were treated with Compound T (150
mg/kg) or
vehicle control by oral gavage thirty minutes prior to administration of 5-
flurouracil (5FU) 150
mg/kg by intraperitoneal injection. Mice received 3 cycles of Compound T or
vehicle control +
5FU on Day 1 of a 21-day cycle. Complete blood cell counts were measured on
Day 10 after the
second dose (52 days after the first dose (Cycle 3 Day 10)). As described in
Example 167, whole
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
blood cells show an improved recovery from chemotherapy (5FU) when treated
with several
cycles of Compound T. FIG. 19B is a graph of neutrophils (1000 cells/up in
untreated mice
(circles), 5-fluoruracil (5FU) plus Compound T treated mice (squares), or 5-FU
treated mice
(triangles) at Cycle 3, Day 10 (Day 52). Experiments were conducted as
described in Fig. 19A.
As described in Example 167, neutrophils show an improved recovery from
chemotherapy (5FU)
when treated with several cycles of Compound T. FIG. 19C is a graph of
lymphocytes (1000
cells/up in untreated mice (circles), 5-fluoruracil (5FU) plus Compound T
treated mice (squares),
or 5-FU treated mice (triangles) at Cycle 3, Day 10 (Day 52). Experiments were
conducted as
described in Fig. 19A. As described in Example 167, lymphocytes show an
improved recovery
from chemotherapy (5FU) when treated with several cycles of Compound T. FIG.
19D is a
graph of red blood cells (1000 cells/up in untreated mice (circles), 5-
fluoruracil (5FU) plus
Compound T treated mice (squares), or 5-FU treated mice (triangles) at Cycle
3, Day 10 (Day
52). Experiments were conducted as described in Fig. 19A. As described in
Example 167, red
blood cells show an improved recovery from chemotherapy (5FU) when treated
with several
cycles of Compound T. FIG. 19E is a graph of platelets (1000 cells/up in
untreated mice
(circles), 5-fluoruracil (5FU) plus Compound T treated mice (squares), or 5-FU
treated mice
(triangles) at Cycle 3, Day 10 (Day 52). Experiments were conducted as
described in Fig. 19A.
As described in Example 167, platelet levels are elevated in recovery from
chemotherapy (5FU)
when treated with several cycles of Compound T.
FIG. 20 is a graph of the percentage of cells in G2-M phase (X), S phase
(triangles), GO-
G1 phase (squares), or <2N (diamonds) vs. variable concentration (nM) of
compound T in
human renal proximal tubule cells. The cells were treated with the indicated
concentrations of
Compound T for 24 hours. Following treatment of Compound T, cells were
harvested and
analyzed for cell cycle distribution. As described in Example 168, human renal
proximal tubule
cells show a clean GI arrest accompanied by a corresponding decrease in the
number of cells in
S-phase.
FIG. 21 is a graph of the percentage of cells in G2-M phase (X), S phase
(triangles), GO-
G1 phase (squares), or <2N (diamonds) vs. variable concentration (nM) of
Compound T in
human renal proximal tubule cells treated with DMSO, etoposide, or cisplatin.
The cells were
treated with the indicated concentrations of Compound T for 24 hours in
combination with
DMSO, etoposide, or cisplatin. Following treatment of Compound T, cells were
harvested and
26
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
analyzed for cell cycle distribution. As described in Example 169, treatment
of human renal
proximal tubule cells with Compound T protects these cells from chemotherapy
induced damage
by etoposide and cisplatin.
FIG. 22 is a graph of the relative y-H2AX activity vs. variable concentration
of
Compound T (nM) in human renal proximal tubule cells treated with Compound T
and
chemotherapy (cisplatin). Cells were treated with the indicated doses of
Compound T (10 nM,
30 nM, 100 nM, 300 nM, or 1000 nM) and chemotherapy (25 uM cisplatin). y-H2AX
foci
formation was measured to evaluate chemotherapy-induced DNA damage. As
described in
Example 170, cells treated with Compound T were protected from DNA damage
induced by the
chemotherapy (cisplatin).
FIG. 23 is a graph of caspase 3/7 activation (as measured by relative light
units) in renal
tubule epithelial cells treated with the indicated concentrations of Compound
T and either
DMSO or cisplatin (25 uM, 50 uM, or 100 uM). Normal renal proximal tubule
epithelial cells
were obtained from American Type Culture Collection (ATCC, Manassas, VA).
Cells were
grown in an incubator at 37 C in a humidified atmosphere of 5% CO2 in Renal
Epithelial Cell
Basal Media (ATCC) supplemented with Renal Epithelial Cell Growth Kit (ATCC)
in 37 C
humidified incubator. Cells were treated with DMSO or 30 nM, 100 nM, 300 nM or
1 uM
Compound T in either the absence or presence of 25, 50 uM, or 100 uM
cisplatin. Caspase 3/7
activation was measured 24 hours later using the Caspase-Glo 3/7 Assay System
(Promega,
Madison, WI) by following the manufacturer's instructions. As described in
Example 170,
Compound T demonstrated a dose-dependent reduction in caspase 3/7 activation
in these cells.
FIGS. 24-26 illustrate several exemplary embodiments of R2 of the compounds of
the
invention.
FIGS. 27A-27C, 28A-D, 29A-29C, 30A-30B, and 31A-31F illustrate exemplary
embodiments of the core structure of the compounds of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Improved compounds, methods, and compositions are provided to minimize the
effect of
chemotherapeutic agent toxicity on CDK4/6 replication dependent healthy cells,
such as
hematopoietic stem cells and/or hematopoietic progenitor cells (together
referred to as HSPCs),
27
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
and/or renal epithelial cells, in subjects, typically humans, that will be,
are being or have been
exposed to the chemotherapeutic agent (typically a DNA-damaging agent).
Definitions
Unless otherwise stated, the following terms used in this application,
including the
specification and claims, have the definitions given below. As used in the
specification and the
appended claims, the singular forms "a," "an" and "the" include plural
referents unless the
context clearly dictates otherwise. Definition of standard chemistry terms may
be found in
reference works, including Carey and Sundberg (2007) Advanced Organic
Chemistry 5th Ed.
Vols. A and B, Springer Science+Business Media LLC, New York. The practice of
the present
invention will employ, unless otherwise indicated, conventional methods of
synthetic organic
chemistry, mass spectroscopy, preparative and analytical methods of
chromatography, protein
chemistry, biochemistry, recombinant DNA techniques and pharmacology.
Conventional
methods of organic chemistry include those included in March's Advanced
Organic Chemistry:
Reactions, Mechanisms, and Structure, 6th Edition, M.B. Smith and J. March,
John Wiley &
Sons, Inc., Hoboken, NJ, 2007.
The term "alkyl," either alone or within other terms such as "haloalkyl" and
"alkylamino," embraces linear or branched radicals having one to about twelve
carbon atoms.
"Lower alkyl" radicals have one to about six carbon atoms. Examples of such
radicals include
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
pentyl, isoamyl, hexyl
and the like. The term "alkylene" embraces bridging divalent linear and
branched alkyl radicals.
Examples include methylene, ethylene, propylene, isopropylene and the like.
The term "alkenyl" embraces linear or branched radicals having at least one
carbon-
carbon double bond of two to about twelve carbon atoms. "Lower alkenyl"
radicals having two
to about six carbon atoms. Examples of alkenyl radicals include ethenyl,
propenyl, allyl,
propenyl, butenyl and 4-methylbutenyl. The terms "alkenyl" and "lower
alkenyl," embrace
radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z"
orientations.
The term "alkynyl" denotes linear or branched radicals having at least one
carbon-carbon
triple bond and having two to about twelve carbon atoms. "Lower alkynyl"
radicals having two
to about six carbon atoms. Examples of such radicals include propargyl,
butynyl, and the like.
28
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Alkyl, alkenyl, and alkynyl radicals may be optionally substituted with one or
more
functional groups such as halo, hydroxy, nitro, amino, cyano, haloalkyl, aryl,
heteroaryl,
heterocyclo and the like.
The term "alkylamino" embraces "N-alkylamino" and "N,N-dialkylamino" where
amino
groups arc independently substituted with one alkyl radical and with two alkyl
radicals,
respectively. "Lower alkylamino" radicals have one or two alkyl radicals of
one to six carbon
atoms attached to a nitrogen atom. Suitable alkylamino radicals may be mono or
dialkylamino
such as N-methylamino, N-ethylamino, N.N-dimethylamino, N,N-diethylamino and
the like.
The term "halo" means halogens such as fluorine, chlorine, bromine or iodine
atoms.
The term "haloalkyl" embraces radicals wherein any one or more of the alkyl
carbon
atoms is substituted with one or more halo as defined above. Examples include
monohaloalkyl,
dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl. A monohaloalkyl
radical, for one
example, may have an iodo, bromo, chloro or fluoro atom within the radical.
Dihalo and
polyhaloalkyl radicals may have two or more of the same halo atoms or a
combination of
different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon
atoms. Examples
of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl,
chloromethyl,
di chloromethyl , trichloromethyl , p entafluoro ethyl , h eptafluoropropyl ,
di fluorochloromethyl ,
di ch I oro flu orom ethyl , difluoro ethyl , di fluoropropyl , di chloro
ethyl and di ch loropropyl .
"Perfluoroalkyl" means an alkyl radical having all hydrogen atoms replaced
with fluoro atoms.
Examples include trifluoromethyl and pentafluoroethyl.
The term "aryl", alone or in combination, means a carbocyclic aromatic system
containing one or two rings wherein such rings may be attached together in a
fused manner. The
term "aryl" embraces aromatic radicals such as phenyl, naphthyl, indenyl,
tetrahydronaphthyl,
and indanyl. More preferred aryl is phenyl. Said "aryl" group may have 1 or
more substituents
such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy, lower
alkylamino, and the
like. An aryl group may be optionally substituted with one or more functional
groups such as
halo, hydroxy, nitro, amino, cyano, haloalkyl, aryl, heteroaryl, heterocyclo
and the like.
The term "heterocycly1" (or "heterocyclo") embraces saturated, and partially
saturated
heteroatom-containing ring radicals, where the heteroatoms may be selected
from nitrogen,
sulfur and oxygen. Heterocyclic rings comprise monocyclic 6-8 membered rings,
as well as 5-16
membered bicyclic ring systems (which can include bridged fused and spiro-
fused bicyclic ring
29
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
systems). It does not include rings containing -0-0-.-0-S- or -S-S- portions.
Said "heterocycly1"
group may have 1 to 3 substituents such as hydroxyl, Boc, halo, haloalkyl,
cyano, lower alkyl,
lower aralkyl, oxo, lower alkoxy, amino, lower alkylamino, and the like.
Examples of saturated heterocyclo groups include saturated 3- to 6-membered
heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl,
imidazolidinyl,
piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered
heteromonocyclic group
containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl];
saturated 3 to 6-
membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3
nitrogen atoms
[e.g., thiazolidinyl]. Examples of partially saturated heterocyclyl radicals
include dihydrothienyl,
dihydropyranyl, dihydrofutyl, dihydrothiazolyl, and the like.
Particular examples of partially saturated and saturated heterocyclo groups
include
pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl,
piperazinyl, morpholinyl,
tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-
benzo[1,4]dioxanyl, indolinyl,
isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl,
1,2-
dihydroquinolyl, 1,2,3,4- tetrahydro-isoquinolyl, 1 ,2,3,4-tetrahydro-
quinolyl, 2,3,4,4a,9,9a-
hexahydro-1H-3-aza-fluorenyl, 5,6,7- trihydro-1,2,4-triazolo [3 ,4-a] isoquino
lyl, 3 ,4-dihydro-2H-
benzo [1,4]ox azinyl , benzo[1,4]dioxanyl,
2,3- dihydro-1H-IX: -ben zo[d]i sothiazol-6-y1 ,
dihydropyranyl, dihydrofuryl and dihydrothiazolyl, and the like.
Heterocyclo groups also includes radicals where heterocyclic radicals are
fused/condensed with aryl radicals: unsaturated condensed heterocyclic group
containing 1 to 5
nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl,
quinolyl,
isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo
[1,5-b]pyridazinyl];
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1
to 3 nitrogen
atoms [e.g. benzoxazolyl, benzoxadiazoly1]; unsaturated condensed heterocyclic
group
containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g.,
benzothiazolyl,
benzothiadiazoly1]; and saturated, partially unsaturated and unsaturated
condensed heterocyclic
group containing 1 to 2 oxygen or sulfur atoms [e.g. benzofuryl, benzothienyl,
2,3-dihydro-
benzo[1,4]dioxinyl and dihydrobenzofuryl].
The term "heteroaryl" denotes aryl ring systems that contain one or more
heteroatoms
selected from the group 0, N and S, wherein the ring nitrogen and sulfur
atom(s) are optionally
oxidized, and nitrogen atom(s) are optionally quartemized. Examples include
unsaturated 5 to 6
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example,
pyrrolyl,
imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl,
pyridazinyl, triazolyl
[e.g., 4H-1,2,4-triazolyl, IH-1 ,2,3-triazolyl, 2H-1,2,3-triazoly1];
unsaturated 5- to 6-membered
heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-
furyl, 3-furyl, etc.;
unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom,
for example, 2-
thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group
containing 1 to 2
oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl,
oxadiazolyl [e.g.,
1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5- oxadiazoly1]; unsaturated 5 to 6-
membered
heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen
atoms, for example,
thiazolyl, thiadiazolyl [e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-
thiadiazoly1].
The term "heteroarylalkyl" denotes alkyl radicals substituted with a
heteroaryl group.
Examples include pyridylmethyl and thienylethyl.
The term "sulfonyl", whether used alone or linked to other terms such as
alkylsulfonyl,
denotes respectively divalent radicals -SO2-.
The terms "carboxy" or "carboxyl", whether used alone or with other terms,
such as
"carboxyalkyl", denotes ¨C(0)¨OH.
The term "carbonyl", whether used alone or with other terms, such as
"aminocarbonyl",
denotes -C(0)-.
The term "aminocarbonyl" denotes an amide group of the Formula -C(0)¨NH2.
The terms "heterocycloalkyl" embrace heterocyclic-substituted alkyl radicals.
Examples
include piperidylmethyl and morpholinylethyl.
The term "arylalkyl" embraces aryl-substituted alkyl radicals. Examples
include benzyl,
diphenylmethyl and phenylethyl. The aryl in said aralkyl may be additionally
substituted with
halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
The term "cycloalkyl" includes saturated carbocyclic groups of 3 to 10
carbons. Lower
cycloalkyl groups include C3-C6 rings. Examples include cyclopentyl,
cyclopropyl, and
cyclohcxyl. Cycloalkyl groups may be optionally substituted with one or more
functional groups
such as halo, hydroxy, nitro, amino, cyano, haloalkyl, aryl, heteroaryl,
heterocyclo and the like.
The term "cycloalkylalkyl" embraces cycloalkyl-substituted alkyl radicals.
"Lower
cycloalkylalkyl" radicals are cycloalkyl radicals attached to alkyl radicals
having one to six
31
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
carbon atoms. Examples of include cyclohexylmethyl. The cycloalkyl in said
radicals may be
additionally substituted with halo, alkyl, alkoxy and hydroxy.
The term "cycloalkenyl" includes carbocyclic groups having one or more carbon-
carbon
double bonds including "cycloalkyldienyl" compounds. Examples include
cyclopentenyl,
cyclopentadienyl, cyclohexenyl and cycloheptadicnyl.
The term "comprising" is meant to be open ended, including the indicated
component but
not excluding other elements.
The term "oxo" as used herein contemplates an oxygen atom attached with a
double
bond.
The term "nitro" as used herein contemplates ¨NO2.
The term "cyano" as used herein contemplates ¨CN.
As used herein, the term "prodrug" means a compound which when administered to
a
host in vivo is converted into the parent drug. As used herein, the term
"parent drug" means any
of the presently described chemical compounds that are useful to treat any of
the disorders
described herein, or to control or improve the underlying cause or symptoms
associated with any
physiological or pathological disorder described herein in a host, typically a
human. Prodrugs
can be used to achieve any desired effect, including to enhance properties of
the parent drug or to
improve the pharmaceutic or pharmacokinetic properties of the parent. Prodrug
strategies exist
which provide choices in modulating the conditions for in vivo generation of
the parent drug, all
of which are deemed included herein. Nonlimiting examples of prodrug
strategies include
covalent attachment of removable groups, or removable portions of groups, for
example, but not
limited to acylation, phosphorylation, phosphonylation, phosphoramidate
derivatives, amidation,
reduction, oxidation, esterification, alkylation, other carboxy derivatives,
sulfoxy or sulfone
derivatives, carbonylation or anhydride, among others.
Throughout the specification and claims, a given chemical formula or name
shall
encompass all optical and stereoisomers, as well as raccmic mixtures where
such isomers and
mixtures exist, unless otherwise noted.
In some embodiments, a CDK4/6-replication dependent healthy cell is a
hematopoietic
stem progenitor cell. Hematopoietic stem and progenitor cells include, but are
not limited to,
long term hematopoietic stem cells (LT-HSCs), short term hematopoietic stem
cells (ST-HSCs),
multipotent progenitors (MPPs), common myeloid progenitors (CMPs), common
lymphoid
32
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
progenitors (CLPs), granulocyte-monocyte progenitors (GMPs), and megakaryocyte-
erythroid
progenitors (MEPs). In some embodiments, the CDK4/6-replication dependent
healthy cell may
be a cell in a non-hematopoietic tissue, such as, but not limited to, the
liver, kidney, pancreas,
brain, lung, adrenals, intestine, gut, stomach, skin, auditory system, bone,
bladder, ovaries,
uterus, testicles, gallbladder, thyroid, heart, pancreatic islets, blood
vessels, and the like. In some
embodiments, the CDK4/6-replication dependent healthy cell is a renal cell,
and in particular a
renal epithelial cell, for example, a renal proximal tubule epithelial cells.
In some embodiments,
a CDK4/6-replication dependent healthy cell is a hematopoietic stem progenitor
cell. In some
embodiments, the CDK4/6-replication dependent healthy cell may be a cell in a
non-
hematopoietic tissue, such as, but not limited to, the liver, kidney,
pancreas, brain, lung, adrenals,
intestine, gut, stomach, skin, auditory system, bone, bladder, ovaries,
uterus, testicles,
gallbladder, thyroid, heart, pancreatic islets, blood vessels, and the like.
The term "selective CDK4/6 inhibitor" used in the context of the compounds
described
herein includes compounds that inhibit CDK4 activity, CDK6 activity, or both
CDK4 and CDK6
activity at an IC50 molar concentration at least about 500, or 1000, or 1500,
or 1800, 2000, 5000
or 10,000 times less than the 1050 molar concentration necessary to inhibit to
the same degree of
CDK2 activity in a standard phosphorylation assay.
By "induces GI-arrest" is meant that the inhibitor compound induces a
quiescent state in
a substantial portion of a cell population at the G1 phase of the cell cycle.
By "hematological deficiency" is meant reduced hematological cell lineage
counts or the
insufficient production of blood cells (i.e., myelodysplasia) and/or
lymphocytes (i.e.,
lymphopenia, the reduction in the number of circulating lymphocytes, such as B-
and T-cells).
Hematological deficiency can be observed, for example, as myelosuppression in
form of anemia,
reduction in platelet count (i.e., thrombocytopenia), reduction in white blood
cell count (i.e.,
leukopenia), or the reduction in granulocytes (e.g., neutropenia).
By "synchronous reentry into the cell cycle" is meant that CDK4/6-replication
dependent
healthy cells, for example HSPCs, in G1-arrest due to the effect of a CDK4/6
inhibitor
compound reenter the cell-cycle within relatively the same collective
timeframe or at relatively
the same rate upon dissipation of the compound's effect. Comparatively, by
"asynchronous
reentry into the cell cycle" is meant that the healthy cells, for example
HSPCs, in G1 arrest due
33
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
to the effect of a CDK4/6 inhibitor compound within relatively different
collective timeframes or
at relatively different rates upon dissipation of the compound's effect such
as PD0332991.
By "off-cycle" or "drug holiday" is meant a time period during which the
subject is not
administered or exposed to a chemotherapeutic. For example, in a treatment
regime wherein the
.. subject is administered the chemotherapeutic for 21 straight days and is
not administered the
chemotherapeutic for 7 days, and the regime is repeated a number of times, the
7 day period of
non-administration is considered the "off-cycle" or "drug holiday." Off-target
and drug holiday
may also refer to an interruption in a treatment regime wherein the subject is
not administered
the chemotherapeutic for a time due to a deleterious side effect, for example,
myelosuppression.
The subject treated is typically a human subject, although it is to be
understood the
methods described herein are effective with respect to other animals, such as
mammals and
vertebrate species. More particularly, the term subject can include animals
used in assays such
as those used in preclinical testing including but not limited to mice, rats,
monkeys, dogs, pigs
and rabbits; as well as domesticated swine (pigs and hogs), ruminants, equine,
poultry, felines,
bovines, murines, canines, and the like.
By "substantial portion" or "significant portion" is meant at least 80%. In
alternative
embodiments, the portion may be at least 85%, 90% or 95% or greater.
In some embodiments, the term "CDK4/6-replication independent cancer" refers
to a
cancer that does not significantly require the activity of CDK4/6 for
replication. Cancers of such
type are often, but not always, characterized by (e.g., that has cells that
exhibit) an increased
level of CDK2 activity or by reduced expression of retinoblastoma tumor
suppressor protein or
retinoblastoma family member protein(s), such as, but not limited to p107 and
p130. The
increased level of CDK2 activity or reduced or deficient expression of
retinoblastoma tumor
suppressor protein or retinoblastoma family member protein(s) can be increased
or reduced, for
.. example, compared to normal cells. In some embodiments, the increased level
of CDK2 activity
can be associated with (e.g., can result from or be observed along with) MYC
proto-oncogene
amplification or overexpression. In some embodiments, the increased level of
CDK2 activity
can be associated with overexpression of Cyclin El, Cyclin E2, or Cyclin A.
As used herein the term "chemotherapy" or "chemotherapeutic agent" refers to
treatment
with a cytostatic or cytotoxic agent (i.e., a compound) to reduce or eliminate
the growth or
proliferation of undesirable cells, for example cancer cells.
Thus, as used herein,
34
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
"chemotherapy" or "chemotherapeutic agent" refers to a cytotoxic or cytostatic
agent used to
treat a proliferative disorder, for example cancer. The cytotoxic effect of
the agent can be, but is
not required to be, the result of one or more of nucleic acid intercalation or
binding, DNA or
RNA alkylation, inhibition of RNA or DNA synthesis, the inhibition of another
nucleic acid-
related activity (e.g., protein synthesis), or any other cytotoxic effect.
Thus, a "cytotoxic agent" can be any one or any combination of compounds also
described as "antineoplastic" agents or "chemotherapeutic agents." Such
compounds include,
but are not limited to, DNA damaging compounds and other chemicals that can
kill cells. "DNA
damaging chemotherapeutic agents" include, but are not limited to, alkylating
agents, DNA
intercalators, protein synthesis inhibitors, inhibitors of DNA or RNA
synthesis, DNA base
analogs, topoisomerase inhibitors, and telomerase inhibitors or telomeric DNA
binding
compounds. For example, alkylating agents include alkyl sulfonates, such as
busulfan,
improsulfan, and piposulfan; aziridines, such as a benzodizepa, carboquone,
meturedepa, and
uredepa; ethylenimines and methylmelamines, such as altretamine,
triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide, and
trimethylolmelamine; nitrogen
mustards such as chlorambucil, chlornaphazine, cyclophosphamide, estramustine,
iphosphamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphal an,
novembichine,
phenesterine, prednimustine, trofosfamide, and uracil mustard; and nitroso
ureas, such as
carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine.
Antibiotics used in the treatment of cancer include dactinomycin,
daunorubicin,
doxorubicin, idarubicin, bleomycin sulfate, mytomycin, plicamycin, and
streptozocin.
Chemotherapeutic antimetabolites include mercaptopurine, thioguanine,
cladribine, fludarabine
phosphate, fluorouracil (5-FU), floxuridine, cytarabine, pentostatin,
methotrexate, and
azathioprine, acyclovir, adenine I3-1-D-arabinoside, amethopterin,
aminopterin, 2-aminopurine,
aphidicolin, 8-azaguanine, azaserine, 6-azauracil, 2'-azido-2'-
deoxynucleosides, 5-
bromodeoxycytidine, cytosine 13-1-D-arabinoside, diazooxynorleucine,
dideoxynucleosides, 5-
fluorodeoxycytidine, 5-fluorodeoxyuridine, and hydroxyurea.
Chemotherapeutic protein synthesis inhibitors include abrin,
aurintricarboxylic acid,
chloramphenicol, colicin E3, cycloheximide, diphtheria toxin, edeine A,
emetine, erythromycin,
ethionine, fluoride, 5-fluorotryptophan, fusidic acid, guanylyl methylene
diphosphonate and
guanylyl imidodiphosphate, kanamycin, kasugamycin, kirromycin, and 0-methyl
threonine.
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Additional protein synthesis inhibitors include modeccin, neomycin, norvaline,
pactamycin,
paromomycine, puromycin, ricin, shiga toxin, showdomycin, sparsomycin,
spectinomycin,
streptomycin, tetracycline, thiostrepton, and trimethoprim. Inhibitors of DNA
synthesis, include
alkylating agents such as dimethyl sulfate, mitomycin C, nitrogen and sulfur
mustards;
intercalating agents, such as acridine dyes, actinomycins, adriamycin,
anthracenes, benzopyrene,
ethidium bromide, propidium diiodide-intertwining; and other agents, such as
distamycin and
netropsin. Topoisomerase inhibitors, such as coumermycin, nalidixic acid,
novobiocin, and
oxolinic acid; inhibitors of cell division, including colcemide, colchicine,
vinblastine, and
vincristine; and RNA synthesis inhibitors including actinomycin D, u-amanitine
and other fungal
amatoxins, cordycepin (3'-deoxyadenosine), dichlororibofuranosyl
benzimidazole, rifampicine,
streptovaricin, and streptolydigin also can be used as the DNA damaging
compound.
Current chemotherapeutic agents whose toxic effects can be mitigated by the
presently
disclosed selective CDK4/6 inhibitors include, but are not limited to,
adrimycin, 5-fluorouracil
(5FU), 6-mercaptopurine, gemcitabine, melphalan, chlorambucil, mitomycin,
irinotecan,
mitoxantrone, etoposide, camptothecin, actinomycin-D, mitomycin, cisplatin,
hydrogen
peroxide, carboplatin, procarbazine, mechlorethamine, cyclophosphamide,
ifosfamide,
m elphal an, chlorambucil, busul fan , nitro surea, dactinomycin , daunorubi
cin, doxorubicin,
bleomycin, pl i comycin , tamox i fen , taxol, transplatinum, vinblastine,
vinbl astin, carmustine,
cytarabine, mechlorethamine, chlorambucil, streptozocin, lomustine,
temozolomide, thiotepa,
altretamine, oxaliplatin, campothecin, and methotrexate, and the like, and
similar acting-type
agents. In one embodiment, the DNA damaging chemotherapeutic agent is selected
from the
group consisting of cisplatin, carboplatin, campothecin, doxorubicin, and
etoposide.
In certain alternative embodiments, the CDK4/6 inhibitors described herein are
used for
an anti-cancer or anti-proliferative effect in combination with a
chemotherapeutic to treat a
CDK4/6 replication independent, such as an Rb-negative, cancer or
proliferative disorder. The
CDK4/6 inhibitors described herein may provide an additive or synergistic
effect to the
chemotherapeutic, resulting in a greater anti-cancer effect than seen with the
use of the
chemotherapeutic alone. In one embodiment, the CDK4/6 inhibitors described
herein can be
combined with one or more of the chemotherapeutic compounds described above.
In one
embodiment, a CDK4/6 inhibitor described herein can be combined with a
chemotherapeutic
selected from, but not limited to, but not limited to, tamoxifen, midazolam,
letrozole,
36
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
bortezomib, anastrozole, goserelin, an mTOR inhibitor, a PI3 kinase
inhibitors, dual mTOR-
P13K inhibitors, MEK inhibitors, RAS inhibitors, ALK inhibitors, HSP
inhibitors (for example,
HSP70 and HSP 90 inhibitors, or a combination thereof), BCL-2 inhibitors,
apopototic inducing
compounds, AKT inhibitors, including but not limited to, MK-2206, GSK690693,
Perifosine,
.. (KRX-0401), GDC-0068, Triciribine, AZD5363, Honokiol, PF-04691502, and
Miltefosine, PD-
1 inhibitors including but not limited to, Nivolumab, CT-011, MK-3475,
BMS936558, and
AMP-514 or FLT-3 inhibitors, including but not limited to, P406, Dovitinib,
Quizartinib
(AC220), Amuvatinib (MP-470), Tandutinib (MLN518), ENMD-2076, and KW-2449, or
combinations thereof. Examples of mTOR inhibitors include but are not limited
to rapamycin
and its analogs, everolimus (Afinitor), temsirolimus, ridaforolimus,
sirolimus, and deforolimus.
Examples of P13 kinase inhibitors include but are not limited to Wortmannin,
demethoxyviridin,
perifosine, idelalisib, PX-866, IPI-145 (Infinity), BAY 80-6946, BEZ235,
RP6503, TGR 1202
(RP5264), MLN1117 (INK1117), Pictilisib, Buparlisib, SAR245408 (XL147),
SAR245409
(XL765), Palomid 529, ZSTK474, PWT33597, RP6530, CUDC-907, and AEZS-136..
Examples
of MEK inhibitors include but are not limited to Tametinib, Selumetinib,
MEK162, GDC-0973
(XL518), and PD0325901. Examples of RAS inhibitors include but are not limited
to Reolysin
and siG12D LODER. Examples of ALK inhibitors include but are not limited to
Crizotinib,
AP26113, and LDK378. HSP inhibitors include but are not limited to
Geldanamycin or 17-N-
Allylamino-17-demethoxygeldanamycin (17AAG), and Radicicol.. In one
embodiment, the
CDK4/6 inhibitor combined with the chemotherapeutic is selected from the group
consisting of a
compound or composition comprising Formula I, Formula II, Formula III, Formula
IV, or
Formula V described above, or a pharmaceutically acceptable composition, salt,
isotopic analog
or prodrug thereof. In one embodiment, the compound is selected from the
compounds provided
for in Table 1, or a pharmaceutically acceptable composition, salt, isotopic
analog or prodrug
thereof. In one embodiment, the compound is selected from compounds T, Q, GG,
U, or AAAA,
or a pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof.
In one embodiment, a CDK4/6 inhibitor described herein can be combined with a
chemotherapeutic selected from, but are not limited to, Imatinib mesylate
(Gleevac03)), Dasatinib
(Spryce10), Nilotinib (Tasigna0), Bosutinib (Bosulif0), Trastuzumab
(Herceptin0),
Pertuzumab (PerjetaTM), Lapatinib (Tykerb0), Gefitinib (Iressa0), Erlotinib
(Tarceva0),
Cetuximab (Erbitux0), Panitumumab (Vectibix ), Vandetanib (Caprelsa0),
Vemurafenib
37
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(Zelboraf0), Vorinostat (Zolinza0), Romidepsin (Istodax0), Bexarotene
(Tagretin0),
Alitretinoin (Panretin0), Tretinoin (Vesanoid0), Carfilizomib (KyprolisTM),
Pralatrexate
(Folotynt), Bevacizumab (Avastin0), Ziv-aflibercept (Zaltrap0), Sorafenib
(Nexavar0),
Sunitinib (Sutent0), Pazopanib (Votrient0), Regorafenib (Stivarga0), and
Cabozantinib
(CometriqTM).
By "long-term hematological toxicity" is meant hematological toxicity
affecting a subject
for a period lasting more than one or more weeks, months, or years following
administration of a
chemotherapeutic agent. Long-term hematological toxicity can result in bone
marrow disorders
that can cause the ineffective production of blood cells (i.e.,
myelodysplasia) and/or lymphocytes
(i.e., lymphopenia, the reduction in the number of circulating lymphocytes,
such as B- and T-
cells). Hematological toxicity can be observed, for example, as anemia,
reduction in platelet
count (i.e., thrombocytopenia) or reduction in white blood cell count (i.e.,
neutropenia). In some
cases, myelodysplasia can result in the development of leukemia. Long-term
toxicity related to
chemotherapeutic agents can also damage other self-renewing cells in a
subject, in addition to
hematological cells. Thus, long-term toxicity can also lead to graying and
frailty.
Active Compounds
In one embodiment, the invention is directed to compounds or the use of such
compounds
of Formula I, II, III, IV, or V:
R2
\--)c
R8
N R
R6 N (R1 )y
0
Z¨N
R
38
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
R2
XV../ R11
R8
X'
(R1)y
0
Z¨N
R
R2
r\¨X R11
%X R8
N
R6 (R1)y
0
Z¨N
R
R11
R8
R2
N \ (R1 )y 0
I\
R6 H\ZNN
R 1V, or
R11
R8
N \ (R1) o
I\
R10 NN
NN
R V,
or a pharmaceutically acceptable salt thereof;
wherein:
Z is ¨(CH2)¨ wherein x is 1, 2, 3 or 4 or ¨0¨(CH2)7¨ wherein z is 2, 3 or 4;
each X is independently CH or N;
each X' is independently, CH or N;
39
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
X" is independently CH2, S or NH, arranged such that the moiety is a stable 5-
membered ring;
R, Rs, and R" are independently H, C1-C3 alkyl or haloalkyl, cycloalkyl or
cycloalkyl containing
one or more heteroatoms selected from N, 0 or S; -(alkylene)m- C3-Cs
cycloalkyl, -(alkylene)m-
aryl, -(alkylene)m-heterocyclo, -(alkylene)m- heteroaryl, -(alkylene)m-NR3R4, -
(alkylene)m-C(0)-
NR3R4; -(alkylene)m-0-R5, -(alkylene)m- S(0)5-R5, or -(alkylene)m-S(0)n-NR3R4
any of which
may be optionally independently substituted with one or more R groups as
allowed by valance,
and wherein two Rx groups bound to the same or adjacent atoms may optionally
combine to form
a ring;
each Rl is independently aryl, alkyl, cycloalkyl or haloalkyl, wherein each of
said alkyl,
cycloalkyl and haloalkyl groups optionally includes 0 or N heteroatoms in
place of a carbon in
the chain and two RI's on adjacent ring atoms or on the same ring atom
together with the ring
atom(s) to which they are attached optionally form a 3-8-membered cycle;
y is 0, 1, 2, 3 or 4;
R2 is ¨(alkylene)m¨heterocyclo,
¨(alkylene)m¨heteroaryl, ¨(alkylene)m¨NR3R4,
¨(alky1ene)m¨C(0)¨NR3R4; ¨(alky1ene)m¨C(0)-0-a1kyl;
¨(alky1ene)m¨O¨R5,
¨(alkylene)m¨S(0)õ¨R5, or ¨(alky1ene)m¨S(0).¨NR3R4 any of which may be
optionally
independently substituted with one or more Rx groups as allowed by valance,
and wherein two
R' groups bound to the same or adjacent atom may optionally combine to form a
ring and
wherein m is 0 or 1 and n is 0, 1 or 2;
R3 and R4 at each occurrence are independently:
(i) hydrogen or
(ii) alkyl, cycloalkyl, heterocyclo, aryl, heteroaryl, cycloalkylalkyl,
heterocycloalkyl,
arylalkyl, or heteroarylalkyl any of which may be optionally independently
substituted with one or more 11' groups as allowed by valance, and wherein two
Rx
groups bound to the same or adjacent atom may optionally combine to form a
ring; or
R3 and R4 together with the nitrogen atom to which they arc attached may
combine to
form a heterocyclo ring optionally independently substituted with one or more
Rx
groups as allowed by valance, and wherein two Rx groups bound to the same or
adjacent atom may optionally combine to form a ring;
R5 and R5* at each occurrence is:
(i) hydrogen or
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(ii) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl,
cycloalkylalkyl,
heterocycloalkyl, arylalkyl, or heteroarylalkyl any of which may be optionally
independently substituted with one or more 11' groups as allowed by valance;
Rx at each occurrence is independently, halo, cyano, nitro, oxo, alkyl,
haloalkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl,
heteroarylalkyl,
cycloalkylalkyl, heterocycloalkyl, -(alkylene)m-0R5, -(alkylene)m-0-alkylene-
0R5,
-(alkylene)m-S(0)n-R5, -(alkylene)m-NR3R4, -(alkylene)m-CN, -(alkylene)m-C(0)-
R5,
-(alkylene)m-C(S)-R5, -(alkylene)m-C(0)-0R5, -(alkylene)m-0-C(0)-R5,
-(alkylene)m-C(S)-0R5, -(alkylene)m-C(0)-(alkylene)m-NR3R4, -(alkylene)m-C(S)-
NR3R4,
-(alkylene)111-N(R3)-C(0)-NR3R4, -(alky1ene)m-N(R3)-C(S)-NR3R4,
-(alkylene)m-N(R)-C(0)-R5, -(alkylene)in- N(R3)-C(S)-R5, -(alkylene)m-O-C(0)-
NR3R4,
-(alkylene)m-O-C(S)-NR3R4, -(alky1ene)m-S02-NR3R4, -(a1kylene)m-N(R3)-S02-R5,
-(alkylene)m-N(R3)-S02-NR3R4, -(alkylene)m-N(R3)-C(0)-0R5)
-(alkylene)m-N(R3)-C(S)-0R5, or -(alkylene)m-N(R3)-S02-R5; wherein:
said alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
heterocyclo, aryl,
heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl
groups
may be further independently substituted with one or more
-(alkylene)m-CN, -(alkylene)m-0R5*, -(alkylene)m-S(0)n-R5*,
-(alkylene)m-NR3*R4*, -(alkylene)m-C(0)-R5*, -(alkylene)m-C(=S)R5*,
-(alkylene)m-C(=0)0 R5*, -(alkylene)m-OC(=0)R5*, -(alkylene)m-C(S)-0R5*,
-(alkylene)1-C(0)-NR3*R4*, -(alkylene)1-C(S)-NR3*R4*,
-(alkylene)1-N(R3*)-C(0)-NR3*R4*, -(alkylene)m-N(R3*)-C(S)-NW*R4*,
-(alkylene)m-N(R3*)-C(0)-R5*, -(alkylene)m-N(R3*)-C(S)-R5*,
-(alkylene)m-O-C(0)-NR3*R4*, -(alkylene)m-0-C(S)-NR3*R4*,
-(alkylene)m-S02-NR3*R4*, -(alkylene)m-N(R3*)-S02-R5*,
-(alkylene)m-N(R3*)-S02-NR3*R4*, -(alkylene)m-N(R3*)-C(0)-0R5*,
-(alkylene)m-N(R3*)-C(S)-0R5*, or -(alkylene)m-N(R3*)-S02-R5*,
n is 0, 1 or 2, and
m is 0 or 1;
R3* and R4* at each occurrence are independently:
(i) hydrogen or
41
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(ii) alkyl, alkenyl, alkynyl cycloalkyl, heterocyclo, aryl, heteroaryl,
cycloalkylalkyl,
heterocycloalkyl, arylalkyl, or heteroarylalkyl any of which may be optionally
independently substituted with one or more Rx groups as allowed by valance; or
R3*
and R4* together with the nitrogen atom to which they are attached may combine
to
form a heterocyclo ring optionally independently substituted with one or more
Rx
groups as allowed by valance; and
R6 is H or lower alkyl, -(alkylene)m-heterocyclo, -(alkylene)m-heteroaryl, -
(alkylene)m-NR3R4,
-(alkylene)m-C(0)-NR3R4; -(alkylene)m-0-R5, -(alkylene)m-S(0)õ-R5, or -
(alkylene)m-S(0),,NR3R4
any of which may be optionally independently substituted with one or more Rx
groups as
allowed by valance, and wherein two Rx groups bound to the same or adjacent
atoms may
optionally combine to form a ring; and
Rth is
(i) NHRA, wherein RA is unsubstituted or substituted Ci-Cs alkyl,
cycloalkylalkyl, or ¨TT-
RR, C1-C8 cycloalkyl or cycloalkyl containing one or more heteroatoms selected
from N, 0, and
S; TT is an unsubstituted or substituted C1-C8 alkyl or C3-Cs cycloalkyl
linker; and RR is a
hydroxyl, unsubstituted or substituted Ci-Co alkoxy, amino, unsubstituted or
substituted C1-C6
alkylamino, unsubstituted or substituted di-C1-C6 alkylamino, unsubstituted or
substituted Co-Cm
aryl, unsubstituted or substituted heteroaryl comprising one or two 5- or 6-
member rings and 1-4
heteroatoms selected from N, 0 and S, unsubstituted or substituted C3-Cio
carbocycle, or
unsubstituted or substituted heterocycle comprising one or two 5- or 6-member
rings and 1-4
heteroatoms selected from N, 0 and S; or (ii) -C(0)-R12 or _C(0)0-R13 ,
wherein R12 is NHRA
or RA and R14 is RA;
or a pharmaceutically acceptable salt, prodrug or isotopic variant, for
example, partially or fully
deuterated form thereof.
In some aspects, the compound is of Formula I or Formula II and R6 is absent.
42
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some aspects, the compound is of Formula III:
R2
X%
X R8
(R1)y
0
Z¨N
and the variables are as defined for compounds of Formulae I and II and
pharmaceutically
acceptable salts thereof.
In some aspects, 12' is not further substituted.
In some aspects, R2 is ¨(alkylene)m¨heterocyclo, ¨(alkylene)m¨heteroaryl,
¨(alkylene)m¨NR3R4,
¨(alkylene)m¨C(0)¨NR3R4; ¨(a1kylene)m¨O¨R5,
¨(a1kylene)m¨S(0)õ¨R5, or ¨(alkylene)m¨S(0)n¨NR3R4 any of which may be
optionally
independently substituted with one or more R8 groups as allowed by valance,
and wherein two
Rx groups bound to the same or adjacent atom may optionally combine to form a
ring and
wherein m is 0 or 1 and n is 0, 1 or 2.
In some aspects, R8 is hydrogen or Ci-C3 alkyl.
In some aspects, R is hydrogen or C1-C3 alkyl.
In some aspects, R2 is ¨(alkylene)m¨heterocyclo, ¨(alkylene)m¨NR3R4,
¨(alkylene)m¨C(0)¨NR3R4, ¨(alkylene)m¨C(0)-0-alkyl or ¨(alkylene)m¨OR' any of
which may
be optionally independently substituted with one or more R8 groups as allowed
by valance, and
wherein two 128 groups bound to the same or adjacent atom may optionally
combine to form a
ring.
In some aspects, R2 is
¨(al kyl en e)m¨h etero cyc o, .. ¨(al kyl en e)m¨NR3R4,
¨(alkylene)m¨C(0)¨NR3R4, ¨(alkylene)m¨C(0)-0-alkyl or ¨(alkylene)m-0R5 without
further
substitution.
In some aspects, m in R2 is 1. In a further aspect, the alkylene in R2 is
methylene.
43
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
-R2* (Rxi )t
In some aspects, R2 is wherein:
2* =
R is a bond, alkylene, -(alkylene)m-0-(alkylene)m-, -(alkylene)m-C(0)-
(alkylene)m-,
-(alkylene)m-S(0)2-(alkylene)m- and -(alkylene)m-NH-(alkylene)m- wherein each
m is
independently 0 or 1;
P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;
each Ru is independently -(alkylene)m-(C(0))m-(alkylene)m-(N(RN))m-(alkyl)m
wherein each m is
independently 0 or 1 provided at least one m is 1, -(C(0))-0-alkyl,
-(alkylene)m-cycloalkyl wherein m is 0 or 1, -N(RN)-cycloalkyl, -C(0)-
cycloalkyl,
-(alkylene)m-heterocyclyl wherein m is 0 or 1, or _N(RN)heterocyclyl, -C(0)-
heterocyclyl,-
S(0)2-(alkylene)1 wherein m is 1 or 2, wherein:
RN is H, C1 to C4 alkyl or C1 to C6 heteroalkyl, and
wherein two Rxi can, together with the atoms to which they attach on P, which
may be
the same atom, form a ring; and
t is 0, 1 or 2.
.1
In some aspects, each R is only optionally substituted by unsubstituted alkyl,
halogen or
hydroxy.
In some aspects, Rxi is hydrogen or unsubstituted C1-C4 alkyl.
In some aspects, at least one Rxi is -(alkylene)m-heterocyclyl wherein m is 0
or 1.
_R2*_N p* (RX1)t
In some aspects, R2 is
wherein P* is a 4- to 8-membered
mono- or bicyclic saturated heterocyclyl group.
¨R2 ¨N NH
In some aspects, R2 is (RX.Nt
.
rµ
N_Rxi
In some aspects, R2 is
44
CA 02906156 2015-09-11
WO 2014/144326 PC T/US2014/028685
-R2*P P1 (Rx2)5
In some aspects, R2 is wherein:
R2' is a bond, alkylene, -(alkylene)m-0-(alkylene)õ-, -(alkylene)m-C(0)-
(alkylene)õ,-,
-(alkylene)m-S(0)2-(alkylene)m- and -(alkylene)m-NH-(alkylene)m- wherein each
m is
independently 0 or 1;
P is a 4- to 8-membered mono- or bicyclic saturated heterocyclyl group;
P1 is a 4- to 6-membered monocyclic saturated heterocyclyl group;
each 11'2 is independently hydrogen or alkyl; and
s is 0, 1 or 2.
¨R2*¨N P1 (or-Nx2)
In some aspects, R2 is
In some aspects, P1 includes at least one nitrogen.
In some aspects, any alkylene in R2* in any previous aspect is not further
substituted.
In some aspects, R2 is selected from the structures depicted in FIGS. 24-26.
aVlIs alftr
VO
0,4
N NO
N
In some aspects, R2 is
PN
H N1/1 H2N or H .
In some aspects, the compound has general Formula I and more specifically one
of the
general structures in FIGS. 27-31 wherein the variables are as previously
defined.
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some aspects, the compound has general Formula Ia:
R2 X,
N 0
. x
N
N N R
y(R1) Ia
wherein R2, R and y are as previously defined.
In some embodiments, the compound has Formula Ia and R is alkyl.
In some embodiments, the compound has Formula la and R is H.
In some embodiments, the compound has Formula Ia and R2 is
_R2*_N p* _______________ (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
In some embodiments, the compound has Formula Ia and R2 is
_R2*_N p* (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or unsubstituted Ci-C4 alkyl and R2* is as
previously
defined.
In some embodiments, the compound has Formula Ib:
R2 X,
. x N
N N
N R
/
lb
wherein R2 and R are as previously defined.
In some embodiments, the compound has Formula Ib and R is alkyl.
In some embodiments, the compound has Formula Ib and R is H.
46
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula lb and R2 is
_R2*_N p* (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
In some embodiments, the compound has Formula lb and R2 is
_R2*_N p* (RXi)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, IV1 is hydrogen or C1-C4 alkyl and R2* is as previously
defined.
In some embodiments, the compound has Formula Ic:
R2 X ,
X N I \
N NN
I I
N¨R
/
Ic,
wherein R2 and R are as previously defined.
In some embodiments, the compound has Formula lc and R is alkyl.
In some embodiments, the compound has Formula Ic and R is H.
In some embodiments, the compound has Formula Ic and R2 is
_R2*_N p* (RX1)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
In some embodiments, the compound has Formula Ic and R2 is
_R2*_N p* (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rd is hydrogen or C1-C4 alkyl and R2* is as previously
defined.
47
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Id:
R2,_
N ,\0
. x
I I
N¨R
/
Id
wherein R2 and R are as previously defined.
In some embodiments, the compound has Formula Id and R is alkyl.
In some embodiments, the compound has Formula Id and R is H.
In some embodiments, the compound has Formula Id and R2 is
_R2*_N p* (RX1)t
wherein P* is a 4- to 8-membered mono- or bicyclic
saturated heterocyclyl group and R2*, Rx1 and t are as previously defined.
In some embodiments, the compound has Formula Id and R2 is
_R2*_N p* (RX1)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or Ci-C4 alkyl and R2* is as previously
defined.
In some embodiments, the compound has Formula Ie:
R2 X,
X N \
I I
N¨R
/
In some embodiments, the compound has Formula Ie and R is alkyl.
In some embodiments, the compound has Formula Ie and R is H.
48
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Ie and R2 is
_R2*_N p* (RXi)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
In some embodiments, the compound has Formula Ie and R2 is
_R2*_N p* (RXi)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rx1 is hydrogen or C1-C4 alkyl and R2* is as previously
defined.
In some embodiments, the compound has Formula If:
RU X..
,
X N I \
NN N.R
I N
In some embodiments, the compound has Formula If and R is alkyl.
In some embodiments, the compound has Formula If and R is H.
In some embodiments, the compound has Formula If and R2 is
¨R2*¨N P* (Rx1 )t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxl and t are as previously defined.
In some embodiments, the compound has Formula If and R2 is
_R2*_N p* (RX1)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or C1-C4 alkyl and R2* is as previously
defined.
49
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Ig:
R2õ.. X , 0
. x IT I ¨R
I I
\%".""N N
In some embodiments, the compound has Formula Ig and R is alkyl.
In some embodiments, the compound has Formula Ig and R is H.
In some embodiments, the compound has Formula Ig and R2 is
_R2*_N p* (RXi)
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rx1 and t are as previously defined.
In some embodiments, the compound has Formula Ig and R2 is
_R2*_N p* RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, R'd is hydrogen or Ci-C4 alkyl and R2* is as previously
defined.
In some embodiments, the compound has Formula Ih:
RU X. ,
X N I \
I I
R
In some embodiments, the compound has Formula lh and R is alkyl.
In some embodiments, the compound has Formula Ih and R is H.
In some embodiments, the compound has Formula Ih and R2 is
_R2*_N p* (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Ih and R2 is
_R2*_ N p* (RX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or Ci-C4 alkyl and R29 is as previously
defined.
In some embodiments, the compound has Formula Ti:
X N
N N N N R
In some embodiments, the compound has Formula Ti and R is alkyl.
In some embodiments, the compound has Formula Ti and R is H.
In some embodiments, the compound has Formula Ii and R2 is
_R24t_N p* (RX1)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group and R2*, Rxi and t are as previously defined.
In some embodiments, the compound has Formula Ii and R2 is
N p* (RX1)
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rx1 is hydrogen or C1-C4 alkyl and R2* is as previously
defined.
In some embodiments, the compound has Formula Ij:
R2 X,
N I \
N N N N R
6-1
In some embodiments, the compound has Formula Ij and R is alkyl.
In some embodiments, the compound has Formula Ij and R is H.
51
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Ij and R2 is
- p* IT\ (oX1
)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
In some embodiments, the compound has Formula Ij and R2 is
- p* (ED.X1
r.µ
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rx1 is hydrogen or Ci-C4 alkyl.
In some embodiments, the compound has Formula Ij and R is H, and both X are N.
In some embodiments, the compound has the structure:
R2
N \
In some embodiments, the compound has Formula Ik and R2 is
- p* (EikXl
r.µ
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
In some embodiments, the compound has Formula Ik and R2 is
R24`- N p* riX1
1-µ
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or Cl-C4 alkyl.
52
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Ti:
R2
N
NNNH
Q.)
In some embodiments, the compound has Formula Ii and R2 is
p* (oX1)
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
In some embodiments, the compound has Formula Ii and R2 is
R24`N p* riX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rx1 is hydrogen or C1-C4 alkyl.
In some embodiments, the compound has Formula IM:
R2
N
N H
Q.)10
In some embodiments, the compound has Formula Im and R2 is
_R2*_N p* (roX1N
)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
53
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Im and R2 is
_R2*_N p* (DX1 )
Iµ
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rx1 is hydrogen or Ci-C4 alkyl.
In some embodiments, the compound has Formula Ha:
R2
I
N r_v_z" NH
In some embodiments, the compound has Formula ha and R2 is
_R2*_N p* caroX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
In some embodiments, the compound has Formula ha and R2 is
p* (oX1
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or C1-C4 alkyl.
In some embodiments, the compound has Formula IIb:
R2
54
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In some embodiments, the compound has Formula Im and R2 is
_R2*_N p* (oX1
)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group.
In some embodiments, the compound has Formula Im and R2 is
_R2*_N p* (DX1
)t
wherein P* is a 4- to 8-membered mono- or bicyclic saturated
heterocyclyl group, Rxi is hydrogen or Ci-C4 alkyl.
In some aspects, the active compound is:
R2
y-x%
R'
/Nr0
z----N
\R
In certain embodiments, the compound is selected from:
N
N N 0
NN N H
T;
CA 02906156 2015-09-11
WO 2014/144326 PC
T/US2014/028685
H N
0 N N
N
N H
N
O-/ Q;
N
0 N
N
N NH
GG;
N
0 N N
11:7n
N N NH
U. or
56
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
0
j[ N
N 2H
AAAA,
wherein R is C(H)X, NX, C(H)Y, or
where X is straight, branched or cyclic CI to C5 alkyl group, including
methyl, ethyl,
propyl, cyclopropyl, isopropyl, butyl, sec-butyl, tert-butyl, isobutyl,
cyclobutyl, pentyl, isopentyl,
neopentyl, tert-pentyl, sec-pentyl, and cyclopentyl; and
Y is NR1R2 wherein R1 and R2 are independently X, or wherein R1 and R2 are
alkyl
groups that together form a bridge that includes one or two heteroatoms (N, 0,
or S);
And wherein two X groups can together form an alkyl bridge or a bridge that
includes
one or two heteroatoms (N,S, or 0) to form a spiro compound.
The IUPAC name for Formula T is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-
yl)amino)-
7',8'-dihydro-6'H-spiro [cyclohexane-1 ,9'-pyrazino [1',2' :1,5 ]pyrro lo [2,3-
d]pyrimidin]-6'-one; for
Formula Q is 2'-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-
spiro [cyc lohexane-
1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one; for Formula GG is
2'4(544-
isopropylpip erazin-l-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro
[cyclohexane-1,9'-
pyrazino[ 1 ',2':.1,5]pyrrolo[2,3-d]pyrimidin]-6'-one;
and for Formula U is 2'-((5-(4-
morpholinopiperidin-l-yl)pyri din-2-yl)amino)-7',8'-dihydro-6'H-spiro [cycl oh
ex an e-1,9'-
pyrazino [1',2' :1,5]pyrrolo [2,3 -d]pyrimidin] -6'-one.
Further specific compounds that fall within the present invention and that can
be used in
the disclosed methods of treatment and compositions include the structures
listed in Table 1
below.
57
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Table 1: Structures of CDK4/6 Inhibitors
Structure Structure
Reference
A
OH
HöJ
I ,
N N NH
vee-N1
\1N N \ 0
I
N N r_k_iN NH
OH N
0.1N= NV \ 0
.,====
N N NH
HN'iN)
)--/.CN N
N N r....\\_iN NH
58
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
N
NN
N \ 0
N N NH
N \ 0
N N NH
HçJ
N
NH
N \ 0
N N NH
59
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
N
N N NH
N N 0
N N NH
N
L`==/11
,
N N r....\\_J" NH
e(`-''N N
I I
N N JN NH
V-)
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
N N N H
0
.C1N N N
N N N H
H N
NCLN \ 0
I
NHöJ
N N H
HN
LNHçJ
N N N H
N
\µõ, 1=,õ N ,,c/L
N
N N N H
HçJ
61
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
N
OH (N
N \ 0
N N /...*.../N NH
N
I
NH
U 0Th
N \
I
N N NH
V HN--**)
AN,
62
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
RV.
N )N, N
NH
X F3C
N N
A: I
N N _/NH
C
0 N N \ 0
N N NH
OHNN
N N NH
63
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
AA
.11\1N)
N ,0,_
1 N
N H N H
\--)
BB
¨2%*`= NCNIN N '. 1 \
....-- õ.1.-.4...
H
CC
1 s'= N AI: 1 \ 0
H
\¨)
DD
N 1)
1009L-'' N 1 N N N '1-****1 .. 0H
H N
..,J. I
N
\ --)
EE (-.N 1 %` IV 1 \
N ,...) ' ....... ,..L.k.
N../N H NH
\ ---)
64
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Structure Structure
Reference
FF
N 1)
1119jL.N`CA`. INV 1 \ 0
H NH
\--)
GG
ILNO.N-
/- N)==,N 7._\___/N H NH
\--)
HH
N
H
\--)
II 0
('..-N 1 'N N )...
N) I ,...- õ...1.k., ' ,
N N 'N NH
H
\--)
IJ 0
----1
1 '`I\I NV 1 \
¨/ ,-' N.-1-.N i_k_iN NH
H
\-2
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
KK
N N N \ 0
I
N N NH
LL 0
I
Cr N1 N JN NH
MM
5H09N N N \
N N NH
NN
== ====)
.1\1=CA` N
N N NH
\¨}
00
\ 0
I õ,õ I
N N NH
66
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Structure Structure
Reference
PP
NV \ 0
N
QQ
N N \ 0
N N JN NH
RR
N N JN NH
SS
N
N'CL= N \ 0
N''Ikµ'N'/----;.\.._/N NH
67
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
TT
Ns
N N
N N 7*. j" NH
UU
..`=al ."
I ,
N N NH
VV
3H .LN
\µ`µ I\V
WW
c"N
0 CLr 0
N ./N NH
XX
N
I ,
N N NH
68
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
YY
N N
NH
ZZ
N NH
C..)
AAA
I ,
N N Jim NH
BBB 0
N N
N
N N NH
CCC
NrTh
N \ 0
I
N N NH
HJ
69
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
DDD
HNILI
leL,N,ONõ.. Nin......f0
1 7 N "IN ''--- NA2H
H
C.)
EEE >CN
OH
I
N N H 4.../
IN)
FFF -7y'N'Th
0)I
,,"' N'' 1 \ ., , I ,
N N NH
H
C..)
GGG
0,1
I
N N /4...Jim NH
H
C.)
HHH
'''=-' N 1 =NI N'' 1 \
N N H j- NH
(N)
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Structure Structure
Reference
III
(N
.....- A.. ....-... ,,
H
C..)
JJJ
H NH
C.)
KKK
c,,, N
0'.
H
c)
LLL
==,õ,õ N 0 ,
H
C)
71
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
MMM
N
.,0
`(1
I
',
NH
H
C.)
NNN
'YN
N N H n_v_ j- NH
C.)
000 0
H
c)
PPP
=)('N'1)
)N
N-41---N
H c.)
,,-...,,,
=N
N N n_v__ _I" NH
QQQ HNrs'..1
/4..... _IN NH
H
IN)
72
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
RRR
N \
N r4..../ 11 NH
IN./\
SSS
L,NNNO
N NH
(N/)
TTT
1-N
1./N NH
C./)
UUU HN
N \
I
HN N NNH
VVV HN
N \
N N NH
H
73
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Structure Structure
Reference
WWW H N
HJ
A I
XXX
N N \
I
N N i...../1\1 NH
Isotopic Substitution
The present invention includes compounds and the use of compounds with desired
isotopic substitutions of atoms, at amounts above the natural abundance of the
isotope, i.e.,
-- enriched. Isotopes are atoms having the same atomic number but different
mass numbers, i.e.,
the same number of protons but a different number of neutrons. By way of
general example and
without limitation, isotopes of hydrogen, for example, deuterium (2H) and
tritium (3H) may be
used anywhere in described structures. Alternatively or in addition, isotopes
of carbon, e.g., 13C
and "C, may be used. A preferred isotopic substitution is deuterium for
hydrogen at one or more
-- locations on the molecule to improve the performance of the drug. The
deuterium can be bound
in a location of bond breakage during metabolism (an a-deuterium kinetic
isotope effect) or next
to or near the site of bond breakage (a I3-deuterium kinetic isotope effect).
Substitution with isotopes such as deuterium can afford certain therapeutic
advantages
resulting from greater metabolic stability, such as, for example, increased in
vivo half-life or
reduced dosage requirements. Substitution of deuterium for hydrogen at a site
of metabolic
break down can reduce the rate of or eliminate the metabolism at that bond. At
any position of
the compound that a hydrogen atom may be present, the hydrogen atom can be any
isotope of
74
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
hydrogen, including protium (1H), deuterium (2H) and tritium (3H). Thus,
reference herein to a
compound encompasses all potential isotopic forms unless the context clearly
dictates otherwise.
The term "isotopically-labeled" analog refers to an analog that is a
"deuterated analog", a
"13C-labeled analog," or a "deuterated/13C-labeled analog." The term
"deuterated analog" means
a compound described herein, whereby a H-isotope, i.e., hydrogen/protium (1H),
is substituted by
a H-isotope, i.e., deuterium (2H). Deuterium substitution can be partial or
complete. Partial
deuterium substitution means that at least one hydrogen is substituted by at
least one deuterium.
In certain embodiments, the isotope is 90, 95 or 99% or more enriched in an
isotope at any
location of interest. In some embodiments it is deuterium that is 90, 95 or
99% enriched at a
desired location.
CDK-Replication Dependent Cells and Cyclin-Dependent Kinase Inhibitors
Tissue-specific stem cells and subsets of other resident proliferating cells
are capable of
self-renewal, meaning that they are capable of replacing themselves throughout
the adult
mammalian lifespan through regulated replication.
Additionally, stem cells divide
asymmetrically to produce "progeny" or "progenitor" cells that in turn produce
various
components of a given organ. For example, in the hematopoietic system, the
hematopoietic stem
cells give rise to progenitor cells which in turn give rise to all the
differentiated components of
blood (e.g., white blood cells, red blood cells, and platelets). See FIG. 1.
Certain proliferating cells, such as HSPCs, require the enzymatic activity of
the
proliferative kinases cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent
kinase 6
(CDK6) for cellular replication. In contrast, the majority of proliferating
cells in adult mammals
(e.g., the more differentiated blood-forming cells in the bone marrow) do not
require the activity
of CDK4 and/or CDK6 (i.e., CDK4/6). These differentiated cells can proliferate
in the absence
of CDK4/6 activity by using other proliferative kinases, such as cyclin-
dependent kinase 2
(CDK2) or cyclin-dependent kinase 1 (CDK1).
The CDK4/6 inhibitor administered is selected from the group consisting of a
compound
or composition comprising Formula I, Formula II, Formula III, Formula IV, or
Formula V, or a
combination thereof. In one embodiment, the compound is selected from the
compounds
described in Table 1.
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
In certain embodiments, the CDK4/6 inhibitor is a CDK4/6 inhibitor of Formula
I, II, III,
IV, or V or a pharmaceutically acceptable composition, salt, isotopic analog,
or prodrug thereof,
wherein the protection afforded by the compound is short term and transient in
nature, allowing a
significant portion of the cells to synchronously renter the cell-cycle
quickly following the
cessation of the chemotherapeutic agent's effect, for example within less than
about 24, 30, 36,
or 40 hours. In one embodiment, the compound is selected from the compounds
described in
Table 1 or a pharmaceutically acceptable composition, salt, isotopic analog or
prodrug thereof.
In one embodiment, the compound is selected from compounds T, Q, GG, U, or
AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. Cells that are
quiescent within the G1 phase of the cell cycle are more resistant to the
damaging effect of
chemotherapeutic agents than proliferating cells. CDK4/6 inhibitory compounds
for use in the
described methods are highly selective, potent CDK4/6 inhibitors, with minimal
CDK2
inhibitory activity. In one embodiment, a CDK4/6 compound for use in the
methods described
herein has a CDK4/CycD1 IC50 inhibitory concentration value that is >1500
times, >1800 times,
>2000 times, >2200 times, >2500 times, >2700 times, >3000 times, >3200 times
or greater
lower than its respective IC50 concentration value for CDK2/CycE inhibition.
In one
embodiment, a CDK4/6 inhibitor for use in the methods described herein has an
IC50
concentration value for CDK4/CycD1 inhibition that is about <1.50 nM, <1.25
nM, <1.0 nM,
<0.90 nM, <0.85 nM, <0.80 nM, <0.75 nM, <0.70 nM, <0.65 nM, <0.60 nM, <0.55
nM, or less.
In one embodiment, a CDK4/6 inhibitor for use in the methods described herein
has an IC50
concentration value for CDK2/CycE inhibition that is about >1.0 M, >1.25 M,
>1.50 M,
>1.75 [tM, >2.0 !AM , >2.25 [tM, >2.50 M, >2.75 [CA, >3.0 M, >3.25 [tM, >3.5
!AM or greater.
In one embodiment, a CDK4/6 inhibitor for use in the methods described herein
has an IC50
concentration value for CDK2/CycA IC50 that is >0.80 M, >0.85 M, >0.90 pM,
>0.95 RIVI,
>.1.0 M, >1.25 M, >1.50 1..tM, >1.75 M, >2.0 M, >2.25 M, >2.50 [6\4,
>2.75 uM, >3.0 M
or greater. In one embodiment, the CDK4/6 inhibitor for use in the methods
described herein are
selected from the group consisting of Formula I, Formula 11, Formula III,
Formula IV, or
Formula V, or a pharmaceutically acceptable composition, salt, or prodrug,
thereof. In one
embodiment, the compound is selected from the compounds described in Table 1,
or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
76
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
embodiment, the compound is selected from compounds T, Q, GG, U, or AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof
In one embodiment, the CDK4/6 inhibitors described herein are used in CDK4/6-
replication dependent healthy cell cycling strategies wherein a subject is
exposed to regular,
repeated chemotherapeutic treatments, wherein the healthy cells are G1-
arrested when
chemotherapeutic agent exposed and allowed to reenter the cell-cycle before
the subject's next
chemotherapeutic treatment. Such cycling allows CDK4/6-replication dependent
cells to
regenerate damaged blood cell lineages between regular, repeated treatments,
for example those
associated with standard chemotherapeutic treatments for cancer, and reduces
the risk associated
with long term CDK4/6 inhibition. This cycling between a state of Gl-arrest
and a state of
replication is not feasible in limited time-spaced, repeated chemotherapeutic
agent exposures
using longer acting CDK4/6 inhibitors such as PD0332991, as the lingering Gl-
arresting effects
of the compound prohibit significant and meaningful reentry into the cell-
cycle before the next
chemotherapeutic agent exposure or delay the healthy cells from entering the
cell cycle and
reconstituting damaged tissues or cells following treatment cessation.
Proliferative disorders that are treated with chemotherapy include cancerous
and non-
cancer diseases. In a typical embodiment, the proliferative disorder is a
CDK4/6-replication
independent disorder. The compounds are effective in protecting healthy CDK4/6-
replication
dependent cells, for example HSPCs, during chemotherapeutic treatment of a
broad range of
tumor types, including but not limited to the following: breast, prostate,
ovarian, skin, lung,
colorectal, brain (i.e., glioma) and renal. Preferably, the selective CDK4/6
inhibitor should not
compromise the efficacy of the chemotherapeutic agent or arrest G1 arrest the
cancer cells.
Many cancers do not depend on the activities of CDK4/6 for proliferation as
they can use the
proliferative kinases promiscuously (e.g., can use CDK 1/2/4/or 6) or lack the
function of the
retinoblastoma tumor suppressor protein (Rb), which is inactivated by the
CDKs. The potential
sensitivity of certain tumors to CDK4/6 inhibition can be deduced based on
tumor type and
molecular genetics using standard techniques. Cancers that are not typically
affected by the
inhibition of CDK4/6 are those that can be characterized by one or more of the
group including,
but not limited to, increased activity of CDK1 or CDK2, loss, deficiency, or
absence of
retinoblastoma tumor suppressor protein (Rb), high levels of MYC expression,
increased cyclin
E (e.g., El or E2) and increased cyclin A, or expression of a Rb-inactivating
protein (such as
77
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
HPV-encoded E7). Such cancers can include, but are not limited to, small cell
lung cancer,
retinoblastoma, HPV positive malignancies like cervical cancer and certain
head and neck
cancers, MYC amplified tumors such as Burkitts' Lymphoma, and triple negative
breast cancer;
certain classes of sarcoma, certain classes of non-small cell lung carcinoma,
certain classes of
melanoma, certain classes of pancreatic cancer, certain classes of leukemia,
certain classes of
lymphoma, certain classes of brain cancer, certain classes of colon cancer,
certain classes of
prostate cancer, certain classes of ovarian cancer, certain classes of uterine
cancer, certain classes
of thyroid and other endocrine tissue cancers, certain classes of salivary
cancers, certain classes
of thymic carcinomas, certain classes of kidney cancers, certain classes of
bladder cancers, and
certain classes of testicular cancers.
The loss or absence of retinoblastoma (Rb) tumor suppressor protein (Rb-null)
can be
determined through any of the standard assays known to one of ordinary skill
in the art,
including but not limited to Western Blot, ELISA (enzyme linked
immunoadsorbent assay), IHC
(immunohistochemistry), and FACS (fluorescent activated cell sorting). The
selection of the
assay will depend upon the tissue, cell line or surrogate tissue sample that
is utilized e.g., for
example Western Blot and ELISA may be used with any or all types of tissues,
cell lines or
surrogate tissues, whereas the IHC method would be more appropriate wherein
the tissue utilized
in the methods of the present invention was a tumor biopsy. FACs analysis
would be most
applicable to samples that were single cell suspensions such as cell lines and
isolated peripheral
blood mononuclear cells. See for example, US 20070212736 "Functional
Immunohistochemical
Cell Cycle Analysis as a Prognostic Indicator for Cancer".
Alternatively, molecular genetic testing may be used for determination of
retinoblastoma
gene status. Molecular genetic testing for retinoblastoma includes the
following as described in
Lohmann and Gallie "Retinoblastoma. Gene
Reviews" (2010)
http://www.ncbi.nlm.nih.govibookshelf/brIcgi?book=gene&part=retinoblastoma or
Parsam et al.
"A comprehensive, sensitive and economical approach for the detection of
mutations in the RBI
gene in retinoblastoma" Journal of Genetics, 88(4), 517-527 (2009).
Increased activity of CDK I or CDK2, high levels of MYC expression, increased
cyclin E
and increased cyclin A can be determined through any of the standard assays
known to one of
ordinary skill in the art, including but not limited to Western Blot, ELISA
(enzyme linked
immunoadsorbent assay), IHC (immunohistochemistry), and FACS (fluorescent
activated cell
78
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
sorting). The selection of the assay will depend upon the tissue, cell line,
or surrogate tissue
sample that is utilized e.g., for example Western Blot and ELISA may be used
with any or all
types of tissues, cell lines, or surrogate tissues, whereas the IHC method
would be more
appropriate wherein the tissue utilized in the methods of the present
invention was a tumor
biopsy. FACs analysis would be most applicable to samples that were single
cell suspensions
such as cell lines and isolated peripheral blood mononuclear cells.
In some embodiments, the cancer is selected from a small cell lung cancer,
retinoblastoma, and triple negative (ER/PR/Her2 negative) or "basal-like"
breast cancer, which
almost always inactivate the retinoblastoma tumor suppressor protein (Rb), and
therefore do not
require CDK4/6 activity to proliferate. Triple negative (basal-like) breast
cancer is also almost
always genetically or functionally Rb-null. Also, certain virally induced
cancers (e.g. cervical
cancer and subsets of Head and Neck cancer) express a viral protein (E7) which
inactivates Rb
making these tumors functionally Rb-null. Some lung cancers are also believed
to be caused by
HPV. In one particular embodiment, the cancer is small cell lung cancer, and
the patient is
treated with a DNA-damaging agent selected from the group consisting of
etoposide, carboplatin,
and cisplatin, or a combination thereof.
The selected CDK4/6 inhibitors described herein can also be used in protecting
healthy
CDK4/6-replication dependent cells during chemotherapeutic treatments of
abnormal tissues in
non-cancer proliferative diseases, including but not limited to: psoriasis,
lupus, arthritis (notably
rheumatoid arthritis), hemangiomatosis in infants, multiple sclerosis,
myelodegenerative disease,
neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's Disease of
the bone,
fibrocystic disease of the breast, Peyronie's and Duputren's fibrosis,
restenosis, and cirrhosis.
Further, selective CDK4/6 inhibitors can be used to ameliorate the effects of
chemotherapeutic
agents in the event of accidental exposure or overdose (e.g., methotrexate
overdose).
According to the present invention, the active compound can be administered to
a subject
on any chemotherapeutic treatment schedule and in any dose consistent with the
prescribed
course of treatment. The selective CDK4/6 inhibitor compound is administered
prior to, during,
or following the administration of the chemotherapeutic agent. In one
embodiment, the CDK4/6
inhibitors described herein can be administered to the subject during the time
period ranging
from 24 hours prior to chemotherapeutic treatment until 24 hours following
exposure. This time
period, however, can be extended to time earlier that 24 hour prior to
exposure to the agent (e.g.,
79
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
based upon the time it takes the chemotherapeutic agent used to achieve
suitable plasma
concentrations and/or the compound's plasma half-life). Further, the time
period can be extended
longer than 24 hours following exposure to the chemotherapeutic agent so long
as later
administration of the CDK4/6 inhibitor leads to at least some protective
effect. Such post-
exposure treatment can be especially useful in cases of accidental exposure or
overdose.
In some embodiments, the selective CDK4/6 inhibitor can be administered to the
subject
at a time period prior to the administration of the chemotherapeutic agent, so
that plasma levels
of the selective CDK4/6 inhibitor are peaking at the time of administration of
the
chemotherapeutic agent. If convenient, the selective CDK4/6 inhibitor can be
administered at
the same time as the chemotherapeutic agent, in order to simplify the
treatment regimen. In
some embodiments, the chemoprotectant and chemotherapeutic can be provided in
a single
formulation.
In some embodiments, the selective CDK4/6 inhibitor can be administered to the
subject
such that the chemotherapeutic agent can be administered either at higher
doses (increased
chemotherapeutic dose intensity) or more frequently (increased
chemotherapeutic dose density).
Dose-dense chemotherapy is a chemotherapy treatment plan in which drugs are
given with less
time between treatments than in a standard chemotherapy treatment plan.
Chemotherapy dose
intensity represents unit dose of chemotherapy administered per unit time.
Dose intensity can be
increased or decreased through altering dose administered, time interval of
administration, or
both. Myelosuppression continues to represent the major dose-limiting toxicity
of cancer
chemotherapy, resulting in considerable morbidity and mortality along with
frequent reductions
in chemotherapy dose intensity, which may compromise disease control and
survival. The
compounds and their use as described herein represent a way of increasing
chemotherapy dose
density and/or dose intensity while mitigating adverse events such as, but not
limited to,
myelosuppression.
If desired, multiple doses of the selected CDK4/6 inhibitor compound can be
administered to the subject. Alternatively, the subject can be given a single
dose of the selected
CDK4/6 inhibitor. For example, the CDK4/6-inhibitor can be administered so
that CDK4/6-
replication dependent healthy cells are G1 arrested during chemotherapeutic
agent exposure
wherein, due to the rapid dissipation of the Gl-arresting effect of the
compounds, a significant
number of healthy cells reenter the cell-cycle and are capable of replicating
shortly after
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
chemotherapeutic agent exposure, for example, within about 24-48 hours or
less, and continue to
replicate until administration of the CDK4/6-inhibitor in anticipation of the
next
chemotherapeutic treatment. In one embodiment, the CDK4/6-inhibitor is
administered to allow
for the cycling of the CDK4/6-replication dependent healthy cells between GI -
arrest and reentry
into the cell-cycle to accommodate a repeated-dosing chemotherapeutic
treatment regimen, for
example, including but not limited to a treatment regimen wherein the
chemotherapeutic agent is
administered: on day 1-3 every 21 days; on days 1-3 every 28 days; on day 1
every 3 weeks; on
day 1, day 8, and day 15 every 28 days, on day 1 and day 8 every 28 days; on
days 1 and 8 every
21 days; on days 1-5 every 21 days; 1 day a week for 6-8 weeks; on days 1, 22,
and 43; days 1
and 2 weekly; days 1-4 and 22-25; 1-4; 22-25, and 43-46; and similar type-
regimens, wherein the
CDK4/6-replication dependent cells are G1 arrested during chemotherapeutic
agent exposure and
a significant portion of the cells reenter the cell-cycle in between
chemotherapeutic agent
exposure.
In one embodiment, the CDK4/6 inhibitor described herein is used to provide
chemoprotection to a subject's CDK4/6-replication dependent healthy cells
during a CDK4/6-
replication independent small cell lung cancer treatment protocol. In one
embodiment, the
CDK4/6 inhibitor is administered to provide chemoprotection in a small cell
lung cancer therapy
protocol such as, but not limited to: cisplatin 60 mg/m2 IV on day 1 plus
etoposide 120 mg,/m2
IV on days 1-3 every 21d for 4 cycles; cisplatin 80 mg/m2 IV on day 1 plus
etoposide 100
mg/m2 IV on days 1-3 every 28d for 4 cycles; cisplatin 60-80 mg/m2 IV on day 1
plus etoposide
80-120 mg/m2 IV on days 1-3 every 21-28d (maximum of 4 cycles); carboplatin
AUC 5-6 IV on
day 1 plus etoposide 80-100 mg/m2 IV on days 1-3 every 28d (maximum of 4
cycles);
Cisplatin 60-80 mg/m2 IV on day 1 plus etoposide 80-120 mg/m2 IV on days 1-3
every
21-28d; carboplatin AUC 5-6 IV on day 1 plus etoposide 80-100 mg/m2 IV on days
1-3 every
.. 28d (maximum 6 cycles); cisplatin 60 mg/m2 IV on day 1 plus irinotecan 60
mg,/m2 IV on days
1, 8, and 15 every 28d (maximum 6 cycles); cisplatin 30 mg/m2 IV on days 1 and
8 or 80 mg/m2
IV on day 1 plus irinotecan 65 mg/m2 IV on days 1 and 8 every 21d (maximum 6
cycles);
carboplatin AUC 5 IV on day I plus irinotecan 50 mg/m2 IV on days 1, 8, and 15
every 28d
(maximum 6 cycles); carboplatin AUC 4-5 IV on day 1 plus irinotecan 150-200
mg/m2 IV on
day 1 every 21d (maximum 6 cycles); cyclophosphamide 800-1000 mg/m2 IV on day
1 plus
doxorubicin 40-50 mg/m2 IV on day 1 plus vincristine 1-1.4 mg/m2 IV on day 1
every 21-28d
81
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(maximum 6 cycles); Etoposide 50 mg/m2 PO daily for 3wk every 4wk; topotecan
2.3 mg,/m2
PO on days 1-5 every 21d; topotecan 1.5 mg/m2 IV on days 1-5 every 21d;
carboplatin AUC 5
IV on day 1 plus irinotecan 50 mg/m2 IV on days 1, 8, and 15 every 28d;
carboplatin AUC 4 - 5
IV on day 1 plus irinotecan 150-200 mg/m2 IV on day 1 every 21d; cisplatin 30
mg,/m2 IV on
days 1, 8, and 15 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d;
cisplatin 60
mg/m2 IV on day 1 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d;
cisplatin 30
mg/m2 IV on days 1 and 8 or 80 mg/m2 IV on day 1 plus irinotecan 65 mg/m2 IV
on days 1 and
8 every 21d; paclitaxel 80 mg/m2 IV weekly for 6wk every 8wk; paclitaxel 175
mg/m2 IV on
day 1 every 3wk; etoposide 50 mg/m2 PO daily for 3wk every 4wk; topotecan 2.3
mg/m2 PO on
days 1-5 every 21d; topotecan 1.5 mg/m2 IV on days 1-5 every 21d; carboplatin
AUC 5 IV on
day 1 plus irinotecan 50 mg/m2 IV on days 1, 8, and 15 every 28d; carboplatin
AUC 4-5 IV on
day 1 plus irinotecan 150-200 mg/m2 IV on day 1 every 21d; cisplatin 30 mg/m2
IV on days 1,
8, and 15 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d;
cisplatin 60 mg/m2 IV on
day 1 plus irinotecan 60 mg/m2 IV on days 1, 8, and 15 every 28d; cisplatin 30
mg/m2 IV on
days 1 and 8 or 80 mg/m2 IV on day 1 plus irinotecan 65 mg/m2 IV on days 1 and
8 every 21d;
paclitaxel 80 mg/m2 IV weekly for 6wk every 8wk; and paclitaxel 175 mg/m2 IV
on day 1 every
3wk.
In one embodiment, a CDK4/6 inhibitor described herein is administered to a
subject
with small cell lung cancer on days 1, 2, and 3 of a treatment protocol
wherein the DNA
damaging agent selected from the group consisting of carboplatin, etoposide,
and cisplatin, or a
combination thereof, is administered on days 1, 2, and 3 every 21 days.
In one embodiment, a CDK4/6 inhibitor described herein is used to provide
chemoprotection to a subject's CDK4/6-replication dependent healthy cells
during a CDK4/6-
replication independent head and neck cancer treatment protocol. In one
embodiment, the
CDK4/6 inhibitor is administered to provide chemoprotection in a CDK4/6-
replication
independent head and neck cancer therapy protocol such as, but not limited to:
cisplatin 100
mg/m2 IV on days 1, 22, and 43 or 40-50 mg/m2 IV weekly for 6-7wk; cetuximab
400 mg,/m2
IV loading dose lwk before the start of radiation therapy, then 250 mg/m2
weekly (premedicate
with dexamethasone, diphenhydramine, and ranitidine); cisplatin 20 mg/m2 IV on
day 2 weekly
for up to 7wk plus paclitaxel 30 mg/m2 IV on day 1 weekly for up to 7wk;
cisplatin 20
mg/m2/day IV on days 1-4 and 22-25 plus 5-FU 1000 mg/m2/day by continuous IV
infusion on
82
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
days 1-4 and 22-25; 5-FU 800 mg/m2 by continuous IV infusion on days 1-5 given
on the days
of radiation plus hydroxyurea 1 g PO ql2h (11 doses per cycle); chemotherapy
and radiation
given every other week for a total of 13wk; carboplatin 70 mg/m2/day IV on
days 1-4, 22-25,
and 43-46 plus 5-FU 600 mg/m2/day by continuous IV infusion on days 1-4, 22-
25, and 43-46;
carboplatin AUC 1.5 IV on day 1 weekly plus paclitaxel 45 mg/m2 IV on day 1
weekly;
cisplatin 100 mg/m2 IV on days 1, 22, and 43 or 40-50 mg/m2 IV weekly for 6-
7wk; docetaxel
75 mg/m2 IV on day 1 plus cisplatin 100 mg/m2 IV on day 1 plus 5-FU 100
mg/m2/day by
continuous IV infusion on days 1-4 every 3wk for 3 cycles, then 3-8wk later,
carboplatin AUC
1.5 IV weekly for up to 7wk during radiation therapy; docetaxel 75 mg/m2 IV on
day 1 plus
cisplatin 75 mg/m2 IV on day 1 plus 5-FU 750 mg/m2/day by continuous IV
infusion on days 1-
4 every 3wk for 4 cycles; cisplatin 100 mg/m2 IV on day 1 every 3wk for 6
cycles plus 5-FU
1000 mg/m2/day by continuous IV infusion on days 1-4 every 3wk for 6 cycles
plus cetuximab
400 mg/m2 IV loading dose on day 1, then 250 mg/m2 IV weekly until disease
progression
(premedicate with dexamethasone, diphenhydramine, and ranitidine); carboplatin
AUC 5 IV on
day 1 every 3wk for 6 cycles plus 5-FU 1000 mg/m2/day by continuous IV
infusion on days 1-4
every 3wk for 6 cycles plus cetuximab 400 mg/m2 IV loading dose on day 1, then
250 mg/m2
IV weekly until disease progression (premedicate with dexamethasone,
diphenhydramine, and
ranitidine); cisplatin 75 mg/m2 IV on day 1 plus docetaxel 75 mg/m2 IV on day
1 every 3wk;
cisplatin 75 mg/m2 IV on day 1 plus paclitaxel 175 mg/m2 IV on day 1 every
3wk; carboplatin
AUC 6 IV on day 1 plus docetaxel 65 mg/m2 IV on day 1 every 3wk; carboplatin
AUC 6 IV on
day 1 plus paclitaxel 200 mg/m2 IV on day 1 every 3wk; cisplatin 75-100 mg/m2
IV on day 1
every 3-4wk plus cetuximab 400 mg/m2 IV loading dose on day 1, then 250 mg/m2
IV weekly
(premedicate with dexamethasone, diphenhydramine, and ranitidine); cisplatin
100 mg/m2 IV on
day 1 plus 5-FU 1000 mg/m2/day by continuous IV infusion on days 1-4 every
3wk;
methotrexate 40 mg/m2 IV weekly (3wk equals 1 cycle); paclitaxel 200 mg/m2 IV
every 3wk;
docetaxel 75 mg/m2 IV every 3wk; cetuximab 400 mg/m2 IV loading dose on day 1,
then 250
mg/m2 IV weekly until disease progression (premedicate with dexamethasone,
diphenhydramine, and ranitidine); cisplatin 100 mg/m2 IV on day 1 every 3wk
for 6 cycles plus
5-FU 1000 mg/m2/day by continuous IV infusion on days 1-4 every 3wk for 6
cycles plus
cetuximab 400 mg/m2 IV loading dose on day 1, then 250 mg/m2 IV weekly
(premedicate with
dexamethasone, diphenhydramine, and ranitidine); carboplatin AUC 5 IV on day 1
every 3wk
83
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
for 6 cycles plus 5-FU 1000 mg/m2/day by continuous IV infusion on days 1-4
every 3wk for 6
cycles plus cetuximab 400 mg/m2 IV loading dose on day 1, then 250 mg/m2 IV
weekly
(premedicate with dexamethasone, diphenhydramine, and ranitidine); cisplatin
75 mg/m2 IV on
day 1 plus docetaxel 75 mg/m2 IV on day 1 every 3wk; cisplatin 75 mg/m2 IV on
day 1 plus
paclitaxel 175 mg/m2 IV on day 1 every 3wk; carboplatin AUC 6 IV on day 1 plus
docetaxel 65
mg/m2 IV on day 1 every 3wk; carboplatin AUC 6 IV on day 1 plus paclitaxel 200
mg,/m2 IV
on day 1 every 3wk; cisplatin 75-100 mg/m2 IV on day 1 every 3-4wk plus
cetuximab 400
mg/m2 IV loading dose on day 1, then 250 mg/m2 IV weekly (premedicate with
dexamethasone, diphenhydramine, and ranitidine); cisplatin 100 mg/m2 IV on day
1 plus 5-FU
1000 mg/m2/day by continuous IV infusion on days 1-4 every 3wk; methotrexate
40 mg/m2 IV
weekly (3wk equals 1 cycle); paclitaxel 200 mg/m2 IV every 3wk; docetaxel 75
mg/m2 IV every
3wk; cetuximab 400 mg/m2 IV loading dose on day 1, then 250 mg/m2 IV weekly
until disease
progression (premedicate with dexamethasone, diphenhydramine, and ranitidine);
cisplatin 100
mg/m2 IV on days 1, 22, and 43 with radiation, then cisplatin 80 mg/m2 IV on
day 1 plus 5-FU
1000 mg/m2/day by continuous IV infusion on days 1-4 every 4wk for 3 cycles;
cisplatin 75
mg/m2 IV on day 1 plus docetaxel 75 mg/m2 IV on day 1 every 3wk; cisplatin 75
mg/m2 IV on
day 1 plus paclitaxel 175 mg/m2 IV on day 1 every 3wk; carboplatin AUC 6 IV on
day 1 plus
docetaxel 65 mg/m2 IV on day 1 every 3wk; carboplatin AUC 6 IV on day 1 plus
paclitaxel 200
mg/m2 IV on day 1 every 3wk; cisplatin 100 mg/m2 IV on day 1 plus 5-FU 1000
mg/m2/day by
continuous IV infusion on days 1-4 every 3wk; cisplatin 50-70 mg/m2 IV on day
1 plus
gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 every 4wk; gemcitabine 1000
mg/m2 IV on
days 1, 8, and 15 every 4wk or gemcitabine 1250 mg/m2 IV on days 1 and 8 every
3wk;
methotrexate 40 mg/m2 IV weekly (3wk equals 1 cycle); paclitaxel 200 mg/m2 IV
every 3wk;
docetaxel 75 mg/m2 IV every 3wk; cisplatin 75 mg/m2 IV on day 1 plus docetaxel
75 mg/m2 IV
on day 1 every 3wk; cisplatin 75 mg/m2 IV on day 1 plus paclitaxel 175 mg/m2
IV on day 1
every 3wk; carboplatin AUC 6 IV on day 1 plus docetaxel 65 mg/m2 IV on day 1
every 3wk;
carboplatin AUC 6 IV on day 1 plus paclitaxel 200 mg,/m2 IV on day 1 every
3wk; cisplatin 100
mg/m2 IV on day 1 plus 5-FU 1000 mg/m2/day by continuous IV infusion on days 1-
4 every
3wk; cisplatin 50-70 mg/m2 IV on day 1 plus gemcitabine 1000 mg/m2 IV on days
1, 8, and 15
every 4wk; gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 every 4wk or
gemcitabine 1250
84
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
mg/m2 IV on days 1 and 8 every 3wk; methotrexate 40 mg/m2 IV weekly (3wk
equals 1 cycle);
paclitaxel 200 mg/m2 IV every 3wk; and docetaxel 75 mg/m2 IV every 3wk.
In one embodiment, the CDK4/6 inhibitor described herein is used to provide
chemoprotection to a subject's CDK4/6-replication dependent healthy cells
during a CDK4/6-
replication independent triple negative breast cancer treatment protocol. In
one embodiment, the
CDK4/6 inhibitor is administered to provide chemoprotection in a CDK4/6-
replication
independent triple negative breast cancer therapy protocol such as, but not
limited to: dose-
dense doxorubicin (adriamycin) and cyclophosphamide (cytoxan) every two weeks
for four
cycles followed by dose-dense paclitaxel (Taxol) every two weeks for four
cycles;
adriamycin/paclitaxel/cyclophosphomide every three weeks for a total of four
cycles;
adriamycin/paclitaxel/cyclophosphomide every two weeks for a total of four
cycles;
adriamycin/cyclophosphomide followed by paclitaxel (Taxol) every three weeks
for four cycles
each; and adriamycin/cyclophosphomide followed by paclitaxel (Taxol) every two
weeks for
four cycles each.
Triple-negative breast cancer (TNBC) is defined as the absence of staining for
estrogen
receptor, progesterone receptor, and HER2/neu. TNBC is insensitive to some of
the most
effective therapies available for breast cancer treatment including HER2-
directed therapy such as
trastuzumab and endocrine therapies such as tamoxifen or the aromatase
inhibitors.
Combination cytotoxic chemotherapy administered in a dose-dense or metronomic
schedule
remains the standard therapy for early-stage TNBC. Platinum agents have
recently emerged as
drugs of interest for the treatment of TNBC with carboplatin added to
paclitaxel and adriamycin
plus cyclophosphamide chemotherapy in the neoadjuvant setting. The poly (ADP-
ribose)
polymerase (PARP) inhibitors are emerging as promising therapeutics for the
treatment of
TNBC. PARPs are a family of enzymes involved in multiple cellular processes,
including DNA
repair.
As a nonlimiting illustration, the subject is exposed to chemotherapeutic
agent at least 5
times a week, at least 4 times a week, at least 3 times a week, at least 2
times a week, at least 1
time a week, at least 3 times a month, at least 2 times a month, or at least 1
time a month,
wherein the subject's CDK4/6-replication dependent healthy cells are G1
arrested during
treatment and allowed to cycle in between chemotherapeutic agent exposure, for
example during
a treatment break. In one embodiment, the subject is undergoing 5 times a week
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
chemotherapeutic treatment, wherein the subject's CDK4/6-replication dependent
healthy cells
are G1 arrested during the chemotherapeutic agent exposure and allowed to
reenter the cell-cycle
during the 2 day break, for example, over the weekend.
In one embodiment, using a CDK4/6 inhibitor described herein, the subject's
CDK4/6-
replicaton dependent healthy cells are arrested during the entirety of the
chemotherapeutic agent
exposure time-period, for example, during a contiguous multi-day regimens, the
cells are
arrested over the time period that is required to complete the contiguous
multi-day course, and
then allowed to recycle at the end of the contiguous multi-day course. In one
embodiment, using
a CDK4/6 inhibitor described herein, the subject's CDK4/6-replication
dependent healthy cells
are arrested during the entirety of the chemotherapeutic regimen, for example,
in a daily
chemotherapeutic exposure for three weeks, and rapidly reenter the cell-cycle
following the
completion of the therapeutic regimen.
In one embodiment, the subject has been exposed to a chemotherapeutic agent,
and, using
a CDK4/6 inhibitor described herein, the subject's CDK4/6-replication
dependent healthy cells
are placed in G1 arrest following exposure in order to mitigate, for example,
DNA damage. In
one embodiment, the CDK4/6 inhibitor is administered at least 1/2 hour, at
least 1 hour, at least 2
hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours,
at least 7 hours, at least 8
hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16
hours, at least 18 hours, at
least 20 hours or more post chemotherapeutic agent exposure.
In some embodiments, the present invention provides methods for protection of
mammals, particularly humans, from the acute and chronic toxic effects of
chemotherapeutic
agents by forcing CDK4/6-replication dependent healthy cells, for example
hematopoietic stem
and progenitor cells (HSPCs) and/or renal epithelial cells, into a quiescent
state by transient (e.g.,
over a less than about 40, 36, 30, 24 hour or less period) treatment with a
CDK4/6 inhibitor
selected from the group consisting of Formula I, Formula II, Formula III,
Formula IV, or
Formula V or a pharmaceutically acceptable composition, salt, isotopic analog,
or prodrug
thereof. In one embodiment, the compound is selected from the compounds
described in Table 1
or a pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. In one
embodiment, the compound is selected from compounds T, Q, GG, U, or AAAA, or a
pharmaceutically acceptable composition, salt, isotopic analog or prodrug
thereof. CDK4/6-
replication dependent cells recover from this period of transient quiescence,
and then function
86
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
normally after treatment with the inhibitor is stopped, and its intra-cellular
effect dissipates.
During the period of quiescence, the CDK4/6-replication dependent cells are
protected from the
effects of chemotherapeutic agents.
In some embodiments, the CDK4/6-replication dependent healthy cells can be
arrested
for longer periods, for example, over a period of hours, days, and/or weeks,
through multiple,
time separated administrations of a CDK4/6 inhibitor described herein. Because
of the rapid and
synchronous reentry into the cell cycle by CDK4/6-replication dependent
healthy cells, for
example HSPCs, upon dissipation of the CDK4/6 inhibitors intra-cellular
effects, the cells are
capable of reconstituting the cell lineages faster than CDK4/6 inhibitors with
longer G1 arresting
profiles, for example PD0332991.
The reduction in chemotoxicity afforded by the selective CDK4/6 inhibitors can
allow for
dose intensification (e.g., more therapy can be given in a fixed period of
time) in medically
related chemotherapies, which will translate to better efficacy. Therefore,
the presently disclosed
methods can result in chemotherapy regimens that are less toxic and more
effective. Also, in
contrast to protective treatments with exogenous biological growth factors,
the selective CDK4/6
inhibitors described herein are orally available small molecules, which can be
formulated for
administration via a number of different routes. When appropriate, the small
molecules can be
formulated for oral, topical, intranasal, inhalation, intravenous or any other
desired form of
administration.
A CDK4/6 inhibitor useful in the methods described herein is a selective
CDK4/6
inhibitor compound that selectively inhibit at least one of CDK4 and CDK6, or
whose
predominant mode of action is through inhibition of CDK4 and/or CDK6. In one
embodiment,
the selective CDK4/6 inhibitors have an IC50 for CDK4 as measured in a
CDK4/CycD1 IC50
phosphorylation assay that is at least 1500, 2000, 5000 or even 10,000 times
or greater lower
than the compound's IC50s for CDK2 as measured in a CDK2/CycE IC50
phosphorylation assay.
In one embodiment, the CDK4/6 inhibitors are at least about 10 times or
greater more potent
(i.e., have an 1050 in a CDK4/CycD1 phosphorylation assay that is at least 10
times or more
lower) than PD0332991.
The use of a selected CDK4/6 inhibitor as described herein can induce
selective G1 arrest
in CDK4/6-dependent cells (e.g., as measured in a cell-based in vitro assay).
In one
embodiment, the CDK4/6 inhibitor is capable of increasing the percentage of
CDK4/6-dependent
87
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
cells in the G1 phase, while decreasing the percentage of CDK4/6-dependent
cells in the G2/M
phase and S phase. In one embodiment, the selective CDK4/6 inhibitor induces
substantially
pure (i.e., "clean") GI cell cycle arrest in the CDK4/6-dependent cells (e.g.,
wherein treatment
with the selective CDK4/6 inhibitor induces cell cycle arrest such that the
majority of cells are
arrested in G1 as defined by standard methods (e.g. propidium iodide (PI)
staining or others)
with the population of cells in the G2/M and S phases combined being less than
about 30%,
about 25%, about 20%, about 15%, about 10%, about 5%, about 3% or less of the
total cell
population. Methods of assessing the cell phase of a population of cells are
known in the art
(see, for example, in U.S. Patent Application Publication No. 2002/0224522)
and include
cytometric analysis, microscopic analysis, gradient centrifugation,
elutriation, fluorescence
techniques including immunofluorescence, and combinations thereof. Cytometric
techniques
include exposing the cell to a labeling agent or stain, such as DNA-binding
dyes, e.g., PI, and
analyzing cellular DNA content by flow cytometry. Immunofluorescence
techniques include
detection of specific cell cycle indicators such as, for example, thymidine
analogs (e.g., 5-bromo-
2-deoxyuridine (BrdU) or an iododeoxyuridine), with fluorescent antibodies.
In some embodiments, the use of a selective CDK4/6 inhibitor described herein
result in
reduced or substantially free of off-target effects, particularly related to
inhibition of kinases
other than CDK4 and or CDK6 such as CDK2, as the selective CDK4/6 inhibitors
described
herein are poor inhibitors (e.g., >1 uM IC50) of CDK2. Furthermore, because of
the high
selectivity for CDK4/6, the use of the compounds described herein should not
induce cell cycle
arrest in CDK4/6-independent cells. In addition, because of the short
transient nature of the G1 -
arrest effect, the CDK4/6-replication dependent cells more quickly reenter the
cell-cycle than,
comparatively, use of PD0332991 provides, resulting in the reduced risk of, in
one embodiment,
hematological toxicity development during long term treatment regimens due to
the ability of
.. HSPCs to replicate between chemotherapeutic treatments.
In some embodiments, the use of a selective CDK4/6 inhibitor described herein
reduces
the risk of undesirable off-target effects including, but not limited to, long
term toxicity, anti-
oxidant effects, and estrogenic effects. Anti-oxidant effects can be
determined by standard
assays known in the art. For example, a compound with no significant anti-
oxidant effects is a
compound that does not significantly scavenge free-radicals, such as oxygen
radicals. The anti-
oxidant effects of a compound can be compared to a compound with known anti-
oxidant activity,
88
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
such as genistein. Thus, a compound with no significant anti-oxidant activity
can be one that has
less than about 2, 3, 5, 10, 30, or 100 fold anti-oxidant activity relative to
genistein. Estrogenic
activities can also be determined via known assays. For instance, a non-
estrogenic compound is
one that does not significantly bind and activate the estrogen receptor. A
compound that is
substantially free of estrogenic effects can be one that has less than about
2, 3, 5, 10, 20, or 100
fold estrogenic activity relative to a compound with estrogenic activity,
e.g., genistein.
Synthesis of Select CDK4/6 Inhibitors
CDK4/6 Inhibitors of the present invention can be synthesized by any means
known to
those of ordinary skill in the art, including for example, according to the
generalized Schemes of
1 through 9 below. Specific syntheses can be found in, for instance,
W02012/061156 (5-(4-
isopropylpiperazin-1-yOpyridine-2-amine and 5 -(4-morpho lino-l-
piperidyl)pyridine-2-amine
respectively). Formula I and Formula II can be synthesized according to Scheme
1 using the
corresponding substituted 2-aminopyrimidines or as described in W02012/061156.
89
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
OEt OEt
..1 (..,0Et
,,,,,,. OEt
N
QNHBocN.,7Igr
V. I
1\ 1Br H2N
pdoppf)cl2
:
CI,..I.N NNHBoc
___________________ ''.I.N I N).NHBoc
,õI.. ,11õ
CI N CI
H cui
N-PI--- TBAF 1 \ OEt AcoH/H20 Oxone >_
õ ir
CI N /...4% H
CIN /.....41iN OEt
\--.2
V...9NHBoc NHBoc
4) DCC/DMAP ..., N -'>
Pd2(dba)3/BINAP/tBuONa ,
..).k. I
,,..1k.. I
CI N /.....\AN OH TEA Cl N /_\____/N NH /¨\
¨N
\---Y
NHBoc \__, R-A N-0¨NH2
A = N or C
R'KM
Li
Scheme 1
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
OEt
OEt
N ,-----,,___NHBoc õ...--/Br õ,.....0Et
/ /
....,,,,Br I-12N NV- , N'' 1
________________________ )....., I NHBcc Pd(dppf)c12 õ..--
...õ.õõNHBoc
Ref - 1 CI N
C N'"--' ul CI N N
H
CI N CI H
Ref - 1
TBAF . .õ.---'-'''s (OEt AcOH/H20 1 Ozone
N
....1,.... ,..1,......
_______________________________ .
CINN., H Ref- 1
Ref - 1
CI N--- ¨N \I OEt Ref- 2
C
(
NHBoc NHBoc
0 0
r-r> ,, (cH3),scHN2 . TFA , y------1--$
0
C1.--lk-N/""M11 \
CI---1/4'N 1`1, OH Ref- 3 ,,) 0¨
C NHBoc Cl2k-s-N------N
C
NHBoc NH2
R,N,...õ,i
Toluene/reflux N --- , \ Pd2(dba)3/BINAP/I3u0Na
.....õLsõ. j....._ '
CI N N NH c /¨ _1,1)_ N NN H
R¨N N \ / NI-12
Ref- 1
0 ,N.õ,õõ.-1 _
R¨N\ r¨\N¨ H2 )¨NO, Pd/C /¨\ N
C1¨ ____ ¨NO2 .
R R¨N\ N \ i¨NH,
/ ¨C/
/ \ CN /
Ref-1
Ref-1
R,N,---..1
....... õ jõ...._ RI/NaH N--- 1 \ Pd2(dba)3/BINAPA3u0Na
CI N N \ ¨___/ NH CI ¨R7
N¨R 7
R¨N N NH2 ni /- \ __(=N)_
N N ¨N¨R7
\ /
Ref-1
Scheme 2
In Scheme 2 , Ref-1 is WO 2010/020675 Al; Ref-2 is White, J. D.; et al. J.
Org. Chem.
1995, 60, 3600; and Ref-3 Presser, A. and Hufner, A. Alonatshefte filr Chemie
2004, 135, 1015.
91
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
OTBDMS .....,õ....:.:;../''''. OTBDMS
N
_,./..--.." /
(CF3C0)20 N.'''. 0
N 1
,...õL ....L.,
.....1. ,..L., __ ..-
Pd(appf)C12 CI N N CF3
CI N NH2 Ref-1 CI N NH2 H
Cul
N õ...,........, IOTBS N ,...----N\ /0TBS TBAF
Pd(appf)Cl2 Bou20
I 2
.).;,.., )----,, .
õ...õ1:;%...
cu i CI N H " CI N------NBoc
0
N.2--.........--k .) /OH
Dess-Martin N õ42,,,....--- //0 Oxone
..
-`,-"
CI N NBoc CI N NBoc Ref-1 Cr-A11 NBoc OH
R2 R1
..,
---. .--"=-,. .---
HBTU/ (iP0 NI2EIN õ...),1---'n 0 TFA y$ ,(0 ---------
0 0
________________________________ .. __________________ .
-. ,-...
NH4OH
CI N \ N NH2 C1----1%-------N NH2 Ref-4
H
BOC
_ R,N,...Th
CI N N ...
___________________ = ll'.N.."--
NH)1\1.')
Rt¨)--- N N R2 1\1\ _NH
RiT
R2
1\1
0 ' 1 \ 0 I \l
r
1;--- 1 \ ______________________ (ph),p0H200H20H2si,,k ,,,.õ--"n
CsF/CH3CN.. ci.)%--"----R
CI-=".N---"N, H
KHMDS
c
c Ref-5
Ref-5 ¨Si¨
NHBoc
/ NHBoc
NHBoc
_ 0
.
\,,,..õ..NH
Scheme 3
In Scheme 3, Ref-1 is WO 2010/020675 Al; Ref-4 is WO 2005/040166 Al; and Ref-5
is
Schoenauer, K and Zbiral, E. Tetrahedron Letters 1983, 24, 573.
92
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
NHBoc NH2 NHBoc NHCbz H2N NHC bz
1) CBzCl/TEA TFA/DCM
__________________________ 1
2) Pd/C/H2
4),,,,,NHCbz N1,.....Br
Br H2N ,&=BrQ
,. 1) HBOAcOH N
CI N CI - 1 CI N ' ..):-...z. J-..., __ NHCbz
Ref N H 2) Boc20/2N NaOH CI,l N N
NHBoc
H
OEt
OEt
',/ OEt
TBAF
/)'N'OE t OEt
Pd(dppf)Cl2 CI
/- NV 1 ___________________ ...
[1,---- I \ ___________________________________________________ (
_.õ1N N
Ref - 1
QNHCbz
Cul H CI-'N"..----NyiEt
Ref - 1
c\---1
NHBoc
___________ D.
______________ ....
CI
________________ ...
c)
Scheme 4
In Scheme 4, Ref¨ 1 is WO 2010/020675 Al.
0
,JL
0 a IR
R
R2 CFPNCEU
KR2z
N-12biNZ 143
RI RI RI
(F11)3P BC 2 FtV01-123 R2
>
/K.VF " 14C1./R2 H2Nirc,,N-Bcc
Ri NNZN
R2
H2Az, N N __ a, N.Za
Ri
zR2 \ ,
0"1/NN7N/N __________________________ 13_,
Cl"(Na H
N^i/NV-N N
* JH
R
IR2
Scheme 5
93
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
I\V- 1 \ R5Z. ),---Br
µY N
......1-::_%... 2,----õ,," , _Ii.NH4 H2N Hy N
NR
CI N NR N N NR
Ri)----/ Ri--)-7
( Pd2(dba)3,
tBuONa
R2 R3 R4
R2 R3 R4 R2 R3 R4 tBuXPhos µZt¨i
R5
Scheme 6
NHCI,, NHC1<z,,
1) MeS02C1/ Hunig's Base N3 1) PPh3/THF NHBoc
R
2) NaN3/ DMS0 R 2) Boc20 R
3) Pd/C/H2
NHI)c,. NH NH13..,
OH
1) MeS02Cl/Hunig's Base N3 1) PPh3/THF NH2
_______________________________ ... ___________________ =
R
R R
Scheme 7
94
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
1-...
'9
/
\
f......5.7,,, .,......,Er
......õ. ...5; .....õ.¨,......õ.,
,---=---i---
......"....õ V:
.. \
C.", , -.44.- --sat: .
....õ ,-, ....."., ......, , ...,
tl' ')tr'''''''.%1 '11 Pditlba)s/ Tokiefzi
(PrOaAS cc 'N 11 .s."
Ft
.---..-1,
1.19ricts
MA' F.; T IV
,
/
/ 7 i
k
\
i
1 \ ...:.,.. _,
ws- `... - !irl.:::7".1--\.,:.>. /0 1.34Itsodoz..54imetroiydantoin 1
If ...,.. /
ocone C.,...--:zz-N.---' "^-14 0.........., Rap* a=-... 'Sr"' .-N),
,. Ow, \ .9Fltscut \ 1 WIR=tt \
..., 1) Ac0E1:114/
1)M:-. DMAPilliF 2) atone
::'.. T FA i
et f 9 ;µ
.
\---1 = ....,,, i;
I di y
......., _.,..t, .
.:.....,,,..õ4.,. ,.,,, ,...;.. 1
,.....,
I ,NFIftotz
\
/ ":1.4- N. .99 ,,, k m *I i
."--... .." 1) D1C, MAI:VW
f41,11.11t =.....,õ ti....õ-.:2'= ......,..--.., õS.' /
. \\\ õ.õ ji / 2) TER
L t , / " \ fr
,...,-- \-:,,,...-- --Ns. Nti
\/
Scheme 8
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
-,
'OM-0MS
_ .."3...PS .:".".
Br =;:::::-I ''.
(CF:r.GC*0
..
.. õ
Cr ''' µNH2 Ref-I Cr -N. NHZ H
Cul
AZ er
Prifdper)CL tr......7õõ,,z,,,, 1.1. TSUPS 1 ,,, pH A.1-.--
Ti ...,..,.., _6/ TRAF er-' `r,-. ,=:\ /
w=- j, 11 ______ >- - ...... 1 LI r 11, , ZZ
,....--,
2) Boc.20
H
a) AfIBIOH)2
At
Ar
OH
Dess-Martr;
Ac
, V -
11--.;,-='..r---k ..;,:) .....-...
1-811ii (1PrEIN 1 I Il \.> 4' 'TA
.. .,,, ,..f..õ..,
Cr ' N, N NH2 crjna-= ..-N NH2 Ref-
2
NI-40H 130C H
At'
0 1
- ______________________ Ir. =-=,,....- -... -,- .,.... -..:..õ
,.,....4
RI
A:
r I .........0 A;
,,...--, \
" "''.\ .P
N-7
i 11: -:..,-IIIPCH2OCH201-i2SIICHgs 1,,
1.! / .1 CeFiCR3CN
" ________________________ w Cr \ N' 'N
Cr-LkµN...11,). " KHMDS i
1 /
C Ref-3 \
NHaot C
NHIBec NliBut:
Ar
L 13 ht
---------t -y. Cr'' 'N'' , = r OH '---' 1.3-011ado-3,34ireethyl-
flAintion
\ Nii
,,,...
Scheme 9
In Scheme 9, Ref-1 is WO 2010/020675 Al; Ref-2 is WO 2005/040166 Al; and Ref-3
is
Schoenauer, K and Zbiral, E. Tetrahedron Letters 1983, 24, 573.
96
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Cl- -r\i-='"--"N NH Bac-anhydride, TEA
CH2Cl2 N NBoc
CI N CO2, Ni
catalyst
0
HOOC N NBoc thionyl chloride, CI NBoc
=
toluene
0
R¨A/--\N_(=N¨NH2 NBoc
0
TFA
A= N or C
RA ,J
I\V
NH
I 0
R-A
Scheme 10
In one embodiment a lactam intermediate is treated with BOC-anhydride in the
presence
of an organic base such as triethylamine in an organic solvent such as
dichloromethanc. The Boc
protected lactam is treated with carbon dioxide in the presence of a nickel
catalyst to generate a
carboxylic acid. The carboxylic acid is reacted with thionyl chloride in the
presence of an
organic solvent such as toluene. The resulting acid chloride is treated with
an amine to generate
an amide that can be deprotected with a strong acid such as trifluoroacetic
acid to generate the
final target inhibitor compound.
Alternatively, the lactam can be generated by reacting the carboxylic acid
with a
protected amine in the presence of a strong acid and a dehydrating agent,
which can be together
97
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
in one moiety as a strong acid anhydride. Examples of strong acid anhydrides
include, but are
not limited to, trifluoroacetic acid anhydride, tribromoacetic acid anhydride,
trichloroacetic acid
anhydride, or mixed anhydrides. The dehydrating agent can be a carbodiimide
based compound
such as but not limited to DCC (N,N-dicyclohcxylcarbodiimide), EDC (1-ethy1-3-
(3-
dimethylaminopropyl)carbodiimide or DIC (N,N-diisopropylcarbodiimide). An
additional step
may be necessary to take off the N-protecting group and the methodologies are
known to those
skilled in the art
Alternatively, the halogen moiety bonded to the pyrimidine ring can be
substituted with
any leaving group that can be displaced by a primary amine, for example to
create an
intermediate for a final product such as Br, I, F, SMe, SO2Me, SOalkyl,
SO2alkyl. See, for
Example, PCT /1J52013/037878 to Tavares.
Other amine intermediates and final amine compounds can be synthesized by
those
skilled in the art. It will be appreciated that the chemistry can employ
reagents that comprise
reactive functionalities that can be protected and de-protected and will be
known to those skilled
in the art at the time of the invention. See for example, Greene, T.W. and
Wuts, P.G.M.,
Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley and
Sons.
Formulas T, Q, GO and U were prepared above were characterized by mass
spectrometry
and NMR as shown below:
Formula T
7.25 (s, 1 H) 7.63 (br. s., 2 H) 7.94 (br. s., 1 H) 8.10 (br. s., 1 H) 8.39
(br. s., 1 H) 9.08 (br. s., 1
H) 11.59 (br. s., 1 H). LCMS ESI (M + H) 447.
Formula Q
1H NMR (600 MHz, DMSO-d6) 6 ppm 0.82 (d, J=7.32 Hz, 2 H) 1.08 - 1.37 (m, 3 H)
1.38 - 1.64
(m, 2 H) 1.71 (br. s., 1 H) 1.91 (br. s., 1 H) 2.80 (br. s., 1 H) 3.12 (s, 1
H) 3.41 (br. s., 4 H) 3.65
(br. s., 4 H) 4.09 (br. s., 1 H) 7.26 (s, 1 H) 7.52 - 7.74 (m, 2 H) 7.94 (br.
s., 1 H) 8.13 (br. s., 1 H)
8.40 (Ur. s., 1 H) 9.09 (br. s., 1 H) 9.62 (br. s., 1 H) 11.71 (br. s., 1 H).
LCMS ESI (M + ) 433
Formula GG
1H NMR (600 MHz, DMSO-d6) 6 ppm 0.85 (br. s., 1 H) 1.17 - 1.39 (m, 7 H) 1.42 -
1.58 (m, 2
H) 1.67 - 1.84 (m,3 H) 1.88 - 2.02 (m, 1 H) 2.76 - 2.93 (m, 1 H) 3.07 - 3.22
(m, 1 H) 3.29 - 3.39
98
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(m, 1 H) 3.41 - 3.61 (m, 4 H) 3.62 - 3.76 (m, 4 H) 3.78 - 3.88 (m, 1 H) 4.12
(br. s., 1H) 7.28 (s, 1
H) 7.60 - 7.76 (m, 2 H) 7.98 (s, 1 H) 8.13 (br. s., 1 H) 8.41 (s, 1 H) 9.10
(br. s., 1 H) 11.21 (br. s.,
1 H) 11.54 (s, 1 H). LCMS EST (M + H) 475
Formula U
1H NMR (600 MHz, DMSO-d6) 5 ppm 0.84 (t, J=7.61 Hz, 2 H) 1.13 - 1.39 (m, 4 H)
1.46 (d,
J=14.05 Hz, 2 H) 1.64 - 1.99 (m, 6 H) 2.21 (br. s., 1 H) 2.66 - 2.89 (m, 2 H)
3.06 (br. s., 1 H)
3.24 - 3.36 (m, 1 H) 3.37 - 3.50 (m, 2 H) 3.56 - 3.72 (m, 2 H) 3.77 - 4.00 (m,
4 H) 4.02 -4.19 (m,
2 H) 7.25 (s, 1 H) 7.50 - 7.75 (m, 2 H) 7.89 (d, J=2.93 Hz, 1 H) 8.14 (d,
J=7.32 Hz, 1 H) 8.38
(br. s., 1 H) 9.06 (s, 1 H) 11.53 (br. s., 1 H). LCMS ESI (M +H) 517
Active Compounds, Salts and Formulations
As used herein, the term "active compound" refers to the selective CDK 4/6
inhibitor
compounds described herein or a pharmaceutically acceptable salt or isotopic
analog thereof.
The active compound can be administered to the subject through any suitable
approach. The
.. amount and timing of active compound administered can, of course, be
dependent on the subject
being treated, on the dosage of chemotherapy to which the subject is
anticipated of being
exposed to, on the time course of the chemotherapeutic agent exposure, on the
manner of
administration, on the pharmacokinetic properties of the particular active
compound, and on the
judgment of the prescribing physician. Thus, because of subject to subject
variability, the
dosages given below are a guideline and the physician can titrate doses of the
compound to
achieve the treatment that the physician considers appropriate for the
subject. In considering the
degree of treatment desired, the physician can balance a variety of factors
such as age and weight
of the subject, presence of preexisting disease, as well as presence of other
diseases.
Pharmaceutical formulations can be prepared for any desired route of
administration including,
but not limited to, oral, intravenous, or aerosol administration, as discussed
in greater detail
below.
The therapeutically effective dosage of any active compound described herein
will be
determined by the health care practitioner depending on the condition, size
and age of the patient
as well as the route of delivery. In one non-limited embodiment, a dosage from
about 0.1 to
about 200 mg/kg has therapeutic efficacy, with all weights being calculated
based upon the
99
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
weight of the active compound, including the cases where a salt is employed.
In some
embodiments, the dosage can be the amount of compound needed to provide a
serum
concentration of the active compound of up to between about 1 and 5, 10, 20,
30, or 40 uM. In
some embodiments, a dosage from about 10 mg/kg to about 50 mg,/kg can be
employed for oral
administration. Typically, a dosage from about 0.5 mg/kg to 5 mg/kg can be
employed for
intramuscular injection. In some embodiments, dosages can be from about 1
umol/kg to about
50 jtmol/kg, or, optionally, between about 22 jtmol/kg and about 33 jtmol/kg
of the compound
for intravenous or oral administration. An oral dosage form can include any
appropriate amount
of active material, including for example from 5 mg to, 50, 100, 200, or 500
mg per tablet or
other solid dosage form.
In accordance with the presently disclosed methods, pharmaceutically active
compounds
as described herein can be administered orally as a solid or as a liquid, or
can be administered
intramuscularly, intravenously, or by inhalation as a solution, suspension, or
emulsion. In some
embodiments, the compounds or salts also can be administered by inhalation,
intravenously, or
intramuscularly as a liposomal suspension. When administered through
inhalation the active
compound or salt can be in the form of a plurality of solid particles or
droplets having any
desired particle size, and for example, from about 0.01, 0.1 or 0.5 to about
5, 10, 20 or more
microns, and optionally from about 1 to about 2 microns. Compounds as
disclosed in the present
invention have demonstrated good pharmacokinetic and pharmacodynamics
properties, for
instance when administered by the oral or intravenous routes.
In one embodiment of the invention, these improved CDK4/6 inhibitors can be
administered in a concerted regimen with a blood growth factor agent. As such,
in one
embodiment, the use of the compounds and methods described herein is combined
with the use
of hematopoietic growth factors including, but not limited to, granulocyte
colony stimulating
factor (G-CSF, for example, sold as Neupogen (filgrastin), Neulasta (peg-
filgrastin), or
lenograstin), granulocyte-macrophage colony stimulating factor (GM-CSF, for
example sold as
molgramostim and sargramostim (Leukine)), M-CSF (macrophage colony stimulating
factor),
thrombopoietin (megakaryocyte growth development factor (MGDF), for example
sold as
Romiplostim and Eltrombopag) interleukin (IL)-12, interleukin-3, interleukin-
11 (adipogenesis
inhibiting factor or oprelvekin), SCF (stem cell factor, steel factor, kit-
ligand, or KL) and
erythropoietin (EPO), and their derivatives (sold as for example epoetin-u as
Darbopoetin,
100
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Epocept, Nanokine, Epofit, Epogin, Eprex and Procrit; epoetin-I3 sold as for
example
NeoRecormon, Recormon and Micera), epoetin-delta (sold as for example Dynepo),
epoetin-
omega (sold as for example Epomax), epoetin zeta (sold as for example Silapo
and Reacrit) as
well as for example Epocept, EPOTrust, Erypro Safe, Repoeitin, Vintor, Epofit,
Erykine, Wepox,
Espogen, Relipoeitin, Shanpoietin, Zyrop and EPIAO).
The pharmaceutical formulations can comprise an active compound described
herein or a
pharmaceutically acceptable salt thereof, in any pharmaceutically acceptable
carrier. If a
solution is desired, water may be the carrier of choice for water-soluble
compounds or salts.
With respect to the water-soluble compounds or salts, an organic vehicle, such
as glycerol,
propylene glycol, polyethylene glycol, or mixtures thereof, can be suitable.
In the latter instance,
the organic vehicle can contain a substantial amount of water. The solution in
either instance can
then be sterilized in a suitable manner known to those in the art, and for
illustration by filtration
through a 0.22-micron filter. Subsequent to sterilization, the solution can be
dispensed into
appropriate receptacles, such as depyrogenated glass vials. The dispensing is
optionally done by
an aseptic method. Sterilized closures can then be placed on the vials and, if
desired, the vial
contents can be lyophilized.
In addition to the active compounds or their salts, the pharmaceutical
formulations can
contain other additives, such as pH-adjusting additives. In particular, useful
pH-adjusting agents
include acids, such as hydrochloric acid, bases or buffers, such as sodium
lactate, sodium acetate,
sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
Further, the
formulations can contain antimicrobial preservatives. Useful antimicrobial
preservatives include
methylparaben, propylparaben, and benzyl alcohol. An antimicrobial
preservative is typically
employed when the formulation is placed in a vial designed for multi-dose use.
The
pharmaceutical formulations described herein can be lyophilized using
techniques well known in
the art.
For oral administration a pharmaceutical composition can take the form of
solutions,
suspensions, tablets, pills, capsules, powders, and the like. Tablets
containing various excipients
such as sodium citrate, calcium carbonate and calcium phosphate may be
employed along with
various disintegrants such as starch (e.g., potato or tapioca starch) and
certain complex silicates,
together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin
and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl
sulfate, and talc are
101
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
often very useful for tableting purposes. Solid compositions of a similar type
may be employed
as fillers in soft and hard-filled gelatin capsules. Materials in this
connection also include lactose
or milk sugar as well as high molecular weight polyethylene glycols. When
aqueous suspensions
and/or elixirs are desired for oral administration, the compounds of the
presently disclosed
subject matter can be combined with various sweetening agents, flavoring
agents, coloring
agents, emulsifying agents and/or suspending agents, as well as such diluents
as water, ethanol,
propylene glycol, glycerin and various like combinations thereof.
In yet another embodiment of the subject matter described herein, there is
provided an
injectable, stable, sterile formulation comprising an active compound as
described herein, or a
salt thereof, in a unit dosage form in a sealed container. The compound or
salt is provided in the
form of a lyophilizate, which is capable of being reconstituted with a
suitable pharmaceutically
acceptable carrier to form a liquid formulation suitable for injection thereof
into a subject. When
the compound or salt is substantially water-insoluble, a sufficient amount of
emulsifying agent,
which is physiologically acceptable, can be employed in sufficient quantity to
emulsify the
compound or salt in an aqueous carrier. Particularly useful emulsifying agents
include
phosphatidyl cholines and lecithin.
Additional embodiments provided herein include liposomal formulations of the
active
compounds disclosed herein. The technology for forming liposomal suspensions
is well known
in the art. When the compound is an aqueous-soluble salt, using conventional
liposome
technology, the same can be incorporated into lipid vesicles. In such an
instance, due to the
water solubility of the active compound, the active compound can be
substantially entrained
within the hydrophilic center or core of the liposomes. The lipid layer
employed can be of any
conventional composition and can either contain cholesterol or can be
cholesterol-free. When
the active compound of interest is water-insoluble, again employing
conventional liposome
formation technology, the salt can be substantially entrained within the
hydrophobic lipid bilayer
that forms the structure of the liposome. In either instance, the liposomes
that are produced can
be reduced in size, as through the use of standard sonication and
homogenization techniques.
The liposomal formulations comprising the active compounds disclosed herein
can be
lyophilized to produce a lyophilizate, which can be reconstituted with a
pharmaceutically
acceptable carrier, such as water, to regenerate a liposomal suspension.
102
Pharmaceutical formulations also are provided which are suitable for
administration as an
aerosol by inhalation. These formulations comprise a solution or suspension of
a desired
compound described herein or a salt thereof, or a plurality of solid particles
of the compound or
salt. The desired formulation can be placed in a small chamber and nebulized.
Nebulization can
be accomplished by compressed air or by ultrasonic energy to form a plurality
of liquid droplets
or solid particles comprising the compounds or salts. The liquid droplets or
solid particles may
for example have a particle size in the range of about 0.5 to about 10
microns, and optionally
from about 0.5 to about 5 microns. The solid particles can be obtained by
processing the solid
compound or a salt thereof, in any appropriate manner known in the art, such
as by
micronization. Optionally, the size of the solid particles or droplets can be
from about 1 to about
2 microns. In this respect, commercial nebulizers are available to achieve
this purpose. The
compounds can be administered via an aerosol suspension of respirable
particles in a manner set
forth in U.S. Pat. No. 5,628,984.
When the pharmaceutical formulation suitable for administration as an aerosol
is in the
form of a liquid, the formulation can comprise a water-soluble active compound
in a carrier that
comprises water. A surfactant can be present, which lowers the surface tension
of the
formulation sufficiently to result in the formation of droplets within the
desired size range when
subjected to nebulization.
The term "pharmaceutically acceptable salts" as used herein refers to those
salts which
are, within the scope of sound medical judgment, suitable for use in contact
with subjects (e.g.,
human subjects) without undue toxicity, irritation, allergic response, and the
like, commensurate
with a reasonable benefit/risk ratio, and effective for their intended use, as
well as the
zwitterionic forms, where possible, of the compounds of the presently
disclosed subject matter.
Thus, the term "salts" refers to the relatively non-toxic, inorganic and
organic acid
addition salts of compounds of the presently disclosed subject matter. These
salts can be
prepared in situ during the final isolation and purification of the compounds
or by separately
reacting the purified compound in its free base form with a suitable organic
or inorganic acid and
isolating the salt thus formed. Pharmaceutically acceptable base addition
salts may be formed
with metals or amines, such as alkali and alkaline earth metal hydroxides, or
of organic amines.
Examples of metals used as cations, include, but are not limited to, sodium,
potassium,
103
Date Recue/Date Received 2021-06-02
magnesium, calcium, and the like. Examples of suitable amines include, but are
not limited to,
N,I=11-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine,
ethylenediamine, N-
methylglucamine, and procaine.
Salts can be prepared from inorganic acids sulfate, pyrosulfate, bisulfate,
sulfite, bisulfite,
nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate,
pyrophosphate, chloride, bromide, iodide such as hydrochloric, nitric,
phosphoric, sulfuric,
hydrobromic, hydriodic, phosphorus, and the like.
Representative salts include the
hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate,
valerate, oleate,
palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate,
citrate, maleate,
fumaratc, succinate, tartrate, naphthylate mesylate, glucoheptonate,
lactobionate,
laurylsulphonate and isethionate salts, and the like. Salts can also be
prepared from organic
acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted
alkanoic acids, hydroxy
alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic
sulfonic acids, etc. and
the like. Representative salts include acetate, propionate, caprylate,
isobutyrate, oxalate,
malonate, succinatc, suberate, sebacate, fumarate, maleate, mandelate,
benzoate, chlorobenzoate,
methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate,
toluenesulfonate, phenylacetate,
citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
Pharmaceutically acceptable
salts can include cations based on the alkali and alkaline earth metals, such
as sodium, lithium,
potassium, calcium, magnesium and the like, as well as non-toxic ammonium,
quaternary
ammonium, and amine cations including, but not limited to, ammonium,
tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine,
ethylamine,
and the like. Also contemplated are the salts of amino acids such as arginate,
gluconate,
galacturonatc, and the like. See, for example, Berge et al., J. Pharni. Sci.,
1977, 66, 1-19.
EXAMPLES
Intermediates B, E, K, L, 1A, IF and 1CA were synthesized according to US
8,598,186
entitled CDK Inhibitors to Tavares, F.X. and Strum, J.C..
The patents WO 2013/148748 entitled Lactam Kinase Inhibitors to Tavares, F.X.,
WO
2013/163239 entitled Synthesis of Lactams to Tavares, F.X., and US 8,598,186
entitled CDK
Inhibitors to Tavares, F.X. and Strum, J.C.
104
Date Recue/Date Received 2021-06-02
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 1
Synthesis of tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-
4y1)aminoiethyl]carbamate,
Compound 1
N
CI
NN
0
To a solution of 5-bromo-2,4-dichloropyrimidine (3.2 g, 0.0135 mol) in ethanol
(80 mL)
was added Hunig's base (3.0 mL) followed by the addition of a solution of N-
(tert-
butoxycarbony1)-1,2-diaminoethanc (2.5 g, 0.0156 mole) in ethanol (20 mL). The
contents were
stirred overnight for 20 hrs. The solvent was evaporated under vacuum. Ethyl
acetate (200 mL)
and water (100 mL) were added and the layers separated. The organic layer was
dried with
magnesium sulfate and then concentrated under vacuum. Column chromatography on
silica gel
using hexane/ethyl acetate (0- 60%) afforded tert-butyl N42-[(5-bromo-2-chloro-
pyrimidin-4-
y0amino]ethyl]carbamate. 1FINMR (d6-DMS0) 6 ppm 8.21 (s, 1H), 7.62 (brs, 1H),
7.27 (brs,
1H), 3.39 (m, 2H), 3.12 (m, 2H), 1.34 (s, 9H). LCMS (ESI) 351 (M + H).
Example 2
Synthesis of tert-butyl N-[2-R2-ehloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl] amino] ethyl] carbamate, Compound 2
N
CI
0
To tert-butyl N-[2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]ethyl]carbamate
(1.265 g,
3.6 mmol) in THF (10 mL) was added the acctal (0.778 mL, 5.43 mmol),
Pd(dppf)CH2C12 (148
mg), and triethylamine (0.757 mL, 5.43 mmol). The contents were degassed and
then purged
105
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
with nitrogen. To this was then added Cul (29 mg). The reaction mixture was
heated at reflux
for 48 hrs. After cooling, the contents were filtered over CELITEI vi and
concentrated. Column
chromatography of the resulting residue using hexane/ethyl acetate (0- 30%)
afforded tert-butyl
N- [2- [ [2-chloro-5 -(3 ,3-diethoxyprop-1-ynyl)pyrimidin-4-yl] amino] ethyl]
carbamate. IHNMR
(d6-DMS0) .6 ppm 8.18 (s, 1H), 7.63 (brs, 1H), 7.40 (brs, 1H), 5.55 (s, 1H),
3.70 (m, 2H), 3.60
(m, 2H), 3.42 (m, 2H), 3.15 (m, 2H), 1.19 ¨ 1.16 (m, 15H). LCMS (ESI) 399 (M +
H).
Example 3
Synthesis of tert-butyl N-P-I2-chloro-6-(diethoxymethyppyrrolo[2,3-d]pyrimidin-
7-
1 0 yl] ethyl] carbamate, Compound 3
N \
CI 0
CN 0
To a solution of the coupled product (2.1 g, 0.00526 mole) in THF (30 mL) was
added
TBAF solid (7.0 g). The contents were heated to and maintained at 65 degrees
for 2 hrs.
Concentration followed by column chromatography using ethyl acetate/hexane (0-
50%) afforded
tert-butyl N- [2- [2-chloro-6-(diethoxymethyl)pyrrolo [2,3-d] pyrimidin-7-yl]
ethyl] carbamate as a
pale brown liquid (1.1 g). iHNMR (d6-DMS0) ö ppm 8.88 (s, 1H), 6.95 (brs, 1H),
6.69 (s, 1H),
5.79 (s, 1H), 4.29 (m, 2H), 3.59 (m, 4H), 3.34 (m, 1H), 3.18 (m, 1H), 1.19 (m,
9H), 1.17 (m,
6H). LCMS (ESI) 399 (M + H).
106
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 4
Synthesis of tert-butyl N42-(2-chloro-6-formyl-pyrrolo[2,3-d]pyrimidin-7-
ypethylkarbamate, Compound 4
N
\
CI N0
0
To the acetal (900 mg) from the preceeding step was added AcOH (8.0 mL) and
water
(1.0 mL). The reaction was stirred at room temperature for 16 hrs. Conc. and
column
chromatography over silica gel using ethyl acetatc/hexanes (0- 60%) afforded
tert-butyl N-[2-(2-
chloro-6-formyl-pyrrolo[2,3-d]pyrimidin-7-yl)ethyl]carbamate as a foam (0.510
g). iHNMR
(d6-DMS0) 6 ppm 9.98 (s, 1H), 9.18 (s, 1H), 7.66 (s, 1H), 6.80 (brs, 1H), 4.52
(m, 2H), 4.36 (m,
2H), 1.14 (s, 9H). LCMS (EST) 325 + H).
Example 5
Synthesis of 7[2-(tert-butoxycarbonylamino)ethyl]-2-chloro-pyrrolo [2,3-d]
pyrimidine-6-
carboxylic acid, Compound 5
N
\ OH
0
CI N
To the aldehyde (0.940 g) from the preceeding step in DMF (4 mL) was added
oxone
(1.95 g, 1.1 eq). The contents were stirred at room temp for 7 hrs. Silica gel
column
chromatography using hexane/ethyl acetate (0- 100%) afforded 742-(tert-
butoxycarbonylamino)ethy1]-2-chloro-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid
(0.545 g).
107
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
IFINMR (d6-DMS0) 6 ppm 9.11 (s, 1H), 7.39 (s, 1H), 4.38 (m, 2H), 4.15 (m, 2H),
1.48 (m, 9H).
LCMS (ESI) 341(M + H).
Example 6
.. Synthesis of methyl 742-(tert-butoxycarbonylamino)ethy1]-2-chloro-
pyrrolo12,3-
d]pyrimidine-6-carboxylate, Compound 6
o
CI N
\
N 0
0
To a solution of 2-chloro-7-propyl-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid
(0.545 g,
0.00156 mole) from the preceeding step in toluene (3.5 mL) and Me0H (1 mL) was
added TMS-
diazomethane (1.2 mL). After stirring overnight at room temperature, the
excess of TMS-
diazomethane was quenched with acetic acid (3 mL) and the reaction was
concentrated under
vacuum. The residue was purified by silica gel column chromatography with
hexane/ethyl
acetate (0- 70%) to afford methyl 742-(tert-butoxycarbonylamino)ethy1]-2-
chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylate as an off white solid (0.52 g). 1FINMR (d6-DMS0) 6
ppm 9.10 (s,
.. 1H), 7.45 (s, 1H), 6.81 (brs, 1H) 4.60 (m, 2H), 3.91 (s, 3H), 3.29 (m, 2H),
1.18 (m, 9H) LCMS
(ESI) 355 (M + H).
Example 7
Synthesis of Chloro tricyclic amide, Compound 7
0
N
C I
To methyl 7-[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylate (0.50 g, 0.0014 mole) from the preceeding step in dichloromethane
(2.0 mL) was
108
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
added TFA (0.830 mL). The contents were stirred at room temperature for 1 hr.
Concentration
under vacuum afforded the crude amino ester which was suspended in toluene (5
mL) and
Hunig's base (0.5 mL). The contents were heated at reflux for 2 hrs.
Concentration followed by
silica gel column chromatography using hexane/ethyl acetate (0- 50%) afforded
the desired
chloro tricyclic amide (0.260 g). ifINMR (d6-DMS0) 6 ppm 9.08 (s, 1H), 8.48
(brs, 1H), 7.21
(s, 1H) 4.33 (m, 2H), 3.64 (m, 2H). LCMS (EST) 223 (M + H).
Example 8
Synthesis of chloro-N-methyltricyclic amide, Compound 8
0
N
CI N-
1 0
To a solution of the chloro tricycliclactam, Compound 7, (185 mg, 0.00083
mole) in
DMF (2.0 mL) was added sodium hydride (55% dispersion in oil, 52 mg). After
stirring for 15
mins, methyl iodide (62 ttL, 1.2 eq). The contents were stirred at room
temperature for 30 mins.
After the addition of methanol (5 mL), sat NaHCO3 was added followed by the
addition of ethyl
acetate. Separation of the organic layer followed by drying with magnesium
sulfate and
concentration under vacuum afforded the N-methylated amide in quantitative
yield. 11INMR
(d6-DMS0) 6 ppm 9.05 (s, 1H), 7.17 (s, 1H) 4.38 (m, 2H), 3.80 (m, 2H), 3.05
(s, 3H). LCMS
(ESI) 237 (M + H).
Example 9
Synthesis of 1-methyl-4-(6-nitro-3-pyridyl)piperazine, Compound 9
-N NO2
To 5-bromo-2-nitropyridine (4.93 g, 24.3 mmole) in DMF (20 mL) was added N-
methylpiperazine (2.96 g, 1.1 eq) followed by the addition of DIPEA (4.65 mL,
26.7 mmole).
The contents were heated at 90 degrees for 24 hrs. After addition of ethyl
acetate (200 mL),
water (100 mL) was added and the layers separated. Drying followed by
concentration afforded
109
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
the crude product which was purified by silica gel column chromatography using
(0-10%)
DCM/Methanol. IHNMR (d6-DMS0) 6 ppm 8.26 (s, 1H), 8.15 (1H, d, J = 9.3 Hz),
7.49 (1H, d,
J = 9.4 Hz), 3.50 (m, 4H), 2.49 (m, 4H), 2.22 (s, 3H).
Example 10
Synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine, Compound 10
N NH2
-
To 1-methyl-4-(6-nitro-3-pyridyl)piperazine (3.4 g) in ethyl acetate (100 mL)
and ethanol
(100 mL) was added 10% Pd/C (400 mg) and then the reaction was stirred under
hydrogen (10
psi) overnight. After filtration through CELITETm, the solvents were
evaporated and the crude
product was purified by silica gel column chromatography using DCM/ 7N ammonia
in Me0H
(0- 5%) to afford 5-(4-methylpiperazin-1-yl)pyridin-2-amine (2.2 g).
(d6-DMS0) 6
ppm 7.56 (1H, d, J = 3 Hz), 7.13 (1H, m), 6.36 (1H, d, J = 8.8 Hz), 5.33 (brs,
2H), 2.88 (m, 4H),
2.47 (m, 4H), 2.16 (s, 3H).
Example 11
Synthesis of tert-butyl 4-(6-amino-3-pyridyl)piperazine-1-carboxylate,
Compound 11
>o
NH2
This compound was prepared as described in WO 2010/020675 Al.
110
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 12
Synthesis of tert-butyl N-[2-(benzyloxycarbonylamino)-3-methyl-butyll
carbamate,
Compound 12
0\
0
0
To benzyl N[1-(hydroxymethyl)-2-methyl-propylicarbamate (11.0 g, 0.0464 mole)
in
dioxane (100 mL) cooled to 0 C was added diphenylphosphoryl azide (10.99 mL,
1.1 eq)
followed by the addition of DBU (8.32 mL, 1.2 eq). The contents were allowed
to warm to room
temperature and stirred for 16 hrs. After the addition of ethyl acetate (300
mL) and water (100
mL), the organic layer was separated and washed with satd. NaHCO3 (100 mL).
The organic
layer was then dried (magnesium sulfate) and concentrated under vacuum. To
this intermediate
in DMSO (100 mL) was added sodium azide (7.54 g) and the contents then heated
to 90 degrees
for 2 hrs. After addition of ethyl acetate and water the layers were
separated. The organic layer
was dried with magnesium sulfate followed by concentration under vacuum to
afford an oil that
was purified by silica gel column chromatography using hexane/ethyl acetate (0-
70 A) to afford
benzyl N-[1-(azidomethyl)-2-methyl-propyl] carbamate 6.9 g as a colorless oil.
To benzyl NEl-(azidomethyl)-2-methyl-propyl] carbamate (6.9 g, 0.0263 mole) in
THF
(100 mL) was added triphenyl phosphine (7.59 g, 1.1 eq). The contents were
stirred for 20 hrs.
After addition of water (10 mL), and stirring for an additional 6 hrs, ethyl
acetate was added and
the layers separated. After drying with magnesium sulfate and concentration
under vacuum, the
crude product was purified by silica gel column chromatography using DCM/Me0H
(0 ¨ 10%)
to afford benzyl N41-(aminomethyl)-2-methyl-propyll carbamate as a yellow oil.
To benzyl N[1-(aminomethyl)-2-methyl-propyl] carbamate (4.65 g, 0.019 mole) in
THF
(70 mL) was added 2N NaOH (20 mL) followed by the addition of di-tert-butyl
dicarbonate
(5.15 g, 1.2 eq). After stirring for 16 hrs, ethyl acetate was added and the
layers separated. After
drying with magnesium sulfate and concentration under vacuum, the crude
product was purified
using hexane/ethyl acetate (0- 40%) over a silica gel column to afford
intermediate A, tert-butyl
N42-(benzyloxycarbonylamino)-3-methyl-butyl] carbamate, (6.1 g). iHNMR (600
MHz,
111
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CHLOROFORM-d) 6 ppm 0.89 (d, J=6.73 Hz, 3 H) 0.92 (d, J=6.73 Hz, 3 H) 1.38 (s,
9 H) 1.70 -
1.81 (m, 1 H) 3.18 (d, J=5.56 Hz, 2 H) 3.47 - 3.60 (m, 1 H) 4.76 (s, 1 H) 4.89
(d, J=7.90 Hz, 1
H) 5.07 (s, 2 H) 7.25 - 7.36 (m, 5 H). LCMS (ESI) 337 (M + H).
Example 13
Synthesis of tert-butyl N-[2-(benzyloxycarbonylamino)-4-methyl-pentyl]
carbamate,
Compound 13
0
0
>--NH HN
600
To a solution of benzyl N41-(hydroxymethyl)-3-methyl-butyl]carbamate (6.3 g,
0.025
mole) in DCM (100 mL) was added diisopropylethyl amine (5.25 mL, 1.2 eq)
followed by the
addition of methane sulfonylchloride (2.13 mL, 1.1 eq) at 0 degrees. After
stirring for 3 hrs,
water (100 mL) was added and the organic layer separated. After drying with
magnesium sulfate
and concentration under vacuum, the crude [2-(benzyloxycarbonylamino)-4-methyl-
pentyl]
methanesulfonate which was taken directly to the next step.
To the crude [2-(benzyloxycarbonylamino)-4-methyl-pentyl] methanesulfonate
from the
above reaction in DMF (50 mL), was added sodium azide 2.43 g. The reaction
mixture was then
heated to 85 degrees for 3 hrs. After cooling, ethyl acetate (300 mL) and
water was added. The
organic layer was separated, dried with magnesium sulfate and then
concentrated under vacuum
to afford the crude benzyl N41-(azidomethyl)-3-methyl-butyl] carbamate. To
this crude
intermediate was added THF (100 ml.) followed by triphenylphosphine 7.21 g and
stirred under
nitrogen for 16 hrs. After addition of water (10 mL), and stirring for an
additional 6 hrs, ethyl
acetate was added and the layers separated. After drying with magnesium
sulfate and
concentration under vacuum, the crude product was columned using DCM/Me0H (0 ¨
10%) to
afford benzyl N-[1-(aminomethyl)-3-methyl-butyl] carbamate (4.5 g).
To benzyl N-[1-(aminomethyl)-3-methyl-butyl] carbamate (4.5 g, 0.018 mole) in
THF
(60 mL) was added 2N NaOH (18 mL) followed by the addition of di-tert-butyl
dicarbonate
112
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(4.19 g, 1.07 eq). After stirring for 16 hrs, ethyl acetate was added and the
layers separated.
After drying with magnesium sulfate and concentration under vacuum, the crude
product was
taken to the next step. 1FINMR (600 MHz, CHLOROFORM-d) ppm 0.89 (d, J=6.73 Hz,
6 H)
1.25 - 1.34 (m, 1 H) 1.39 (s, 9 H) 1.57 - 1.71 (m, 2 H) 3.04 - 3.26 (m, 2 H)
3.68 - 3.80 (m, 1 H)
4.72 - 4.89 (m, 2 H) 5.06 (s, 2 H) 7.25 - 7.38 (m, 5 H). LCMS (ES1) 351 (M +
H).
Example 14
Synthesis of tert-butyl N-[(2R)-2-(benzyloxycarbonylamino)-3-methyl-butyl]
carbamate,
Compound 14
HN
0
Compound 14 was synthesized from benzyl N-[(1R)-1-(hydroxymethyl)-2-methyl-
propyl] carbamate using similar synthetic steps as that described for Compound
13. The
analytical data (NMR and mass spec) was consistent with that for Compound 12.
Example 15
Synthesis of tert-butyl N-[(2S)-2-(benzyloxycarbonylamino)-3-methyl-
butyllcarbamate,
Compund 15
o
0
0
Compound 15 was synthesized from benzyl N-R1S)-1-(hydroxymethyl)-2-methyl-
propyl] carbamate using similar synthetic steps as that described for Compound
13. The
analytical data (NMR and mass spec) was consistent with that for Compound 12.
113
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 16
Synthesis of tert-butyl N-[(1S)-1-(aminomethyl)-2-methyl-propylicarbamate,
Compound 16
\(
0
H2N
HN 0
To a solution of tert-butyl N-[(1S)-1-(hydroxymethyl)-2-methyl-
propyl]carbamate
carbamate (6.3 g, 0.025 mole) in THF (100 mL) was added diisopropylethyl amine
(5.25 mL, 1.2
eq) followed by the addition of methane sulfonylchloride (2.13 mL, 1.1 eq) at
0 degrees. After
stiffing for 3 hrs, water (100 mL) was added and the organic layer separated.
After drying with
magnesium sulfate and concentration under vacuum, the crude [(2S)-2-(tert-
butoxycarbonylamino)-3-methyl-butyl] methanesulfonate was taken directly to
the next step.
To the crude [(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butyl]
methanesulfonate from
the above reaction in DMSO (50 mL), was added sodium azide (2.43 g). The
reaction mixture
was then heated to 85 degrees for 3 hrs. After cooling, ethyl acetate (300 mL)
and water were
added. The organic layer was separated, dried with magnesium sulfate and then
concentrated
under vacuum to afford the crude benzyl N41-(azidomethyl)-3-methyl-butyl]
carbamate. To this
crude intermediate was added THF (100 mL) followed by triphenylphosphine (7.21
g) and the
reation was stirred under nitrogen for 16 hrs. After addition of water (10
mL), and stirring for an
additional 6 hrs, ethyl acetate was added and the layers separated. After
drying with magnesium
sulfate and concentration under vacuum, the crude product was purified by
silica gel column
chromatography using DCM/Me0H (0 ¨ 10%) to afford benzyl N41-(aminomethyl)-3-
methyl-
butyl] carbamate (4.5 g). LCMS (ESI) 203 (M + H).
114
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 17
Synthesis of tert-butyl N-[(1R)-1-(aminomethyl)-2-methyl-propylicarbamate,
Compound 17
0
HN
0
Compound 17 was synthesized from tert-butyl N-[(1R)-1-(hydroxymethyl)-2-methyl-
propyl] carbamate using a similar synthetic sequence as described for Compound
16. The
analytical data (NMR and mass spec) was consistent with Compound 16.
Example 18
Synthesis of tert-butyl N-[(2S)-2-(benzyloxycarbonylamino)-4-methyl-pentyl]
carbamate,
Compound 18
NHHN
0
Compound 18 was synthesized from benzyl N-[(1S)-1-(hydroxymethyl)-3-methyl-
butylicarbamate using a similar synthetic sequence as described for Compound
13. The
analytical data (NMR and mass spec) was consistent with Compound 13.
115
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 19
Synthesis of tert-butyl N-R25)-2-(benzyloxycarbonylamino)-2-phenyl-ethyl]
carbamate,
Compound 19
0
0
Compound 19 was synthesized from benzyl N-[(1S)-2-hydroxy-1-phenyl-ethyl]
carbamate using a similar synthetic sequence as described for Compound 13.
1FINMR (600
MHz, DMSO-d6) 6 ppm 1.20- 1.33 (m, 9 H) 3.11 (t, J=6.29 Hz, 2 H) 4.59 -4.68
(m, 1 H) 4.88 -
5.01 (m, 2 H) 6.81 (t, J=5.42 Hz, 1 H) 7.14 - 7.35 (m, 10 H) 7.69 (d, J=8.49
Hz, 1 H). LCMS
(ESI) 371 (M + H).
Example 20
Synthesis of tert-butyl N-[(2S)-2-(benzyloxycarbonylamino)-3-methyl-pentyl]
carbamate,
Compound 20
o
0
Compound 20 was synthesized from benzyl N-[(1S)-1-(hydroxymethy0-2-methyl-
butyl]
carbamate using a similar synthetic sequence as described for Compound 13.
1FINMR (600
MHz, CHLOROFORM-d) 6 ppm 0.85 - 0.92 (m, 6 H) 1.05 - 1.15 (m, 1 H) 1.35 - 1.41
(m, 9 H)
1.45 - 1.56 (m, 2 H) 3.14 - 3.24 (m, 2 H) 3.54 - 3.64 (m, 1 H) 4.78 (s, 1 H)
4.96 (d, J=7.91 Hz, 1
H) 5.06 (s, 2 H) 7.27 - 7.37 (m, 5 H). LCMS (ESI) 351 (M + H).
116
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 21
Synthesis of tert-butyl N-R25)-2-(benzyloxycarbonylamino)-3,3-dimethyl-butyll
carbamate,
Compound 21
07(
0
0
Compound 21 was synthesized from benzyl N-[(1S)-1-(hydroxymethyl)-2,2-dimethyl-
propyl]carbamate using a similar synthetic sequence as described for Compound
13. LCMS
(ESI) 351.
Example 22
Synthesis of tert-butyl N-[[1-(benzyloxycarbonylamino)cyclohexyl]methyl]
carbamate,
Compound 22
0
0 a j
To a solution of benzyl N-[1-(aminomethyl)cyclohexyl]carbamate (10.0 g, 0.0381
mole)
in THF (150 mL) was added di-tert-butyl dicarbonatc (9.15 g, 1.1 cq) and the
contents were
stirred at room temperature for 16 hrs. Ethyl acetate and water were then
added. The organic
layer was separated, dried over magnesium sulfate and then concentrated under
vacuum to afford
tert-butyl N- [ [1-(benzyloxycarbonyl amino)cycl oh exyl ]methyl] carbamate
(13.1 g). iHNMR
(600 MHz, DMSO-d6) 6 ppm 0.92 - 1.54 (m, 17 H) 1.76 - 2.06 (m, 2 H) 3.09 (d,
J=6.15 Hz, 2 H)
4.92 (s, 2 H) 6.63 (d, J=17.27 Hz, 1 H) 7.16 - 7.49 (m, 6 H). LCMS (ESI) 363
(M + H).
117
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 23
Synthesis of tert-butyl N-D-(benzyloxycarbonylamino)cyclopentyl]methyl]
carbamate,
Compound 23
>NHHN
0
tert-butyl N-[[1-(benzyloxycarbonylamino)cyclopentyl]methylicarbamate was
synthesized in an analogous manner to tert-butyl N-[[1-
(benzyloxycarbonylamino)
cyclohexyl]methyl] carbamate. LCMS (ESI) 349 (M + H).
Example 24
Synthesis of 2-nitro-544-(1-piperidy1)-1-piperidyl]pyridine, Compound 24
( ( No2
To 5-bromo-2-nitropyridine (1.2 g, 5.9 mmol) in DMSO (4 mL) was added 1-(4-
piperidyl)piperidine (1.0 g, 5.9 mmole ) and triethylamine (0.99 mL, 7.1
mmole). The contents
were heated to 120 C in a CEM Discovery microwave system for 3 hours. The
crude reaction
was then purified by silica gel column chromatography with DCM/methanol (0-20%
) to afford
2-nitro-544-(1-piperidy1)-1-piperidyl]pyridine as an oil (457 mg). 1FINMR (600
MHz, DMSO-
d6) 6 ppm 1.26- 1.36 (m, 2 H) 1.43 (m, 6 H) 1.76 (m, 2 H) 2.37 (m, 5 H) 2.94
(t, J=12.74 Hz, 2
H) 4.06 (d, J=13.47 Hz, 2 H) 7.41 (dd, J=9.37, 2.64 Hz, 1 H) 8.08 (d, J=9.37
Hz, 1 H) 8.20 (d,
1=2.64 Hz, 1 H).
118
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 25
Synthesis of 544-(1-piperidy1)-1-piperidyl]pyridin-2-amine, Compound 25
( ( NH2
544-(1-piperidy1)-1-piperidyllpyridin-2-amine was prepared in a manner similar
to that
used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine. 1FINMR
(600 MHz, DMSO-
d6) 6 ppm 1.13 - 1.37 (m, 6 H) 1.40- 1.63 (m, 6 H) 1.71 (m, 2 H), 2.24 (m, 1H)
2.43 (m, 2 H)
3.33 (d, J=12.30 Hz, 2 H) 5.31 (s, 2 H) 6.33 (d, J=8.78 Hz, 1 H) 7.10 (dd,
J=8.78, 2.93 Hz, 1 H)
7.55 (d, J=2.64 Hz, 1 H). LCMS (ESI) 261 (M + H).
Example 26
Synthesis of 441-(6-nitro-3-pyridy1)-4-piperidyl] morpholine, Compound 26
( \//NO2
\ __
441-(6-nitro-3-pyridy1)-4-piperidyllmorpholine was synthesized in a manner
similar to
that used in the synthesis of 2-nitro-544-(1-piperidy1)-1-piperidyllpyridine.
1HNMR (600 MHz,
DMSO-d6) 6 ppm 1.41 (m, 2 H) 1.82 (m, 2 H) 2.42 (m, 5 H) 2.98 (t, J=12.44 Hz,
2 H) 3.52 (s, 4
H) 4.04 (d, J=12.88 Hz, 2 H) 7.42 (d, J=9.37 Hz, 1 H) 8.08 (d, J=9.08 Hz, 1 H)
8.21 (s, 1 H).
Example 27
Synthesis of 5-(4-morpholino-1-piperidyl) pyridin-2-amine, Compound 27
0/ \ __________ ( NH2
\ ____
119
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
5-(4-morpholino-1-piperidyl)pyridin-2-amine was prepared in a manner similar
to that
used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine. 1HNMR (600
MHz,
DMSO-d6) ppm 1.34 - 1.52 (m, 2 H) 1.78 (m, 2 H) 2.14 (m, 1 H) 2.43 (m, 4 H)
3.32 (d,
J=12.30 Hz, 4 H) 3.47 - 3.59 (m, 4 H) 5.32 (s, 2 H) 6.34 (d, J=8.78 Hz, 1 H)
7.11 (dd, J=8.93,
2.78 Hz, 1 H) 7.47 - 7.62 (m, 1 H). LCMS (ESI) 263 (M + H).
Example 28
Synthesis of 441-(6-nitro-3-pyridy1)-4-piperidyl] thiomorpholine, Compound 28
( _________________________________ No2
__ \
441-(6-nitro-3-pyridy1)-4-piperidyl] thiomorpholine was synthesized in a
manner similar
to that used in the synthesis of 2-nitro-5-[4-(1-piperidy1)-1-
piperidyl]pyridine. 1HNMR (600
MHz, DMSO-d6) 6 ppm 1.40 - 1.52 (m, 2 H) 1.71 (m, 2 H) 2.49 - 2.55 (m, 4 H)
2.56 - 2.63 (m, 1
.. H) 2.68 - 2.75 (m, 4 H) 2.88 - 2.98 (m, 2 H) 4.09 (d, J=13.18 Hz, 2 H) 7.42
(dd, J=9.22, 3.07 Hz,
1 H) 8.08 (d, J=9.37 Hz, 1 H) 8.20 (d, J=3.22 Hz, 1 H).
Example 29
Synthesis of 5-(4-thiomorpholino-1-piperidyl) pyridin-2-amine, Compound 29
( \N NH2
S\
5-(4-thiomorpholino-1-piperidyl) pyridin-2-amine was prepared in a manner
similar to
that used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine.
1FINMR (600 MHz,
-- DMSO-d6) 6 ppm 1.47 - 1.59 (m, 2 H) 1.65 (m, 2 H) 2.22 - 2.38 (m, 1 H) 2.50
- 2.59 (m, 6 H)
2.68 - 2.82 (m, 4 H) 3.33 (d, J=12.00 Hz, 2 H) 5.31 (s, 2 H) 6.33 (d, J=9.08
Hz, 1 H) 7.10 (dd,
J=8.78, 2.93 Hz, 1 H) 7.55 (d, J=2.64 Hz, 1 H). LCMS (EST) 279 (M + H).
120
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 30
Synthesis of 2-nitro-5-(1-piperidyl)pyridine, Compound 30
( _______________________ No2
2-nitro-5-(1-piperidyl) pyridine was synthesized in a manner similar to that
used in the
synthesis of 2-nitro-5-[4-(1-piperidy1)-1-piperidyl]pyridine. iHNMR (600 MHz,
DMSO-d6) 6
ppm 1.56 (m, 6 H) 3.49 (d,1=4.39 Hz, 4 H) 7.30 - 7.47 (m, 1 H) 8.02 - 8.12 (m,
1 H) 8.15 - 8.26
(m, 1 H).
Example 31
Synthesis of 5-(1-piperidyl)pyridin-2-amine, Compound 31
( _______________________ NH2
5-(1-piperidyl) pyridin-2-amine was prepared in a manner similar to that used
in the
synthesis of 5-(4-methylpiperazin-l-yl)pyridin-2-amine. ifINMR (600 MHz, DMSO-
d6) 6 ppm
1.39- 1.46 (m, 2 H) 1.51 - 1.62 (m, 4 H) 2.75 -2.92 (m, 4 H) 5.30 (s, 2 H)
6.34 (d, J=8.78 Hz, 1
H) 7.09 (dd, J=8.78, 2.93 Hz, 1 H) 7.54 (d, J=2.93 Hz, 1 H). LCMS (ESI) 178 (M
+ H).
Example 32
Synthesis of 4-(6-nitro-3-pyridyl) thiomorpholine, Compound 32
\7/NO2
121
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
4-(6-nitro-3-pyridyl) thiomorpholine was synthesized in a manner similar to
that used in
the synthesis of 2-nitro-5-[4-(1-piperidy1)-1-piperidyl]pyridine. IHNMR (600
MHz, DMSO-d6)
6 ppm 2.56 - 2.69 (m, 4 H) 3.79 - 3.92 (m, 4 H) 7.43 (dd, J=9.22, 3.07 Hz, 1
H) 8.10 (d, J=9.37
Hz, 1 H) 8.20 (d, J=2.93 Hz, 1 H).
Example 33
Synthesis of 5-thiomorpholinopyridin-2-amine, Compound 33
\N ___________________ NH2
5-thiomorpholinopyridin-2-amine was prepared in a manner similar to that used
in the
synthesis of 5-(4-methylpiperazin-1-y1) pyridin-2-amine. IHNMR (600 MHz, DMSO-
d6) 6 ppm
2.59 - 2.73 (m, 4 H) 3.04 - 3.20 (m, 4 H) 5.41 (s, 2 H) 6.35 (d, J=8.78 Hz, 1
H) 7.10 (dd, J=8.78,
2.93 Hz, 1 H) 7.57 (d, J=2.64 Hz, 1 H). LCMS (ESI) 196 (M + H).
Example 34
Synthesis of tert-butyl (4R)-5-(6-nitro-3-pyridy1)-2,5-
diazabicyclo[2.2.1]heptane-2-
carboxylate, Compound 34
( Nik
NO2
tert-butyl (4R)-5-(6-nitro-3-pyridy1)-2,5-diazabicyclo [2.2 .1] heptane-2-c
arboxylate was
synthesized in a manner similar to that used in the synthesis of 2-nitro-544-
(1-piperidy1)-1-
122
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
piperidyllpyridine. 1HNMR (600 MHz, DMSO-d6) 6 PPm 1.33 (d, J=32.21 Hz, 11 H)
1.91 (m, 2
H) 3.15 (d, J=10.25 Hz, 1 H) 3.58 (m, 1 H) 4.46 (m, 1 H) 4.83 (s, 1 H) 7.16
(s, 1 H) 7.94 (s, 1 H)
8.05 - 8.16 (m, 1 H).
Example 35
Synthesis of tert-butyl (4R)-5-(6-amino-3-pyridy1)-2,5-
diazabicyclo[2.2.1]heptane-2-
carboxylate, Compound 35
(
NH2
tert-butyl (4R)-5-(6-amino-3-pyri dy1)-2,5 -di az abi cycl o [2 .2. 1]h eptan
e-2-carboxyl ate was
prepared in a manner similar to that used in the synthesis of 5-(4-
methylpiperazin-1-yl)pyridin-2-
amine. 1I-INMR (600 MHz, DMSO-d6) 6 ppm 1.31 (d, J=31.91 Hz, 11 H) 1.83 (m, 2
H) 2.71 -
2.82 (m, 1 H) 3.44 (m,1 H) 4.30 (d, 2H) 5.08 (s, 2 H) 6.35 (d, J=8.78 Hz, 1 H)
6.77 - 6.91 (m, 1
H) 7.33 (s, 1 H). LCMS (ESI) 291 (M + H).
Example 36
Synthesis of N,N-dimethy1-1-(6-nitro-3-pyridyl) piperidin-4-amine, Compound 36
( No2
/
N,N-dimethy1-1-(6-nitro-3-pyridyl)piperidin-4-amine was synthesized in a
manner
similar to that used in the synthesis of 2-nitro-544-(1-piperidy1)-1-
piperidyl]pyridine. 1HNMR
123
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(600 MHz, DMSO-d6) 6 PPm 1.30 - 1.45 (m, 2 H) 1.79 (m, 2 H) 2.14 (s, 6 H) 2.33
(m, 1 H) 2.92
- 3.04 (m, 2 H) 4.03 (d, J=13.76 Hz, 2 H) 7.42 (dd, J=9.22, 3.07 Hz, 1 H) 8.04
- 8.11 (m, 1 H)
8.21 (d, J=2.93 Hz, 1 H).
Example 37
Synthesis of 5[4-(dimethylamino)-1-piperidyl] pyridin-2-amine, Compound 37
( \N __________________________ NH2
5[4-(dimethylamino)-1-piperidyl]pyridin-2-amine was prepared in a manner
similar to
that used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine. 11-
INMR (600 MHz,
DMSO-d6) ppm 1.35- 1.50 (m, 2 H) 1.69- 1.81 (m, 2 H) 2.00 - 2.10 (m, 1 H) 2.11
- 2.22 (s, 6
H) 3.17 - 3.36 (m, 4 H) 5.19 - 5.38 (s, 2 H) 6.34 (d, J=8.78 Hz, 1 H) 7.10
(dd, J=8.78, 2.93 Hz, 1
H) 7.55 (d, J=2.63 Hz, 1 H). LCMS (ESI) 221 (M + H).
Example 38
Synthesis of 4-(6-nitro-3-pyridyl) morpholine, Compound 38
0 N ________ NO2
4-(6-nitro-3-pyridyl) morpholinc was synthesized in a manner similar to that
used in the
synthesis of 2-nitro-5 -[4-(1-pip eridy1)-1-pip eridyl] pyridine.
Example 39
Synthesis of 5-morpholinopyridin-2-amine, Compound 39
______________________ NH2
124
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
5-morpholinopyridin-2-amine was prepared in a manner similar to that used in
the
synthesis of 5-(4-methylpiperazin-1-y1) pyridin-2-amine. 1HNMR (600 MHz,
CHLOROFORM-
d) 6 ppm 2.91 - 3.00 (m, 4 H) 3.76 - 3.84 (m, 4 H) 4.19 (br. s., 2 H) 6.45 (d,
J=8.78 Hz, 1 H)
7.12 (dd, J=8.78, 2.93 Hz, 1 H) 7.72 (d, J=2.93 Hz, 1 H).
Example 40
Synthesis of 5-(4-isobutylpiperazin-1-y1) pyridin-2-amine, Compound 40
___________ N/
( N _________ N H2
1-isobuty1-4-(6-nitro-3-pyridyl)piperazine was synthesized in a manner similar
to that
used in the synthesis of 2-nitro-544-(1-piperidy1)-1-piperidyl]pyridine which
was then converted
5-(4-isobutylpiperazin-1-yl)pyridin-2-amine in a manner similar to that used
in the synthesis of
5-(4-methylpiperazin-1 -yl)pyridin-2-amine. ItINMR (600 MHz, CHLOROFORM-d) 6
ppm
0.88 (d, J=6.73 Hz, 6 H) 1.71 - 1.84 (m, 1 H) 2.10 (d, J=7.32 Hz, 2 H) 2.46 -
2.58 (m, 4 H) 2.97 -
3.07 (m, 4 H) 4.12 (s, 2 H) 6.45 (d, J=8.78 Hz, 1 H) 7.14 (dd, J=8.78, 2.93
Hz, 1 H) 7.75 (d,
J=2.93 Hz, 1 H). LCMS (ESI) 235 (M + H).
Example 41
Synthesis of 5-(4-isopropylpiperazin-1-y1) pyridin-2-amine, Compound 41
\N ____________________________ NH2
1-isopropyl-4-(6-nitro-3-pyridyl)piperazine was synthesized in a manner
similar to that
used in the synthesis of 2-nitro-544-(1-piperidy1)-1-piperidyl]pyridine which
was then converted
to 5-(4-isopropylpiperazin-1-yl)pyridin-2-amine in a manner similar to that
used in the synthesis
of 5-(4-methylpiperazin-1-yl)pyridin-2-amine. IHNMR (600 MHz, CHLOROFORM-d) 6
ppm
125
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
1.06 (d, J=6.44 Hz, 6 H) 2.59 - 2.75 (m, 5 H) 2.97 - 3.10 (m, 4 H) 4.13 (s, 2
H) 6.45 (d, J=8.78
Hz, 1 H) 7.15 (dd, J=9.08, 2.93 Hz, 1 H) 7.76 (d, J=2.93 Hz, 1 H). LCMS (ESI)
221 (M + H).
Example 42
Synthesis of 5-R2R,6S)-2,6-dimethylmorpholin-4-ylipyridin-2-amine, Compound 42
0)
-
(2S,6R)-2,6-dimethy1-4-(6-nitro-3-pyridyl)morpholine was synthesized in a
manner
similar to that used in the synthesis of 2-nitro-544-(1-piperidy1)-1-
piperidyl]pyridine which was
.. then converted to 5-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-amine in
a manner similar to
that used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine.
1FINMR (600 MHz,
CHLOROFORM-d) 6 ppm 1.20 (d, J=6.44 Hz, 6 H) 2.27 - 2.39 (m, 2 H) 3.11 - 3.21
(m, 2 H)
3.70 - 3.84 (m, 2 H) 4.15 (s, 2 H) 6.45 (d, J=8.78 Hz, 1 H) 7.12 (dd, J=8.78,
2.93 Hz, 1 H) 7.72
(d, J=2.63 Hz, 1 H). LCMS (ESI) 208 (M + H).
Example 43
Synthesis of 54(3R,5S)-3,5-dimethylpiperazin-1-Apyridin-2-amine, Compound 43
HNN __________________ NH2
(3S,5R)-3,5-dimethy1-1-(6-nitro-3-pyridyl)piperazine was synthesized in a
manner
similar to that used in the synthesis of 2-nitro-544-(1-piperidy1)-1-
piperidyl]pyridine which was
then converted to 5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]pyridin-2-amine in a
manner similar to
that used in the synthesis of 5-(4-methylpiperazin-1-yl)pyridin-2-amine. 11-
INMR (600 MHz,
CHLOROFORM-d) 6 ppm 1.09 (d, J=6.44 Hz, 6 H) 2.20 (t, J=10.83 Hz, 2 H) 2.95 -
3.08 (m, 2
126
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
H) 3.23 (dd, J=11.71, 2.05 Hz, 2 H) 4.13 (s, 2 H) 6.45 (d, J=8.78 Hz, 1 H)
7.14 (dd, J=8.78, 2.93
Hz, 1 H) 7.73 (d, J=2.63 Hz, 1 H). LCMS (ESI) 207 (M + H).
Example 44
Synthesis of Compound 44
N
N
CI N H
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-yl)amino1-3-methyl-butyl]
carbamate
Br
07( CI N
0
A solution of intermediate A in ethanol (100 mL) was hydrogenated under 30 psi
of
hydrogen using 10% Pd/C (0.7 g) in a pressure bomb for 7 hrs. After filtration
of the reaction
mixture through CELITETm, the organic layer was concentrated under vacuum to
afford tert-
butyl N-(2-amino-3-methyl-butyl) carbamate (3.8 g).
To a solution of 5-bromo-2,4-dichloro-pyrimidine (7.11 g, 0.0312 mole) in
ethanol (100
mL) was added diisopropylethyl amine (5.45 mL, 1.0 eq) and tert-butyl N-(2-
amino-3-methyl-
butyl) carbamate (6.31 g, 0.0312 mole). The reaction mixture was stirred at
room temperature
for 20 hrs. After concentration under vacuum, ethyl acetate and water were
added. The organic
layer was separated, dried with magnesium sulfate and then concentrated under
vacuum. The
crude product was purified by silica gel column chromatography using
hexane/ethyl acetate (0-
30%) to afford tert-butyl N- [2-[(5
carbamate. iHNMR (600 MHz, DMSO-d6) 6 ppm 0.77 - 0.85 (d, J=6.5 Hz, 3 H) 0.87
(d, J=6.73
127
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Hz, 3 H) 1.31 - 1.39 (m, 9 H) 1.82- 1.93 (m, 1 H) 2.94 (d, J=5.56 Hz, 1 H)
3.08 - 3.22 (m, 2 H)
3.98 (d, J=8.20 Hz, 1 H) 6.96 (d, J=8.78 Hz, 1 H) 8.21 (s, 1 H). LCMS (EST)
393 (M + H).
tert-butyl N-[2-[2-chloro-6-(diethoxymethyl)pyrrolo [2,3-d]pyrimidin-7-y1]-3-
methyl-
butyl]carbamate
N \
tert-butyl N4242-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]pyrimidin-7-y1]-3-
methyl-
butyl]carbamate was synthesized by hosting tert-butyl N-[2-[(5-bromo-2-chloro-
pyrimidin-4-
yl)amino]-3-methyl-butyl]carbamate to Sonogoshira conditions as described for
tert-butyl N-[2-
[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]ethyl]carbamate
followed by
subsequent treatment with TBAF as described in the synthesis of tert-butyl N-
[242-chloro-6-
(diethoxymethyppyrrolo[2,3-d]pyrimidin-7-yl]ethyl]carbamate. 1HNMR (600 MHz,
DMSO-d6)
6 ppm 1.11 (d, J=6.44 Hz, 3 H) 1.18 (t, J=7.03 Hz, 6H) 1.21 - 1.26 (m, 12 H)
2.88 (br. s., 1 H)
3.43 - 3.78 (m, 6 H) 3.97 - 4.08 (m, 1 H) 5.61 (s, 1 H) 6.65 (s, 1 H) 6.71 -
6.78 (m, 1 H) 8.87 (s,
1 H). LCMS (ESI) 441 (M + H).
7-[1-[(tert-butoxycarbonylamino)methy1]-2-methyl-propyl]-2-chloro-pyrrolo[2,3-
d]pyrimidine-
6-carboxylic acid
N
C 21-1
\)(
0
To a solution tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-
4-
yl]amino]ethyl]carbamate in THF was added TBAF and the contents were heated at
reflux for 3
128
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
hrs. Ethyl acetate and water were then added and the organic layer separated,
dried with
magnesium sulfate and then concentrated under vacuum. To this crude reaction
was added
acetic acid/water (9:1) and the contents were stirred for 12 hrs at room
temperature. After
concentration under vacuum, sat NaHCO3 and ethyl acetate were added. The
organic layer was
separated, dried and then concentrated under vacuum. The crude reaction
product thus obtained
was dissolved in DMF, oxone was then added and the contents stirred for 3 hrs.
After addition
of ethyl acetate, the reaction mixture was filtered through CELITETm and
concentrated under
vacuum. Column chromatography of the crude product over silica gel using
hexane/ethyl acetate
(0- 100%) afforded 7-[1- [(tert-b utoxycarbonylamino)methy1]-2-methyl-
propyl]-2-chloro-
pyrrolo[2,3-d]pyrimidine-6-carboxylic acid. iHNMR (600 MHz, DMSO-d6) 6 ppm
0.85 (d,
J=7.03 Hz, 3 H) 0.97 (d, J=6.73 Hz, 3 H) 1.52 (s, 9 H) 1.99 - 2.23 (m, 1 H)
3.98 (dd, J=14.05,
3.51 Hz, 1 H) 4.47 -4.71 (m, 2 H) 7.47 (s, 1 H) 9.17 (s, 1 H). LCMS (ESI) 383
(M + H).
Compound 44
To 7-[1-Rtert-butoxycarbonylamino)methy11-2-methyl-propy1]-2-chloro-
pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid (0.050 g, 0.00013 mole) in DCM (1.5 mL) was
added DIC (32.7
mg) and DMAP (10 mg). The contents were stirred for 2 hrs. Trifluoroacetic
acid (0.4 mL) was
then added and stirring continued for an additional 30 minutes. After addition
of satd NaHCO3
to neutralize the excess acid, ethyl acetate was added and the organic layer
separated, dried using
.. magnesium sulfate and then concentrated under vacuum. The crude product was
purified by
silica gel column chromatography using hexane/ethyl acetate (0- 100%) to
afford the product.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.72 (d, J=6.73 Hz, 3 H) 0.97 (d, J=6.73 Hz, 3
H) 2.09 -
2.22 (m, 1 H) 3.57 (dd, J=13.18, 4.98 Hz, 1 H) 3.72 (dd, J=13.61, 4.25 Hz, 1
H) 4.53 (dd,
J=8.05, 3.95 Hz, 1 H) 7.20 (s, 1 H) 8.34 (d, J=4.98 Hz, 1 H) 9.08 (s, 1 H).
LCMS (EST) 265 (M
+H).
129
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 45
Synthesis of Compound 45
N
CI N H
Compound 14 was hydrogenated with 10% Pd/C to afford the intermediate tert-
butyl N-
[(2R)-2-amino-3-methyl-butyl] carbamate, which was then treated with 5-bromo-
2,4-dichloro-
pyrimidine using analogous reaction conditions as described for Compound 44 to
afford
Compound 45 The analytical data is consistent with that reported for the
racemate (Intermediate
1A).
Example 46
Synthesis of Compound 46
N
C I H
Compound 15 was hydrogenated with 10% Pd/C to afford the intermediate tert-
butyl N-
[(2S)-2-amino-3-methyl-butyl]carbamate, which was then treated with 5-bromo-
2,4-dichloro-
pyrimidine using analogous reaction conditions as described for Compound 44 to
afford
Compound 46. The analytical data (NMR and LCMS) was consistent with that
reported for the
racemate Compound 44.
130
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 47
Synthesis of Compound 47
N 0
To a solution of Compound 44 (80 mg, 0.00030 mole) in DMF (3 mL) was added a
60%
dispersion of sodium hydride in oil (40 mg). After stirring for 15 minutes,
methyl iodide (37 jut,
2eq) was added. The contents were stirred at room temperature for 30 minutes.
Saturated
NaHCO3 was then added followed by ethyl acetate. The organic layer was dried
with
magnesium sulfate and then concentrated under vacuum to afford the product .
11-INMR (600
MHz, DMSO-d6) 6 ppm 0.74 (d, J=6.73 Hz, 3 H) 0.91 (d, J=6.73 Hz, 3 H) 2.04 -
2.20 (m, 1 H)
3.04 (s, 3 H) 3.69 (dd, J=13.76, 1.17 Hz, 1 H) 3.96 (dd, J=13.76, 4.68 Hz, 1
H) 4.58 (dd, J=7.32,
3.51 Hz, 1 H) 7.16 (s, 1 H) 9.05 (s, 1 H). LCMS (ESI) 279 (M + H).
Example 48
Synthesis of Compound 48
N
CII\J'N NH
131
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-R2S)-2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino1-4-methyl-
pentyl]carbamate
C1.7.1\j/-- NH HN 07(
o
Compound 18 was hydrogenated with 10% Pd/C in ethanol under a blanket of
hydrogen
at 50 psi in a pressure bomb to afford tert-butyl N-[(2S)-2-amino-4-methyl-
pentyl]carbamate
which was then reacted with 5-bromo-2,4-dichloro-pyrimidine using analogous
reaction
conditions as described for tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-
yl)amino]-3-methyl-
butyl]carbamate to afford tert-butyl N-[(2S)-2-[(5-bromo-2-chloro-pyrimidin-4-
yl)amino]-4-
methyl-pentyl]carbamate. itINMR (600 MHz, CHLOROFORM-d) .6 ppm 0.91 (d, J=6.44
Hz, 3
H) 0.94 (d, 1=6.44 Hz, 3 H) 1.32 - 1.51 (m, 11 H) 1.55 - 1.67 (m, 1 H) 3.28
(t, 1=5.86 Hz, 2 H)
4.21 - 4.42 (m, 1 H) 4.84 (s, 1 H) 5.84 (d, J=7.32 Hz, 1 H) 8.07 (s, 1 H).
LCMS (ESI) 407 (M +
H).
OEt
N
I 07(HN
To a solution of tert-butyl N-[(2S)-2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-
4-
methyl-pentyl]carbamate (5.0 g, 12.3 mmole) in tolune (36 mL) and
triethylamine (7.2 mL) was
added under nitrogen, 3,3-diethoxyprop-1-yne (2.8 mL, 19.7 mmole), Pd2(dba);
(1.1g, 1.23
mmole), and triphenylarsine (3.8 g, 12.3 mmole). The contents were heated to
70 degrees for 24
132
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
hrs. After cooling to room temperature, the reaction mixture was filtered
through CELITETm and
then concentrated under vacuum. The crude product was purified by silica gel
column
chromatography using hexane/ethyl acetate (0- 30%) to afford (2S)-N2-[2-chloro-
5-(3,3-
diethoxyprop-1-ynyl)pyrimidin-4-y1]-4-methyl-pentane-1,2-diamine. LCMS (ESI)
455 (M + H).
N
\ ________________________ CO2H
ci N
7- [(1 S)-1- [(tert-butoxycarbonylamino)me thy]] -3 -methyl-b uty1]-2-chloro-
pyrro lo [2,3-
d]pyrimidine-6-carboxylic acid was synthesized using the analogous synthetic
sequence as that
described for 7-[1-[(tert-butoxycarbonylamino)methyl]-2-methyl-propy1]-2-
chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid. 1HNMR (600 MHz, DMSO-d6) 6 ppm 0.88 (d, J=6.44
Hz, 3 H)
0.97 (d, J=6.44 Hz, 3 H) 1.47 (s, 9 H) 1.49 - 1.54 (m, 1 H) 1.56 (t, J=7.17
Hz, 2 H) 3.98 (dd,
J=13.91, 3.07 Hz, 1 H) 3.76 (dd, J=13.31, 4.13 Hz, 1 H) 4.38 (d, J=14.05 Hz, 1
H) 4.90 (t,
J=7.17 Hz, 1 H) 7.41 (s, 1 H) 9.11 (s, 1 H). LCMS (M + H) 397.
Compound 48 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. 1IFINMR (600 MHz, DMSO-d6) 6' ppm 0.82 (d, J=6.73 Hz, 3 H)
0.97 (d,
J=6.44 Hz, 3 H) 1.34 - 1.46 (m, 1 H) 1.48- 1.65 (m, 2 H) 3.40 (dd, J=13.32,
5.42 Hz, 1 H) 3.76
(dd, J=13.47, 4.10 Hz, 1 H) 4.76 - 4.92 (m, 1 H) 7.17 (s, 1 H) 8.34 (d, J=5.27
Hz, 1 H) 9.04 (s, 1
H). LCMS (ESI) 279 (M + H).
133
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 49
Synthesis of Compound 49
0
N
Compound 49 was synthesized in a manner similar to that described for Compound
47.
11-INMR (600 MHz, DMSO-d6) 6 ppm 0.82 (d, J=6.44 Hz, 3 H) 0.97 (d, J=6.44 Hz,
3 H) 1.37 -
1.68 (m, 3 H) 3.04 (s, 3 H) 3.56 (d, J=13.47 Hz, 1 H) 4.00 (dd, J=13.32, 4.25
Hz, 1 H) 4.82 -
4.94 (m, 1 H) 7.16 (s, 1 H) 9.03 (s, 1 H). LCMS (EST) 293 (M + H).
Example 50
Synthesis of Compound 50
0
N
C I H
tert-butyl N-[(2S)-2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-3-methyl-
pentyllcarbamate
Br
N
CIN
I 07(
HN
Compound 20 was hydrogenated using 10% Pd/C under hydrogen at 50 psi in a
pressure
vessel to afford tert-butyl N-[(2S)-2-amino-3-methyl-pentylicarbamate which
was reacted with
5-bromo-2,4-dichloro-pyrimidine using analogous reaction conditions as
described for tert-butyl
134
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
N-[2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-3-methyl-butyl]carbamate to
afford tert-butyl
N- [(2S)-2- [(5-bromo-2-chloro-pyrimidin-4-yl)amino]-3-methyl-
pentyl]carbamate. I HNMR (600
MHz, CHLOROFORM-d) 6 ppm 0.88 -0.95 (m, 6 H) 1.11 - 1.20 (m, 1 H) 1.34 (s, 9
H) 1.44 -
1.54 (m, 1 H) 1.64 - 1.72 (m, 1 H) 3.17 - 3.27 (m, 1 H) 3.33 - 3.43 (m, 1 H)
4.11 - 4.21 (m, 1 H)
4.81 (s, 1 H) 5.92 (d, J=8.20 Hz, 1 H) 8.05 (s, 1 H). LCMS (ES1) 407.
tert-butyl N- [(2 S)-2-[ [2-chloro-5 -(3,3-d iethoxyprop-1 -ynyl)pyrimidin-4-
yl] amino]-3 -methyl-
pentyl]carbamate
0 Et
OEt
N 0
CI
o
tert-butyl N-[(2S)-2-[[2-chloro-5-(3 ,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino] -3-
methyl-pentylicarbamate was synthesized using similar experimental conditions
to that used in
the synthesis of (2S)-N2-[2-chloro-5 -(3,3 -diethoxyprop-1-ynyl)pyrimidin-4-
y1]-4-methyl-
pentanc-1,2-diamine. 11-1NMR (600 MHz, DMSO-d6) 6 ppm 0.76 - 0.89 (m, 6 H)
1.03 (q, J=7.22
Hz, 3 H) 1.10- 1.17(m, 3 H) 1.25 - 1.42 (m, 11 H) 1.59- 1.73 (m, 1 H) 3.35 -
3.47 (m, 4 H) 3.51
- 3.73 (m, 2 H) 3.99 - 4.11 (m, 1 H) 5.52 - 5.56 (m, 1 H) 6.76 - 7.03 (m, 2 H)
8.12 - 8.23 (m, 1
H). LCMS (EST) 455 (M + H).
7- [(1 S)-1 - [(tert-butoxycarbonylamino)methyl]-2-methyl-buty1]-2-chloro-
pyrrolo [2,3 -
d]pyrimidine-6-carboxylic acid
N \
____________________ CO2H
o
CI
135
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7-[(1 S)-1- [(tert-butoxycarbonylamino)methyl]-2-methyl-butyl]-2-chloro-pyrro
lo [2,3-
d]pyrimidine-6-carboxylic acid was synthesized using the analogous synthetic
sequence as that
described for 7-[1-[(tert-butoxycarbonylamino)methyl]-2-methyl-propy1]-2-
chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid. 11-1NMR (600 MHz, DMSO-d6) 6 ppm 0.80 (t,
J=7.47 Hz, 3 H)
0.86 (d, J=7.03 Hz, 3 H) 1.06 - 1.30 (m, 2 H) 1.48 (s, 9 H) 1.79 - 1.96 (m, 1
H) 3.95 (dd,
J=14.05, 3.22 Hz, 1 H) 4.52 (d, J=14.35 Hz, 1 H) 4.61 -4.73 (m, 1 H) 7.43 (s,
1 H) 9.13 (s, 1 H).
LCMS (EST) 397 (M + H).
Compound 50 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. 1FINMR (600 MHz, DMSO-d6) 6 ppm 0.74 (t, J=7.32 Hz, 3 H) 0.89
(d,
J=6.73 Hz, 3 H) 1.00 - 1.12 (m, 2 H) 1.82 - 1.94 (m, 1 H) 3.55 (dd, J=13.91,
4.83 Hz, 1 H) 3.70
(dd, J=13.61, 4.25 Hz, 1 H) 4.57 (dd, J=7.91, 4.10 Hz, 1 H) 7.17 (s, 1 H) 8.31
(d, J=5.27 Hz, 1
H) 9.05 (s, 1 H). LCMS (ESI) 279 (M + H).
Example 51
Synthesis of Compound 51
N 0
CI
Compound 51 was synthesized in a manner similar to Compound 47. 1FINMR (600
MHz, DMSO-d6) 6 ppm 0.77 (t, J=7.47 Hz, 3 H) 0.84 (d, J=6.73 Hz, 3 H) 1.07 -
1.16 (m, 2 H)
1.82 - 1.95 (m, 1 H) 3.03 (s, 3 H) 3.68 (d, J=13.76 Hz, 1 H) 3.96 (dd,
J=13.76, 4.39 Hz, 1 H)
4.59 -4.70 (m, 1 H) 7.16 (s, 1 H) 9.04 (s, 1 H). LCMS (ESI) 293 (M + H).
136
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 52
Synthesis of Compound 52
N 0
JNH
tert-butyl N-R2S)-2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino] -3,3 - dimethyl-
butyl] carbamate
07( CI
0
Compound 21 was hydrogenated using 10% Pd/C under hydrogen at 50 psi in a
pressure
vessel to afford tert-butyl N-[(2S)-2-amino-3,3-dimethyl-butyl]carbamate which
was then
reacted with 5-bromo-2,4-dichloro-pyrimidine using analogous reaction
conditions as described
using analogous reaction conditions as described for tert-butyl N-[2-[(5-bromo-
2-chloro-
pyrimidin-4-y0amino]-3-methyl-butyl]carbamate to afford tert-butyl N-[(2S)-2-
[(5-bromo-2-
chloro-pyrimidin-4-yl)amino]-3,3-dimethyl-butylicarbamate. LCMS (ESI) 407 (M +
H).
tert-butyl N- [(2 S)-2-[ [2- chloro-5 -(3,3-diethoxyprop -1-ynyl)pyrimi din-4-
yl] amino] -3 ,3 - dimethyl-
butyl] carbamate
OEt
OEt
N
07(
NH
CI
0
137
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[(2S)-2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yllamino]-3,3-
dimethyl-butyl]carbamate was synthesized using similar experimental conditions
to that used in
the synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-y1]-
4-methyl-
pentane-1,2-diamine. LCMS (ESI) 455 (M + H).
7-[(1S)-1- [(tert-butoxycarbonylamino)methyl ]-2,2-dim ethyl-propyl] -2-chloro-
pyrrolo [2,3 -
d]pyrimidine-6-carboxylic acid
____________________ co2H
o
CI
ss:\
0
7-[(1S)-1- Rtert-butoxycarbonylamino)methyll -2,2-dimethyl-propy1]-2-chloro-
pyrrolo[2,3-d]pyrimidine-6-carboxylic acid was synthesized using the analogous
synthetic
sequence as that described for 741-[(tert-butoxycarbonylamino)methy1]-2-methyl-
propyl]-2-
chloro-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid. LCMS (ESI) 397 (M + H).
Intermediate IF was synthesized using an analogous synthetic sequence as that
described for
intermediate 1A. LCMS (ESI) 279 (M + H).
Example 53
Synthesis of Compound 53
N 0
CI
/.\
Compound 53 was synthesized in a manner similar to that described for
Intermediate
1CA. LCMS (ESI) 293 (M + H).
138
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 54
Synthesis of Compound 54
\
=
tert-butyl N- [(2S)-2- [(5 -brom o-2-ch loro-pyrimi din-4-y1 )ami n o] -2-ph
enyl -ethyl] carb am ate
N Br
CINN
07(
0
Compound 21 was hydrogenated using 10% Pd/C under hydrogen at 50 psi in a
pressure
vessel to afford tert-butyl N-[(2S)-2-amino-2-phenyl-ethyl]carbamate which was
then reacted
with 5-bromo-2,4-dichloro-pyrimidine using analogous reaction conditions as
described for tert-
butyl N42-[(5-bromo-2-chloro-pyrimidin-4-y0amino]-3-methyl-butyl]carbamate to
afford tert-
butyl N-[(2S)-2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-2-phenyl-
ethyl]carbamate. iHNMR
(600 MHz, DMSO-d6) ppm 1.32 (s, 9 H) 3.29 - 3.50 (m, 2 H) 5.12 - 5.24 (m, 1 H)
7.10 (t,
J=5.27 Hz, 1 H) 7.21 (t, J=6.88 Hz, 1 H) 7.26 - 7.34 (m, 4 H) 7.89 (d, J=7.32
Hz, 1 H) 8.24 (s, 1
H). LCMS (ESI) 427 (M + H).
139
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[(2S)-2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]-2-phenyl-
ethyl]carbamate
OEt
0 Et
N
I 0
CI N H
tert-butyl N-[(2S)-2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]-2-
phenyl-ethylicarbamate was synthesized using similar experimental conditions
to those used in
the synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-ynyOpyrimidin-4-y1]-4-
methyl-
pentane-1,2-diamine. 11-INMR (600 MHz, DMSO-d6) 6 ppm 1.14 (t, J=7.03 Hz, 6 H)
1.32 (s, 9
H) 3.39 (s, 2 H) 3.52 - 3.61 (m, 2 H) 3.64 - 3.73 (m, 2 H) 5.17 - 5.26 (m, 1
H) 5.57 (s, 1 H) 7.07 -
7.14 (m, 1 H) 7.20 - 7.25 (m, 1 H) 7.26 - 7.33 (m, 4 H) 7.90 (d, J=7.61 Hz, 1
H) 8.19 (s, 1 H).
LCMS (ESI) 475 (M + H).
7-[(1S)-2-(tert-butoxycarbonylamino)-1-phenyl-ethyl]-2-chloro-pynolo[2,3-
d]pyrimidine-6-
carboxylic acid
CO2H
= 0
7-[(1S)-2-(tert-butoxycarbonylamino)-1-phenyl-ethyl]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid was synthesized using the analogous synthetic
sequence as that
described for 7- [1-[(tert-butoxyc arbonyl amino)methy1]-2-m ethyl -propy1]-2-
ch loro-pyrro I o [2,3 -
d]pyrimidine-6-carboxylic acid. LCMS (EST) 417 (M + H).
140
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 54
Compound 54 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. 11-1NMR (600 MHz, DMSO-d6) 6 ppm 3.58 - 3.69 (m, 1 H) 4.13
(dd,
J=13.47, 4.39 Hz, 1 H) 6.07 (d, J=3.81 Hz, 1 H) 6.85 (d, J=7.32 Hz, 2 H) 7.19 -
7.31 (m, 3 H)
7.34 (s, 1 H) 8.27 (d, J=5.27 Hz, 1 H) 9.13 (s, 1 H). LCMS (ESI) 299 (M + H).
Example 55
Synthesis of Compound 55
N../.... 0
1 \
CI "......'...N.-....--..--- N\ N H
2-
tert-butyl N-[(1S)-1-[[(5-bromo-2-chloro-pyrimidin-4-yl)amino]methyl]-2-methyl-
propyl]
carbamate
1 07(c,,------,NH HN 0
tert-butyl N-[(1S)-1-[[(5-bromo-2-chloro-pyrimidin-4-yl)amino]methy1]-2-methyl-
propyl]carbamate was synthesized using 5-bromo-2,4-dichloro-pyrimidine and
Intermediate E
using analogous reaction conditions as described for tert-butyl N-[2-[(5-bromo-
2-chloro-
pyrimidin-4-y0amino]-3-methyl-butyl]carbamate. ifINMR (600 MHz, CHLOROFORM-d)
6
ppm 0.95- 1.02 (m, 6 H) 1.35- 1.45 (m, 9 H) 1.75- 1.90 (m, 1 H) 3.35 - 3.48
(m, 1 H) 3.52 -
3.61 (m, 1 H) 3.64 - 3.76 (m, 1 H) 4.56 (d, J=8.49 Hz, 1 H) 6.47 (s, 1 H) 8.07
(s, 1 H). LCMS
(ESI) 393 (M + H).
141
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[(1S)-1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]methy1]-2-
methyl-propyl] carbamate
OEt
0 Et
N
I 07(CI H
tert-butyl N-R1S)-1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]methyl]-2-methyl-propyl]carbamate was synthesized using similar
experimental
conditions to those used in the synthesis (2S)-N242-chloro-5-(3,3-diethoxyprop-
1-
ynyl)pyrimidin-4-y1]-4-methyl-pentane-1,2-diamine. 1FINMR (600 MHz, CHLOROFORM-
d) 6
ppm 0.90 - 1.00 (m, 6 H) 1.18 - 1.25 (m, 6 H) 1.34 - 1.36 (m, 9 H) 1.69 - 1.90
(m, 1 H) 3.34 -
3.82 (m, 6 H) 4.53 - 4.77 (m, 1 H) 5.45 - 5.55 (m, 1 H) 6.37 (dd, J=15.37,
6.59 Hz, 1 H) 6.56 (s,
1 H) 8.05 (s, 1 H). LCMS (ESI) 441 (M + H).
7-[(2S)-2-(tert-butoxyearbonylamino)-3-methyl-buty1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid
___________________ 0 (HN
CO2H
7-[(25)-2-(tert-butoxycarbonylamino)-3-methyl-buty11-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid was synthesized using the analogous synthetic
sequence as that
described for 7- [1-[(tert-butoxyc arbonyl amino)methy1]-2-m ethyl -propy1]-2-
ch loro-pyrro I o [2,3 -
d]pyrimidine-6-carboxylic acid. 1FINMR (600 MHz, CHLOROFORM-d) 6 ppm 0.90 (d,
J=6.73
Hz, 3 H) 0.96 (d, J=7.03 Hz, 3 H) 1.55 - 1.66 (m, 10 H) 4.14 (dd, J=13.61,
3.95 Hz, 1 H) 4.52 -
142
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
4.63 (m, 1 H) 4.84 (dd, J=13.61, 1.32 Hz, 1 H) 7.37 (s, 1 H) 8.95 (s, 1 H).
LCMS (ESI) 383 (M
+H).
Compound 55
Compound 55 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. LCMS (EST) 265 (M + H).
Example 56
Synthesis of Compound 56
N 0
N H
Compound 56 was synthesized using 5-bromo-2,4-dichloro-pyrimidine and Compound
17 as starting materials, and following a similar sequence of synthetic steps
as for Compound 55.
The analytical data was consistent with that described for its antipode
(Compound 55). 11-1NMR
(600 MHz, DMSO-d6) 6 ppm 0.88 (d, J=6.44 Hz, 6 H) 1.73 - 1.86 (m, 1 H) 3.67 -
3.76 (m, 2 H)
4.11 -4.21 (m, 1 H) 7.13 -7.19 (m, 1 H) 8.56 (s, 1 H) 9.05 (s, 1 H). LCMS
(EST) 265 (M + H).
Example 57
Synthesis of Compound 57
N
N H
143
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-y0amino]-2-methyl-
propyl]carbamate
Br
07( CI N
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-2-methyl-
propyl]carbamate
was synthesized using 5-bromo-2,4-dichloro-pyrimidine and tert-butyl N-(2-
amino-2-methyl-
propyl)carbamate using analogous reaction conditions as described for tert-
butyl N-[245-
bromo-2-chloro-pyrimidin-4-yl)amino]-3-methyl-butylicarbamate. LCMS (ESI) 379
(M + H).
tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]-2-
methyl-
propyl]carbamate
OEt
Et
N
I 07(CINN
tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]-2-
methyl-
propyl]carbamate was synthesized using similar experimental conditions to
those used in the
synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-y1]-4-
methyl-pentane-
1,2-diamine. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.11- 1.22(m, 6H) 1.31 - 1.45 (m,
15 H)
3.10 - 3.24 (m, 2 H) 3.51 -3.76 (m, 4 H) 5.60 (s, 1 H) 6.94 (s, 1 H) 7.33 (t,
J=6.44 Hz, 1 H) 8.18
(s, 1 H). LCMS (ESI) 427 (M + H).
144
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7- [2-(tert-butoxycarbonylamino)-1 ,1-dimethyl-ethyl] -2-chloro-pyrro lo [2,3 -
d]pyrimidine-6-
carboxylic acid
\ _____ co,H
o
CI
7- [2-(tert-butoxycarbonylamino)-1 ,1-dimethyl-ethyl]-2-chloro-pyrro lo [2,3 -
d]pyrimidine-
6-carboxylic acid was synthesized using the analogous synthetic sequence as
that described for
7- [1 - [(tert-butoxycarbonylamino)methyl]-2-methyl-propyl]-2-chloro-pyrrolo
[2 ,3-d]pyrimidine-
6-carboxylic acid. 11-INMR (600 MHz, DMS0-4) 6 ppm 1.43 (s, 9H) 1.73 (s, 6 H)
4.06 (s, 2 H)
7.46 (s, 1 H) 9.23 (s, 1H). LCMS (ESI) 369 (M + H).
Compound 57
Compound 57 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. ifINMR (600 MHz, DMSO-do) 6 ppm 1.73 (s, 6 H) 3.50 (d, 1=2.93
Hz, 2 H)
7.25 (s, 1 H) 8.46 - 8.55 (m, 1 H) 9.07 (s, 1 H). LCMS (ESI) 251 (M + H).
Example 58
Synthesis of Compound 58
0
N ===-=
C I N H
145
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[ [1-[(5 -bromo-2-chloro-pyrimidin-4-yl)amino] cyclohexyllmethyl]
carbamate
0
\\0
tert-butyl N-[[145-bromo-2-chloro-pyrimidin-4-yl)amino]cyclohexyl]methyl]
carbamate
was synthesized using 5-bromo-2,4-dichloro-pyrimidine and Intermediate K using
the analogous
reaction conditions as described for tert-butyl N42-[(5-bromo-2-chloro-
pyrimidin-4-yl)amino]-
3-methyl-butyl] carbamate. 1I-1NMR (600 MHz, DMSO-d6) 6 ppm 1.18 - 1.54 (m, 17
H) 2.23 (d,
J=14.35 Hz, 2 H) 3.36 (d, J=6.44 Hz, 2 H) 5.82 (s, 1 H) 6.93 (s, 1 H) 8.22 (s,
1 H). LCMS (ESI)
419 (M + H).
tert-butyl N-[ [1- [ [2-chloro-5 -(3 ,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]
amino] cyclohexyl]
methyl] carbamate
OEt
N
I 0
tert-butyl N-[ [1 -[ [2-chloro-5-(3 ,3 -diethoxyprop-1-ynyl)pyrimidin-4-
yl] amino] cyclohexyl]methyl] carbamate was synthesized using similar
experimental conditions
to those used in the synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-
ynyl)pyrimidin-4-y1]-
4-methyl-pentane-1,2-diamine. 1HNMR (600 MHz, DMSO-d6) 6 PPm 1.08 - 1.16 (m, 6
H) 1.17
- 1.54 (m, 17 H) 2.13 (br. s., 2 H) 3.36 (d, J=6.73 Hz, 2 H) 3.50 - 3.69 (m, 4
H) 5.72 (s, 1 H) 6.94
(s, 1 H) 5.72 (br. s., 1H) 8.17 (s, 1 H). LCMS (ESI) 467 (M + H).
146
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7- [1 - [(tert-butoxycarbonylamino)methyl] cyc lohexy11-2-chloro-pyrro lo [2,3
-d]pyrimidine-6-
carboxylic acid
N ==/- \
________________________ CO2 H
o7(
7- [1- [(tert-butoxyc arbonylamino)methyl] cyc lohexyl]-2-chloro-pyrro lo [2,3
-di pyrimidine-
6-carboxylic acid was synthesized using analogous synthetic sequence as that
described for 741-
[(tert-butoxycarbonylamino)methyl]-2-methyl-propy1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.37 - 1.54 (m, 13 H) 1.75
(br. s., 4 H)
2.74 (br. s., 2 H) 3.78 - 3.84 (m, 2 H) 7.44 - 7.51 (m, 1 H) 8.23 (s, 1 H)
9.11 (s, 1 H). LCMS
(ESI) 409 (M + H).
Compound 58
Compound 58 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.28 (br. s., 2 H) 1.42 (br.
s., 2 H) 1.70
(br. s., 4 H) 1.85 - 1.95 (m, 2 H) 2.69 (m, 2 H) 7.16 - 7.25 (m, 1 H) 8.41
(br. s., 1 H) 9.04 (s, 1
H). LCMS 291 (M + H).
Example 59
Synthesis of Compound 59
N \
CI NN H
147
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[[1-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]cyclopentyl]methyll
carbamate
0
CI N H
iHN
0
tert-butyl N-[[1-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]cyclopentyl] methyl]
carbamate was synthesized using 5-bromo-2,4-dichloro-pyrimidine and
Intermediate L using
analogous reaction conditions as described for tert-butyl N-[2-[(5-bromo-2-
chloro-pyrimidin-4-
yl)amino]-3-methyl-butyl]carbamate. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.34 (s, 9
H) 1.50 -
1.58 (m, 2 H) 1.63 - 1.78 (m, 4 H) 1.96 - 2.06 (m, 2 H) 3.25 (d, J=6.15 Hz, 2
H) 6.71 (s, 1 H)
7.18 (t, J=6.29 Hz, 1 H) 8.20 (s, 1 H). LCMS (ESI) 405 (M + H).
tert-butyl N-[ [1-[[2-chloro-5-(3 ,3-di ethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]cycl op entyl]
methyl] carbamate
OEt
,OEt
N
I
0
tert-butyl N-[[1-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]cyclopentyl]methyl]carbamate was synthesized using similar
experimental conditions
to that used in the synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-
ynyOpyrimidin-4-y1]-4-
methyl-pentane-1,2-diamine. LCMS (ESI) 453 (M + H).
148
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7- [1 - [(tert-butoxycarbonylamino)methyl] cyc lop enty1]-2-chloro-pyrro lo
[2,3 -d] pyrimidine-6-
carboxylic acid
N \ ___ co2H
o
CI
7- [1- Rtert-butoxycarbonylamino)methyll cyclopenty1]-2-chloro-pyrrolo [2,3-
d]pyrimidine-6-carboxylic acid was synthesized using the analogous synthetic
sequence as that
described for 7-[1-[(tert-butoxycarbonylamino)methyl]-2-methyl-propy1]-2-
chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.47 (s, 9 H)
1.74 (br. s.,
2 H) 1.88 (br. s., 2 H) 2.04 (br. s., 2 H) 2.41 -2.45 (m, 2 H) 4.06 (s, 2 H)
7.45 (s, 1 H) 9.11 (s, 1
H). LCMS (ESI) 395 (M H).
Compound 59
Compound 59 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.72 (br. s., 2 H) 1.86 -
1.93 (m, 2 H)
1.99 (d, J=3.81 Hz, 2 H) 2.40 (br. s., 2 H) 3.48 (d, J=2.34 Hz, 2 H) 7.22 (s,
1 H) 8.53 (br. s., 1 H)
9.05 (s, 1 H). LCMS (ESI) 277 (M + H).
Example 60
Synthesis of Compound 60
N
CIZ1
N H
149
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-y0amino]-4-methyl-pentyl]
carbamate
NõBr
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]-4-methyl-
pentyl]carbamate
was synthesized using 5-bromo-2,4-dichloro-pyrimidine and Intermediate B using
analogous
reaction conditions as described for tert-butyl N- [2-
The analytical data is consistent with that described for the L-
enantiomer.
tert-butyl N-[2-112-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yllamino]-4-
methyl-pentyl]
carbamate
OEt
N
07( CI ,rq,NH
r"
tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]aminol-4-
methyl-
pentyl]carbamate was synthesized using similar experimental conditions to that
used in the
synthesis of tert-butyl N-[2- [[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-
4-
yl]amino]ethyl]carbamate. IHNMR (600 MHz, CHLOROFORM-d) 6 ppm 1.21 ¨ 1.31 (m,
12
H) 1.38¨ 1.46 (m, 11 H) 1.70 (m, 1H) 3.24 (m, 2 H) 3.65 - 3.82 (m, 4 H) 4.86
(br s., 1H), 5.65
(s, 1 H) 5.85 (br s., 1H) 6.94 (s, 1 H) 8.21 (s, 1 H). LCMS (ESI) 455 (M + H).
150
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7- [1 - [(tert-butoxycarbonylamino)methyl] -3-methyl-butyl]-2-chloro-pyrrolo
[2,3 - d]pyrimidine-6-
carboxylic acid
N \ __ CO2H
CI
0
7- [1- [(tert-butoxycarbonyl amino)m ethyl] -3 -methyl-butyl]-2-chloro-pyrro I
o [2,3-
-- d]pyrimidine-6-carboxylic acid was synthesized using analogous synthetic
sequence as that
described for 7-[1-[(tert-butoxycarbonylamino)methyl]-2-methyl-propy1]-2-
chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid. The analytical data was consistent with that
described for the L-
isomer.
-- Compound 60
Compound 60 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. The analytical data was consistent with that described for
the L-isomer.
Example 61
Synthesis of Compound 61
0
N
C I ¨
To a solution of Compound 60 (100 mg, 0.00024 mole) in DMF (3.0 mL) was added
sodium hydride (60 % dispersion in oil), (27.6 mg, 3 eq). After stirring for
15 mins, methyl
iodide (30, 2 eq) was added. The contents were stirred at room temperature for
30 mins. After
the addition of sat NaHCO3, ethyl acetate was added. Separation of the organic
layer followed
151
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
by drying with magnesium sulfate and concentration under vacuum afforded the
product.
Analytical data was similar to the Compound 49.
Example 62
Synthesis of Compound 62
0
N -- I \
CIN.----"N
I. N H
tert-butyl N- [(1 S ,2 S)-2-1(5 -bromo-2-chloro-pyrimidin-4-yl)aminolcyc lop
entyl] c arbamate
N"- Br
1
CINNH </CI
:
0 HN (
:
tert-butyl N- [(1 S ,2 S)-2- [(5 -bromo-2-chloro-pyrimidin-4-yeamino] cyclop
entyl] carb amate
was synthesized by treating tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate
with 5-bromo-
2,4-dichloro-pyrimidine using analogous reaction conditions as described for
tert-butyl N42-[(5-
bromo-2-chloro-pyrimidin-4-yl)amino]-3-methyl-butylicarbamate. 1FINMR (600
MHz, DMSO-
d6) 6 ppm 1.27 (s, 9H) 1.42 - 1.54 (m, 2H) 1.56 - 1.65 (m, 2 H) 1.80- 1.88 (m,
1 H) 1.96 - 2.01
(m, 1 H) 3.88 - 3.96 (m, 1 H) 4.03 - 4.09 (m, 1 H) 6.91 (d, J=8.20 Hz, 1 H)
7.41 (d, J=7.32 Hz, 1
.. H) 8.18 (s, 1 H). LCMS (ESI) 391 (M + H).
152
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[(1S,2S)-2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]cyclopentylicarbamate
.'o
N
I /0
CIN <
HN __________________________
I
0 (
tert-butyl N - [(1S ,2 S)-2-[ [2-chloro-5-(3 ,3 -diethoxyprop-1-ynyl)pyrimidin-
4-
yl]amino]cyclopentyl]carbamate was synthesized using similar experimental
conditions to that
used in the synthesis of (2S)-N2-[2-chloro-5-(3,3-diethoxyprop-1-
ynyl)pyrimidin-4-y1]-4-
methyl-pentane-1,2-diamine. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.13 (t, 6 H) 1.28
(s, 9 H)
1.42- 1.52 (m, 2 H) 1.58- 1.65 (m, 2 H) 1.81 -1.90 (m, 1 H) 1.99 - 2.08 (m, 1
H) 3.49 - 3.60 (m,
2 H) 3.63 - 3.71 (m, 2 H) 3.84 - 3.93 (m, 1 H) 3.96 -4.04 (m, 1 H) 5.53 (s, 1
H) 6.96 (d, J=7.90
Hz, 1 H) 7.34 (d, J=7.03 Hz, 1 H) 8.14 (s, 1 H). LCMS (ESI) 439 (M + H).
7-[(1S,2S)-2-(tert-butoxycarbonylamino)cyclopenty1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid
X I \ CO2H
H 0
d 0
7-[(1S,2S)-2-(tert-butoxycarbonylamino)cyclopenty1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-
6-carboxylic acid was synthesized using the analogous synthetic sequence as
that described for
7-[1-[(tert-butoxycarbonylamino)methy1]-2-methyl-propyl]-2-chloro-pyrrolo[2,3-
d]pyrimidine-
6-carboxylic acid. 1FINMR (600 MHz, DMSO-d6) 6 ppm 1.41 - 1.52 (m, 9 H) 1.55 -
1.68 (m, 1
153
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
H) 1.88 -2.00 (m, 2 H) 2.05 -2.15 (m, 1 H) 2.26 - 2.35 (m, 1 H) 2.71 -2.89 (m,
1 H) 4.01 -4.16
(m, 1 H) 4.28 - 4.45 (m, 1 H) 7.41 (s, 1 H) 9.11 (s, 1 H). LCMS (ESI) 381 (M +
H).
Compound 62
Compound 62 was synthesized using an analogous synthetic sequence as that
described
for Compound 44. ITINMR (600 MHz, DMSO-d6) 6 ppm 1.48 - 1.60 (m, I H) 1.88 -
1.98 (m, 3
H) 1.99 -2.08 (m, 1 H) 2.66 -2.75 (m, 1 H) 3.63 - 3.74 (m, 1 H) 3.99 -4.12 (m,
1 H) 7.21 (s, 1
H) 8.89 (s, 1 H) 9.04 (s, 1 H). LCMS (ESI) 263 (M + H).
Example 63
Synthesis of Compound 63
N N 0
\
JINN
To chloro tricycliclactam (0.050 g, 0.225 mmole) in dioxane (2.0 mL) under
nitrogen was
added 5-(4-methylpiperazin-1-yl)pyridin-2-amine (0.052 g, 1.2 eq, 0.270 mmole)
followed by
the addition of Pd2(dba)3 (18.5 mg), BINAP (25 mg) and sodium-tert-butoxide (
31 mg, 0.324
mmole). The contents of the flask are degassed for 10 minutes and then heated
to 100 degrees
for 12 hours. The crude reaction was loaded on a silica gel column and eluted
with DCM/Me0H
(0- 15%) to afford the desired product (26 mg). To this compound dissolved in
DCM/Me0H
(10%) was added 3N HC1 in iso-propanol (2 eq) and the reaction was stirred
overnight.
Concentration under vacuum afforded the hydrochloride salt. 1HNMR (d6-DMS0) 6
ppm 11.13
(brs, 1H), 9.07 (s, 1H), 8.42 (s, 1H), 8.03 (br m 1H), 7.99 (s, 1H), 7.67
(brm, 1H), 7.18 (s, 1H),
4.33 (m, 2H), 3.79 (m, 2H), 3.64 (m, 2H), 3.50 (m, 2H), 3.16 (m, 4H), 2.79 (s,
3H). LCMS (ESI)
379 (M + H).
154
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 64
Synthesis of Compound 64
N
N 0
NH
To chloro tricycliclactam (0.075 g, 0.338 mmole) in dioxane (3.5 mL) under
nitrogen was
added tert-butyl 4-(6-amino-3-pyridyl)piperazine-1-carboxylate (0.098 g, 1.05
eq) followed by
the addition of Pd2(dba)3 (27 mg), BINAP (36 mg) and sodium- tert-butoxide (45
mg). The
contents were heated at reflux for 11 hrs. The crude reaction was loaded onto
a silica gel column
and eluted with DCM/Me0H (0- 10 %) to afford the desired product (32 mg). 11-
INMR (d6-
DMS0) 6 ppm 9.48 (s, 1H), 8.84 (s, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 7.99 (s,
1H), 7.42 (m, 1H),
6.98 (s, 1H), 4.23 (m, 2H), 3.59 (m, 2H), 3.45 (m, 4H), 3.50 (m, 2H), 3.05 (m,
4H). LCMS (ESI)
465 (M + H).
Example 65
Synthesis of Compound 65
HN
N 0
JNH
To a solution of Compound 64 (23 mg) in 10% DCM/Me0H was added 10 mL of a 3M
solution of HC1 in iso-propanol. The contents were stirred for 16 hrs.
Concentration of the
reaction mixture afforded the hydrochloride salt. IHNMR (d6-DMS0) 6 ppm 9.01
(s, 1H), 7.94
(m, 1H), 7.86 (m, 1H), 7.23 (s, 1H), 4.30 (m, 2H), 3.64 (m, 2H), 3.36 (m, 4H),
3.25 (m, 4H).
LCMS (ESI) 465 (M + H).
155
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 66
Synthesis of Compound 66
0
N N
I I
N-
To chloro-N-methyltricyclic amide (0.080 g, 0.338 mmole) in dioxane (3.5 mL)
under
nitrogen was added tert-butyl 4-(6-amino-3-pyridyl)piperazine-1-carboxylate
0.102 g (1.1 eq)
followed by the addition of Pd2(dba)3 (27 mg), BINAP (36 mg) and sodium- tert-
butoxide (45
mg). The contents were heated at reflux for 11 hrs. The crude product was
purified using silica
gel column chromatography with an eluent of dichloromethane/methanol (0- 5%)
to afford the
.. desired product (44 mg). 1HNMR (d6-DMS0) 6 ppm 9.49 (s, 1H), 8.85 (s, 1H),
8.32 (m, 1H),
8.02 (s, 1H), 7.44 (m, 1H), 7.00 (s, 1H), 4.33 (m, 2H), 3.80 (m, 2H), 3.48 (m,
4H), 3.07 (m, 4H),
3.05 (s, 3H), 1.42 (s, 9H). LCMS (ESI) 479 (M + H).
Example 67
Synthesis of Compound 67
HN
N 0
\
N¨
To Compound 66 (32 mg) was added 3N HCL (10 mL) in isopropanol and the
contents
were stirred at room temperature overnight for 16 hrs. Concentration afforded
the hydrochloride
salt. 1HNMR (d6-DMS0) 6 ppm 9.13 (m, 2H), 8.11 (m, 1H), 8.10 (s, 1H), 7.62 (m,
1H), 7.21 (s,
1H), 4.43 (m, 2H), 3.85 (m, 2H), 3.41 (m, 4H), 3.28 (m, 4H), 3.08 (s, 3H).
LCMS (ESI) 379 (M
+H).
156
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 68
Synthesis of Compound 68
0
N N 0
I \
NNJNH
Compound 68 was synthesized using similar experimental conditions to that
described
for compound 64. 11-INMR (600 MHz, DMSO-d6) 6 ppm 0.79 (d, J=7.03 Hz, 3 H)
1.01 (d,
.1=6.73 Hz, 3 H) 1.35 - 1.48 (m, 9 H) 2.16 (dd, .J=14.64, 6.73 Hz, 1 H) 3.00 -
3.14 (m, 4 H) 3.40 -
3.51 (m, 4 H) 3.51 - 3.60 (m, 1 H) 3.63 - 3.74 (m, 1 H) 4.44 (dd, J=7.90, 3.81
Hz, 1 H) 6.99 (s, 1
H) 7.46 (dd, J=8.93, 2.78 Hz, 1 H) 7.94 - 8.09 (m, 2 H) 8.31 (dd, J=9.08, 1.46
Hz, 1 H) 8.85 (s, 1
H) 9.46 (s, 1 H). LCMS (ESI) 507 (M + H) .
Example 69
Synthesis of Compound 69
N 0
N
H
Compound 69 was synthesized using similar experimental conditions to those
described
for compound 63 and was recovered as an HC1 salt. IHNMR (600 MHz, DMSO-d6) 6
ppm 0.77
- 0.86 (m, 3 H) 0.96 (d, J=7.03 Hz, 3 H) 2.10 - 2.24 (m, 1 H) 3.07 (s, 3 H)
3.37 - 3.79 (m, 8 H)
4.00 (dd, J=13.61, 4.54 Hz, 2 H) 4.63 - 4.73 (m, 1 H) 7.20 (s, 1 H) 7.58 -
7.71 (m, 1 H) 7.99 (d,
J=2.34 Hz, 1 H) 8.12 (d, J=9.37 Hz, 1 H) 9.11 (s, 1 H) 9.41 (br. s., 2 H)
11.76 (br. s., 1 H).
LCMS (ES!) 421 (M + H).
157
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 70
Synthesis of Compound 70
H
N N 0
H
Compound 70 was synthesized using similar experimental conditions to those
described
for compounds 64 and 65 and was recovered as an HC1 salt. The characterization
data (NMR
and LCMS) was consistent with that reported for compound 71 .
Example 71
Synthesis of Compound 71
H N
N
N
NNIJN H
Compound 71 was synthesized using similar experimental conditions to those
described
for compounds 64 and 65 and was recovered as an HC1 salt. 1FINMR (600 MHz,
DMSO-d6) 6
ppm 0.79 (d, J=6.73 Hz, 3 H) 1.01 (d, J=6.73 Hz, 3 H) 2.18 (dd, J=14.49, 7.17
Hz, 1 H) 3.18
3.84 (m, 10 H) 4.53 - 4.71 (m, 1 H) 7.24 (s, 1 H) 7.65 (d, J=9.37 Hz, 1 H)
8.01 (d, J=2.64 Hz, 1
H) 8.14 (d, J=1.46 Hz, 1 H) 8.35 (d, J=5.27 Hz, 1 H) 9.14 (s, 1 H) 9.46 (s, 2
H) 11.80 (s, 1 H)
LCMS (ESI) 407 (M+H).
158
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 72
Synthesis of Compound 72 (Compound UUU)
HN
N N
N H
Compound 72 was synthesized using similar experimental conditions to that
described
for compounds 64 and 65 and was recovered as an HC1 salt. 11-1NMR (600 MHz,
DMSO-d6) 6
ppm 0.77 (d, J=7.03 Hz, 3 H) 0.99 (d, J=6.73 Hz, 3 H) 2.10 -2.24 (m, 1 H) 3.18
- 3.81 (m, 10 H)
4.54 - 4.69 (m, 1 H) 7.22 (s, 1 H) 7.63 (d, J=9.08 Hz, 1 H) 7.99 (d, J=2.63
Hz, 1 H) 8.11 (s, 1 H)
8.33 (d,1=5.27 Hz, 1 H) 9.12 (s, 1 H) 9.43 (s, 2 H) 11.77 (s, 1 H). LCMS (ESI)
407 (M+H).
Example 73
Synthesis of Compound 73
HN
N
Compound 73 was synthesized using similar experimental conditions to those
described
for compounds 64 and 65 and was recovered as an HC1 salt. 1HNMR (600 MHz, DMSO-
d6) 6
ppm 0.84 (d, J=6.73 Hz, 3 H) 0.98 (d, J=6.73 Hz, 3 H) 2.12 - 2.26 (m, 1 H)
3.09 (s, 3 H) 3.22 -
3.81 (m, 8 H) 4.01 (dd, J=13.61, 4.25 Hz, 2 H) 4.59 - 4.72 (m, 1 H) 7.19 (s, 1
H) 7.74 (s, 1 H)
7.96 - 8.10 (m, 2 H) 9.08 (s, 1 H) 9.22 (s, 2 H). LCMS (ESI) 421 (M+H).
159
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 74
Synthesis of Compound 74
N 0
NH
Compound 74 was synthesized using similar experimental conditions to those
described
for compound 63 and was recovered as an HC1 salt. llnINMR (600 MHz, DMSO-d6) 6
ppm 0.85
(d, J=4.98 Hz, 3 H) 0.95 (d, J=4.98 Hz, 3 H) 1.42 - 1.70 (m, 3 H) 2.77 (d,
J=2.93 Hz, 3 H) 3.07 -
4.14 (m, 10 H) 4.95 (s, 1 H) 7.20 (s, 1 H) 7.66 (d, J=9.66 Hz, 1 H) 7.94 (s, 1
H) 8.08 - 8.16 (m, 1
H) 8.33 (d, J=4.68 Hz, 1 H) 9.09 (s, 1 H) 11.38 (s, 1 H) 11.71 (s, 1 H). LCMS
(ESI) 435 (M+H).
Example 75
Synthesis of Compound 75
HN
N 0
NH
Compound 75 was synthesized using similar experimental conditions to those
described
for compounds 64 and 65 and was recovered as an HC1 salt. 11-INMR (600 MHz,
DMSO-d6) 6
ppm 0.87 (d, J=6.15 Hz, 3 H) 0.94 (d, J=6.15 Hz, 3 H) 1.57 (d, J=84.61 Hz, 3
H) 3.05 (s, 3 H)
3.13 - 3.55 (m, 8 H) 3.69 (d, J=78.17 Hz, 2 H) 4.90 (s, 1 H) 7.15 (s, 1 H)
7.63 - 7.85 (m, 1 H)
7.93 (s, 1 H) 8.26 (s, 1 H) 9.03 (s, 1 H) 9.20 (s, 2 H). LCMS (ESI) 421 (M+H).
160
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 76
Synthesis of Compound 76
N N 0
\
Compound 76 was synthesized using similar experimental conditions to those
described
for compound 63 and was recovered as an HC1 salt. 1FINMR (600 MHz, DMSO-d6) 6
ppm 0.85
(d, J=6.44 Hz, 3 H) 0.95 (d, J=6.44 Hz, 3 H) 1.43 - 1.70 (m, 3 H) 2.78 (d,
J=2.93 Hz, 3 H) 3.05
(s, 3 H) 3.24 - 3.84 (m, 8 H) 4.01 (d, J=9.66 Hz, 2 H) 4.89 - 5.01 (m, 1 H)
7.15 (s, 1 H) 7.77 (s, 1
H) 7.91 - 8.05 (m, 2 H) 9.03 (s, 1 H) 10.96- 11.55 (m, 2 H). LCMS (ESI) 449
(M+H).
Example 77
Synthesis of Compound 77
HN
N N
Compound 77 was synthesized using similar experimental conditions to those
described
for compounds 64 and 65 and was recovered as an HC1 salt. lEINMR (600 MHz,
DMSO-d6) 6
ppm 0.83 - 0.88 (d, J=6.15 Hz, 3 H) 0.95 (d, J=6.15 Hz, 3 H) 1.40 - 1.71 (m, 3
H) 3.28 - 3.83 (m,
161
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
8 H) 4.00 (d, J=3.22 Hz, 2 H) 4.91 - 5.08 (m, 1 H) 7.17 (s, 1 H) 7.68 (d,
J=9.66 Hz, 1 H) 7.93 (s,
1 H) 8.07 (s, 1 H) 9.06 (s, 1 H) 9.40 (s, 2 H) 11.59 (s, 1 H). LCMS (ESI) 435
(M+H).
Example 78
Synthesis of Compound 78
N N 0
N H
To Compound 50 0.060 g (0.205 mmole) was added 5-(4-methylpiperazin- 1-
yl)pyridin-
2-amine (35.42 mg, 0.9 eq) followed by the addition of 1,4-dioxane (3 mL).
After degassing
with nitrogen, Pd2dba3 (12 mg), BINAP (16 mg) and sodium tert-butoxide (24 mg)
were added.
The contents were then heated at 90 degrees in a CEM Discovery microwave for 3
hrs. The
reaction was then loaded onto a silica gel column and purified by eluting with
DCM/Me0H (0-
15%). 1FINMR (600 MHz, DMSO-d6) 6 ppm 0.75 (t, J=7.47 Hz, 3 H) 0.91 (d, J=6.73
Hz, 3 H)
1.04 - 1.20 (m, 2 H) 1.80 - 1.98 (m, 1 H) 2.77 (d, J=3.81 Hz, 3 H) 2.94 - 3.90
(m, 10 H) 4.54 -
4.68 (m, 1 H) 7.06 - 7.23 (m, 2 H) 7.56 - 7.75 (m, 1 H) 7.90 - 8.12 (m, 2 H)
8.29 (s, 1 H) 9.07 (s,
1 H) 10.98 - 11.74 (m, 2 H). LCMS (ESI) 435 (M + H).
162
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 79
Synthesis of Compound 79
HN
N N
N H
Compound 79 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.75 (t, J=7.32 Hz, 3 H) 0.90 (d, J=6.73 Hz, 3
H) 1.07 -
1.15 (m, 2 H) 1.85 - 1.94 (m, 1 H) 3.17 - 3.75 (m, 10 H) 4.58 -4.67 (m, 1 H)
7.17 (s, 1 H) 7.71
(s, 1 H) 7.96 (s, 1 H) 7.98 - 8.05 (m, 1 H) 8.28 (d, J=4.10 Hz, 1 H) 9.06 (s,
1 H) 9.39 (s, 2 H).
LCMS (ESI) 421 (MAI).
Example 80
Synthesis of Compound 80
N
N 0
\
Compound 80 was synthesized in a similar manner to that described for compound
78.
iHNMR (600 MHz, DMSO-d6) 6 ppm 0.78 (t, J=7.32 Hz, 3 H) 0.86 (d, J=6.73 Hz, 3
H) 1.13 -
1.21 (m, 2 H) 1.84 - 1.96 (m, 1 H) 2.77 (d, J=4.39 Hz, 3 H) 3.04 (s, 3 H) 3.11
- 3.84 (m, 8 H)
3.98 (dd, J=13.61, 4.25 Hz, 2 H) 4.66 - 4.74 (m, 1 H) 7.17 (s, 1 H) 7.64 (s, 1
H) 7.96 (d, J=2.34
163
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Hz, 1 H) 8.03 - 8.13 (m, 1 H) 9.08 (s, 1 H) 11.26 (s, 1 H) 11.66 (s, 1 H).
LCMS (ESI) 449
(M+H).
Example 81
Synthesis of Compound 81
HI\J
N N 0
\
JN-
\
The compound was synthesized in a similar manner to that described for
compound 78
followed by the deblocking step described for compound 65 and was converted to
an HO salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.78 (t, J=7.32 Hz, 3 H) 0.85 (d, J=6.73 Hz, 3
H) 1.10 -
1.27 (rn, 2 H) 1.82 - 1.99 (m, 1 H) 3.04 (s, 3 H) 3.28 -3.77 (rn, 8 H) 3.97
(dd, J=13.91, 4.54 Hz,
2 H) 4.62 - 4.75 (m, 1 H) 7.07 - 7.24 (m, 1 H) 7.62 - 7.75 (m, 1 H) 7.94 (d,
J=2.34 Hz, 1 H) 7.97
- 8.08 (m, 1 H) 9.05 (s, 1 H) 9.29 (s, 2 H). LCMS (ESI) 435 (M+H).
Example 82
Synthesis of Compound 82
HN
N 0
\
NH
The compound was synthesized in a similar manner to that described for
compound 78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.96 (s, 9 H) 3.15 - 3.87 (m, 10 H) 4.42 - 4.53
(m, 1 H)
164
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
6.99 (s, 1 H) 7.24 (s, 1 H) 8.06 (s, 1 H) 8.11 - 8.21 (m, 1 H) 8.79 - 8.98 (m,
2 H) 9.25 (s, 2 H)
9.88 (s, 1 H). LCMS (ESI) 421 (M+H).
Example 83
Synthesis of Compound 83
HN
N N 0
\
Compound 83 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HO salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.95 (s, 9 H) 2.79 (d, J=4.10 Hz, 3 H) 3.06 -
3.86 (m, 10
.. H) 4.56 - 4.67 (m, 1 H) 7.17 (s, 1 H) 7.70 (s, 1 H) 7.96 (d, J=2.63 Hz, 1
H) 7.99 - 8.08 (m, 1 H)
8.26 (s, 1 H) 9.06 (s, 1 H) 10.80 (s, 1 H). LCMS (ES1) 435 (M+H).
Example 84
Synthesis of Compound 84
N 0
N H
Compound 84 was synthesized in a similar manner to that described for compound
78
and was converted to an HC1 salt. 11-1NMR (600 MHz, DMSO-d6) 6 ppm 2.75 - 2.81
(m, 3 H)
165
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
3.12 - 3.16 (m, 2 H) 3.46 - 3.54 (m, 4 H) 3.60 - 3.69 (m, 2 H) 3.72 - 3.79 (m,
1 H) 4.07 -4.18 (m,
2 H) 6.06 - 6.09 (m, 1 H) 6.90 (d, J=7.61 Hz, 2 H) 7.20 - 7.31 (m, 3 H) 7.33
(s, 1 H) 7.49 - 7.55
(m, 1 H) 7.62 - 7.70 (m, 1 H) 7.92 (d, J=2.93 Hz, 1 H) 8.22 (s, 1 H) 9.14 (s,
1 H). LCMS (ESI)
455 (M + H).
Example 85
Synthesis of Compound 85
HN
N
N H
Compound 85 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 3.21 (s, 4 H) 3.35 - 3.67 (m, 5 H) 4.07 - 4.20
(m, 2 H)
6.13 (s, 1 H) 6.90 (d, J=7.32 Hz, 2 H) 7.22 - 7.31 (m, 3 H) 7.36 (s, 1 H) 7.48
(d, J=9.37 Hz, 1 H)
7.93 (d, J=2.34 Hz, 1 H) 8.04 - 8.11 (m, 1 H) 8.25 (d, J=4.98 Hz, 1 H) 9.17
(s, 1 H) 11.77 (br, s.,
1H). LCMS (ESI) 441 (M + H).
166
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 86
Synthesis of Compound 86
H N
N N
N 0
H
Compound 86 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 0.90 (d, J=6.15 Hz, 6 H) 1.72 - 1.89 (m, 1 H)
3.15 - 3.92
(m, 9 H) 4.10 - 4.46 (m, 2 H) 7.18 (s, 1 H) 7.59 (d, J=8.78 Hz, 1 H) 8.00 (s,
1 H) 8.13 (d, J=9.37
Hz, 1 H) 8.55 (s, 1 H) 9.09 (s, 1 H) 9.67 (s, 2 H) 11.91 (s, 1 H). LCMS (ES1)
407 (ES1).
Example 87
Synthesis of Compound 87
H N
N N
N 0
N N N H
Compound 87 was synthesized in a manner similar to compound 86 and was
converted to
an HC1 salt. The characterization data (NMR and LCMS) was similar to that
obtained for the
antipode compound 86.
167
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 88
Synthesis of Compound 88
HN
N N 0
\ -
Compound 88 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 3-and was converted
to an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 1.78 (s, 6 H) 3.40 - 3.53 (m, 6 H) 3.64 - 3.73
(m, 4 H)
7.27 (s, 1 H) 7.66 (d, J=9.37 Hz, 1 H) 7.98 (d, J=2.34 Hz, 1 H) 8.12 (br. s.,
1 H) 8.47 (br. s., 1 H)
9.11 (s, 1 H) 9.45 (br. s., 2 H) 11.62 (br. s., 1 H). LCMS (ES1) 393 (M + H).
.. Example 89
Synthesis of Compound 89 (also referred to as Compound T)
N 0
N H
Compound 89 was synthesized in a similar manner to that described for compound
78
and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.47 (br. s.,
6 HT 1.72
(br. s., 2 H) 1.92 (br. s., 2 H) 2.77 (br. s., 3 H) 3.18 (br. s., 2 H) 3.46
(br. s., 2 H) 3.63 (br. s., 2 H)
3.66 (d, J=6.15 Hz, 2 H) 3.80 (br. s., 2 H) 7.25 (s, 1 H) 7.63 (br. s., 2 H)
7.94 (br. s., 1 H) 8.10
(br. s., 1 H) 8.39 (br. s., 1 H) 9.08 (br. s., 1 H) 11.59 (br. s., 1 H). LCMS
(EST) 447 (M + H).
168
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 90
Synthesis of Compound 90 (also referred to as Compound Q)
HN
N N
N H
Compound 90 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 1.27 - 1.64 (m, 6 H) 1.71 (br. s., 2 H) 1.91
(br. s., 2 H)
2.80 (br. s., 1 H) 3.17 - 3.24 (m, 2 H) 3.41 (br. s., 4 H) 3.65 (br. s., 4 H)
7.26 (br. s., 1 H) 7.63
(br. s., 1 H) 7.94 (br. s., 1 H) 8.13 (br. s., 1 H) 8.40 (br. s., 1 H) 9.09
(br. s., 1 H) 9.62 (br. s., 1 H)
11.71 (br. s., 1 H). LCMS (ESI) 433 (M + H).
Example 91
Synthesis of Compound 91 (also referred to as Compound ZZ)
N N
NN7JN
Compound 91 was synthesized using similar conditions to those described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.64 -
1.75 (m, 2 H)
1.83 - 1.92 (m, 2 H) 1.96 - 2.06 (m, 2 H) 2.49 - 2.58 (m, 2 H) 2.79 (d, J=3.81
Hz, 3 H) 3.06 -
3.18 (m, 4H) 3.59 - 3.69 (m, 2 H) 3.73 - 3.83 (m, 2 H) 4.04 - 4.12 (m, 2H)
7.17 (br. s., 1 H)
7.60 - 7.70 (m, 2 H) 7.70 - 7.92 (m, 2 H) 7.96 (br. s., 1 H) 8.41 (br. s., 1
H) 8.98 (br. s., 1 H)
10.77 (br. s., 1 H). LCMS (ESI) 433 (M + H).
169
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 92
Synthesis of Compound 92
HN
N N
N H
Compound 92 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 1.64 - 1.75 (m, 2 H) 1.84 - 1.92 (m, 2 H) 1.96 -
2.05 (m, 2
H) 2.48 - 2.56 (m, 2 H) 3.22 (br. s., 4 H) 3.42 - 3.48 (rn, 4 H) 3.60 - 3.69
(m, 2 H) 4.05 - 4.13 (m,
1 H) 7.18 (s, 1 H) 7.65 (d, J=13.47 Hz, 1 H) 7.70 - 7.77 (m, 1 H) 7.94 (d,
J=1.76 Hz, 1 H) 8.42
(br. s., 1 H) 9.00 (s, 1 H) 9.15 (br. s., 2 H). LCMS (EST) 419 (M + H).
Example 93
Synthesis of Compound 93
HN
N
Compound 93 was synthesized in a similar manner to that described for compound
78
followed by the deblocking step described for compound 65 and was converted to
an HC1 salt.
1HNMR (600 MHz, DMSO-d6) 6 ppm 1.76 (br. s., 2 H) 1.89 (br. s., 2 H) 2.03 (br.
s., 2 H) 2.47 -
2.58 (m, 2 H) 3.04 (s, 3 H) 3.22 (br. s., 4 H) 3.39 (br. s., 4 H) 3.66 (s, 2
H) 7.21 (s, 1 H) 7.67 (d,
170
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
J=9.37 Hz, 1 H) 7.93 (br. s., 1 H) 7.98 - 8.09 (m, 1 H) 9.04 (s, 1 H) 9.34
(br. s., 2 H) 11.31 (br.
s., 1 H). LCMS (ESI) 433 (M + H).
Example 94
Synthesis of Compound 94
o
N N 0
NN7JN H
Compound 94 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) .8 ppm 1.66 -
1.77 (m, 2 H)
1.84 - 1.94 (m, 2 H) 1.96 - 2.08 (m, 2 H) 2.48 - 2.57 (m, 2 H) 3.36 - 3.52 (m,
4 H) 3.60 - 3.80 (m,
6 H) 7.21 (s, 1 H) 7.53 -7.74 (m, 2 H) 7.86 (s, 1 H) 8.02 (s, 1 H) 8.45 (s, 1
H) 9.03 (s, 1 H) 11.19
(br. s., 1 H). LCMS (ESI) 420 (M+H).
Example 95
Synthesis of Compound 95
N 0
Compound 95 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 Ppm 1.65 -
1.79 (m, 2 H)
1.85 - 1.95 (m, 2 H) 1.97 - 2.08 (m, 2 H) 2.47 - 2.54 (m, 2 H) 3.40 - 3.58 (m,
5 H) 3.65 (dd,
171
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
J=21.67, 5.56 Hz, 1 H) 3.69 - 3.78 (m, 4 H) 7.24 (s, 1 H) 7.97 - 8.17 (m, 2 H)
8.48 (s, 1 H) 9.08
(s, 1 H) 11.81 (s, 1 H). LCMS (ESI) 421 (M+H).
Example 96
Synthesis of Compound 96
0
N \
N H
HOJ
Compound 96 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 8 Ppm 1.55 -
1.74 (m, 2 H)
1.80 - 1.98 (m, 4 H) 2.48 - 2.60 (m, 2 H) 3.40 - 3.50 (m, 4 H) 3.57 - 3.72 (m,
2 H) 3.90 -4.20 (m,
4 H) 7.08 (s, 1 H) 7.37 - 7.57 (m, 2 H) 7.70 (m, 2 H) 8.32 (s, 1 H) 8.88 (s, 1
H) 9.98 (s, 1 H).
LCMS (ESI) 419 (M+H).
Example 97
Synthesis of Compound 97 (also referred to as Compound III)
N
N
Compound 97 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.30 (d,
J=5.27 Hz,
6 H) 1.65 - 1.78 (m, 2 H) 1.83 - 1.95 (m, 2 H) 1.97 -2.10 (m, 2 H) 2.45 -2.55
(m, 2H) 3.25 -
172
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
3.36 (m, 1 H) 3.39 - 3.48 (m, 4 H) 3.60 - 3.70 (m, 4 H) 3.75 - 4.15 (m, 2 H)
7.24 (s, 1 H) 7.54 -
7.75 (m, 2 H) 7.95 (s, 1 H) 8.10 (s, 1 H) 8.49 (s, 1 H) 9.07 (s, 1 H) 11.25
(s, 1 H) 11.48 (s, 1 H).
LCMS (ESI) 461 (M+H).
Example 98
Synthesis of Compound 98
N 0
QN H
.)
Compound 98 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1FINMR (600 MHz, DMSO-d6) 6 ppm 0.99 (d,
J=6.15 Hz,
6 H) 1.65 - 1.78 (m, 2 H) 1.90 (m, 2 H) 1.97 - 2.08 (m, 2 H) 2.08 - 2.17 (m, 1
H) 2.45 - 2.55 (m,
2H) 2.88 - 3.02 (m, 2 H) 3.33 - 3.48 (m, 4 H) 3.50 - 3.90 (m, 6 H) 7.24 (s, 1
H) 7.67 (s, 2 H) 7.94
(s, 1 H) 8.12 (s, 1 H) 8.49 (s, 1 H) 9.07 (s, 1 H) 10.77 (s, 1 H) 11.51 (s, 1
H). LCMS (ESI) 475
(M+H).
Example 99
Synthesis of Compound 99
o
N.====="' 0
N H
173
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 99 was synthesized using similar conditions to those described for
compound
78 and was converted to an HC1 salt. IHNMR (600 MHz, DMSO-d6) 6 ppm 1.13 (d,
J=5.86 Hz,
6 H) 1.66 - 1.77 (m, 2 H) 1.84- 1.94 (m, 2 H) 1.97 - 2.09 (m, 2 H) 2.40 - 2.53
(m, 2 H) 3.37 -
3.49 (m, 2 H) 3.50 - 3.59 (m, 2 H) 3.59 - 3.73 (m, 4 H) 7.23 (s, 1 H) 7.64 (m,
3 H) 7.85 (s, 1 H)
8.11 (s, 1 H) 8.47 (s, 1 H) 9.05 (s, 1 H). 11.35 (br s., 1H). LCMS (ESI) 448
(M+H).
Example 100
Synthesis of Compound 100
H2 C
N 0
N H
Compound 100 was synthesized using similar conditions to that described for
compound
78 and was converted to an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.50 -
1.57 (m, 2 H)
1.62- 1.68 (m, 3 H) 1.68- 1.75 (m, 2 H) 1.84- 1.92 (m, 2 H) 1.97 - 2.08 (m, 2
H) 2.48 - 2.53 (m,
2 H) 3.14 - 3.23 (m, 4 H) 3.43 - 3.47 (m, 2 H) 3.58 - 3.70 (m, 2 H) 7.22 (s, 1
H) 7.58 - 7.70 (m, 2
H) 7.85 - 8.00 (m, 1 H) 8.16 (d, 1 H) 8.46 (s, 1 H) 9.04 (s, 1 H) 11.37 (br
s., 1H). LCMS (ESI)
418 (M + H).
Example 101
Synthesis of Compound 101 (also referred to as Compound WW)
o=
N'NN 0
I I \
___/N NH
Q.)
174
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 101 was synthesized using similar conditions to those described for
compound 78 and was converted to an HC1 salt. IHNMR (600 MHz, DMSO-d6) 6 ppm
1.72 (s,
2 H) 1.90 (s, 4 H) 2.03 (s, 2 H) 2.21 (s, 2 H) 2.48 - 2.54 (m, 2 H) 2.73 (s, 2
H) 3.03 (s, 2 H) 3.25
-3.35 (m, 1 H) 3.38 -3.48 (m, 4 H) 3.65 -3.99 (m, 5 H) 7.23 (s, 1 H) 7.63 (d,
J=9.66 Hz, 1 H)
7.90 (s, 1 H) 8.13 (s, 1 H) 8.47 (s, 1 H) 9.06 (s, 1 H) 10.50 (hr s., 1H).
LCMS (ES1) 503 (M +
H).
Example 102
Synthesis of Compound 102 (also referred to as Compound HHH)
N 0
\
NH
1 0
Compound 102 was synthesized using similar conditions to those described for
compound 78 and was converted to an HC1 salt. IHNMR (600 MHz, DMSO-d6) 6 ppm
1.63 -
1.85 (m, 6 H) 1.87- 1.92 (m, 2 H) 1.99 - 2.06 (m, 2 H) 2.15 -2.23 (m, 2 H)
2.47 - 2.53 (m, 1 H)
2.69 - 2.79 (m, 2 H) 2.81 -2.91 (m, 2 H) 2.98 - 3.08 (m, 2 H) 3.32 - 3.48 (m,
4 H) 3.57 - 3.72 (m,
4 H) 3.77 - 3.85 (m, 2 H) 7.22 (s, 1 H) 7.60 - 7.68 (m, 2 H) 7.90 (s, 1 H)
8.07 (s, 1 H) 8.46 (s, 1
H) 9.04 (s, 1 H). 11.41 (br s., 1H). LCMS (ESI) 501 (M + H).
Example 103
Synthesis of Compound 103
N N N 0
I \
N N H
175
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 103 was synthesized using similar conditions to those described for
compound 78 and was converted to an HC1 salt. IHNMR (600 MHz, DMSO-d6) 6 ppm
1.64 -
1.76 (m, 2 H) 1.87 - 1.93 (m, 2 H) 2.00 -2.07 (m, 2 H) 2.48 - 2.53 (m, 2 H)
2.67 -2.72 (m, 4 H)
3.44 - 3.47 (m, 2 H) 3.50 - 3.55 (m, 4 H) 7.24 (s, 1 H) 7.61 (d, J=9.37 Hz, 2
H) 7.86 (d, J=2.63
Hz, 1 H) 8.09 (d, J=12.88 Hz, 1 H) 8.48 (s, 1 H) 9.06 (s, 1 H) 11.41 (br s.,
1H). LCMS (ES1)
436 (M + H).
Example 104
Synthesis of Compound 104
HN
N N 0
I \
JN NH
Compound 104 was synthesized using similar conditions to those described for
compound 78 and was converted to an HCl salt. IHNMR (600 MHz, DMSO-d6) 6 ppm
1.29 (d,
J=6.73 Hz, 6 H) 1.66 - 1.79 (m, 2 H) 1.84 - 1.95 (m, 2 H) 1.98 -2.09 (m, 2 H)
2.46 - 2.55 (m, 2
H) 3.29 - 3.39 (m, 2H) 3.58 -3.70 (m, 4H) 3.77 - 3.86 (m, 4H) 7.24 (s, 1 H)
7.66 (d, J=9.37 Hz,
1 H) 7.96 (d, J=2.93 Hz, 1 H) 8.08 (s, 1 H) 8.48 (s, 1 H) 9.06 (s, 1 H) 9.28
(s, 1 H) 9.67 (s, 1 H)
11.36 (s, 1H). LCMS (ESI) 447 (M + H).
176
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 105
Synthesis of Compound 105
N 0
I I \
iN NH
L=s)
Compound 105 was synthesized using similar conditions to those described for
compound 78 and was converted to an HC1 salt. 1FINMR (600 MHz, DMSO-d6) 6 ppm
1.73 (s,
2 H) 1.76- 1.85 (m, 2 H) 1.85 - 1.94 (m, 2 H) 1.98 -2.07 (m, 2 H) 2.19 - 2.26
(m, 2 H) 2.48 -
2.52 (m, 1 H) 2.70 -2.81 (m, 4 H) 3.13 -3.20 (m, 1 H) 3.30 -3.48 (m, 3 H) 3.58
-3.71 (m, 4 H)
3.78 - 3.84 (m, 4 H) 7.24 (s, 1 H) 7.62 (d, 1=9.37 Hz, 2 H) 7.89 (d, 1=1.17
Hz, 1 H) 8.09 - 8.18
(m, 1 H) 8.48 (s, 1 H) 9.06 (s, 1 H) 11.46 (br s., 1H). LCMS (ESI) 519 (M +
H).
Example 106
Synthesis of Compound 106
N
NH
/
N 0
Compound 106 was synthesized using similar conditions to those described for
compound 78 followed by the deblocking step described for compound 65 and was
converted to
an HC1 salt. 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.65 - 1.75 (m, 2 H) 1.85 - 1.93
(m, 2 H)
1.93 - 1.99 (m, 1 H) 2.00 - 2.06 (m, 2 H) 2.08 - 2.14 (m, 1 H) 2.47 -2.55 (m,
2 H) 3.07 - 3.25 (m,
177
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
2 H) 3.25 - 3.69 (m, 5 H) 4.46 (s, 1 H) 4.67 (s, 1 H) 7.22 (s, 1 H) 7.58 -
7.69 (m, 2 H) 8.46 (s, 1
H) 9.02 (s, 1 H) 9.34 (s, 1 H) 9.65 (s, 1 H). LCMS (ESI) 431 (M + H).
Example 107
Synthesis of Compound 107 (also referred to as Compound YY)
N N 0
\
_JN NH
IN'\2
Compound 107 was synthesized using similar conditions to those described for
compound 78 and was converted to an HC1 salt. 1FINMR (600 MHz, DMSO-d6) ppm
1.65 -
1.82 (m, 3 H) 1.89 (br. s., 2 H) 1.98 -2.08 (m, 2 H) 2.13 (br. s., 2 H) 2.47 -
2.55 (m, 2 H) 2.68 (d,
-- J=4.98 Hz, 6 H) 2.71 - 2.80 (m, 2 H) 3.29 - 3.71 (m, 10 H) 7.16 - 7.26 (m,
1 H) 7.67 (d, J=9.66
Hz, 2 H) 7.91 (d, J=2.05 Hz, 1 H) 8.14 (br. s., 1 H) 8.48 (br. s., 1 H) 9.05
(s, 1 H) 11.14 (br. s., 1
H) 11.43 (br. s., 1 H). LCMS (ESI) 461 (M + H).
Example 108
Synthesis of Compound 108
EHNI
N 0
I I \
N H
Compound 108 was synthesized in a manner similar to that described for
compounds 64
and 65 and was recovered as an HC1 salt. The analytical data was consistent
with that described
for the antipode compound 75 .
178
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 109
Synthesis of Compound 109
FIN-
I I
'N'k'NN 5 Compound 109 was synthesized in a manner similar to that
described for compounds 64
and 65 and was recovered as an MCI salt. The analytical data was consistent
with that described
for the antipode compound 75.
Example 110
-- Synthesis of Compound 110
-.,.......................,..... N
l'NNI'-'N
/ N H
,\
Compound 110 was synthesized in a similar manner to that described for
compound 78
and then converted to its hydrochloride salt. 1FINMR (600 MHz, DMSO-d6) 6 ppm
1.50 - 1.65
(m, 1 H) 1.92 -2.02 (m, 3 H) 2.06 -2.15 (m, 1 H) 2.78 (d, J=3.81 Hz, 4 H) 3.10
- 3.20 (m, 4 H)
3.47 - 3.51 (m, 2 H) 3.64 - 3.71 (m, 1 H) 3.76 - 3.83 (m, 2 H) 3.98 -4.14 (m,
1 H) 7.20 (s, 2 H)
7.77 (s, 1 H) 7.97 (s, 2 H) 8.81 (s, 1 H) 9.03 (s, 1 H) 10.97 (br s., 1H).
LCMS (EST) 419 (M +
H).
179
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 111
Synthesis of Compound 111
HN
N
N D
H
Compound 111 was synthesized in a similar manner to that described for
compound 78
and then converted to its hydrochloride salt. 11-1NMR (600 MHz, DMSO-d6) ppm
1.54 - 1.59
(m, 1 H) 1.92 - 2.01 (m, 3 H) 2.06 - 2.15 (m, 1 H) 2.76 - 2.84 (m, 1 H) 3.17 -
3.24 (m, 6 H) 3.64 -
3.71 (m, 2 H) 4.02 - 4.11 (m, 2 H) 7.22 (s, 2 H) 7.64 (s, 1 H) 7.97 (s, 2 H)
8.75 (s, 1 H) 8.97 (s, 1
H) 9.21 (s, 1 H). LCMS (ESI) 405 (M + H).
Example 112
Synthesis of Compound 112
XON
N 0
I
N NH
180
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 112 was synthesized using similar experimental conditions to that
described for
compound 64.
Example 113
Synthesis of tert-butyl N-12-[(5-bromo-2-chloro-pyrimidin-4-
yDamino]ethyl]carbamate,
Compound 113
CN
GI,
To a solution of 5-bromo-2,4-dichloropyrimidine (12.80 g, 0.054 mole) in
ethanol (250
mL) was added Hunig's base (12.0 mL) followed by the addition of a solution of
N-(tert-
butoxycarbony1)-1,2-diaminoethane (10 g, 0.0624 mole) in ethanol (80 mL). The
contents were
stirred overnight for 20 hrs. The solvent was evaporated under vacuum. Ethyl
acetate (800 mL)
and water (300 mL) were added and the layers separated. The organic layer was
dried with
magnesium sulfate and then concentrated under vacuum. Column chromatography on
silica gel
using hexane/ethyl acetate (0- 60%) afforded tert-butyl N-[2-[(5-bromo-2-
chloro-pyrimidin-4-
yOamino]ethyl]carbamate. LCMS (ESI) 351 (M + H).
Example 114
Synthesis of tert-butyl N-12-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4
yl]amino]ethyl]carbamate, Compound 114
N
CI
11 --
0
To tert-butyl N-[2-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]ethyl]carbamate (5
g, 14.23
mmole) in toluene (42 mL) and triethylamine (8.33 mL) under nitrogen was added
triphenyl
181
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
arsine (4.39 g), 3,3-diethoxyprop-1-yne (3.24 mL) and Pddba (1.27 g). The
contents were heated
at 70 degrees for 24 hrs. After filtration through CELITEO, the crude reeacton
was columned
using hexane/ethyl acetate (0- 20%) to afford the desired product 3.9 g).
Column
chromatography of the resulting residue using hexane/ethyl acetate (0- 30%)
afforded tert-butyl
N - [2- [ [2-chloro-5 -(3 ,3-diethoxyprop-1-ynyl)pyrimidin-4-yl] amino]
ethylic arbamate LCMS
(EST) 399 (M + H).
Example 115
Synthesis of tert-butyl N-12-[2-chloro-6-(diethoxymethyl)pyrrolo [2,3-d]
pyrimidin-7-
yl] ethyl] carbamate, Compound 115
\2> (
\o
\\.
0
To a solution of Compound 114 (3.9 g, 0.00976 mole) in THF (60 mL) was added
TBAF
(68.3 mL, 7eq). The contents were heated to 45 degrees for 2 hrs.
Concentration followed by
column chromatography using ethyl acetate/hexane (0-50%) afforded tert-butyl N-
[2-[2-chloro-
6-(diethoxymethyppyrrolo[2,3-d]pyrimidin-7-yllethylicarbamate as a pale brown
liquid (1.1 g).
1HNMR (d6-DMS0) 6 ppm 8.88 (s, 1H), 6.95 (brs, 1H), 6.69 (s, 1H), 5.79 (s,
1H), 4.29 (m, 2H),
3.59 (m, 4H), 3.34 (m, 1H), 3.18 (m, 1H), 1.19 (m, 9H), 1.17 (m, 6H). LCMS
(ESI) 399 (M+H).
182
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 116
Synthesis of tert-butyl N-1242-chloro-6-(diethoxymethyl)-5-iodo-pyrrolo[2,3-
d]pyrimidin-
7-yllethyl]carbamate, Compound 116
K1
I \ ________________
oi o __
To tert-butyl N42-[2-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]pyrimidin-7-
yl]ethyl]carbamate (0.1 g, 0.00025 mol) in acetonitrile (2 mL) was added 1,3-
diiodo-5,5-
dimethylhydantoin (95 mg, 1 eq), and solid NaHCO3 (63 mg, 3 eq). The reacation
was stirred at
room tempreature for 16 hrs. The reaction was filtered and concentrated in
vacuo. The product
was purified by silica gel column chromatography using hexane/ethylacetate (0
¨ 50%) to afford
.. tert-butylN4242-chloro-6-(diethoxymethyl)-5-iodo-pyrrolo[2,3-d]pyrimidin-7-
yl]ethyl]carbamate as a pale yellow solid (0.03 g). LCMS (ESI) 525 (M + H).
183
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 117
Synthesis of tert-Butyl N-[242-chloro-6-(diethoxymethy0-5-(o-tolyBpyrrolo[2,3-
d]pyrimidin-7-yliethyl]carbamate, Compound 117
N
I \
et 'N
0 ________________________ \
.\9'o
To tert-butyl N42-[2-chloro-6-(diethoxymethyl)-5-iodo-pyrrolo[2,3-d]pyrimidin-
7-
yllethyl]carbamate (0.1g , 0.19 mmolc) in dioxanc (3 mL) was added 2-
methylphenylboronic
acid (28 mg), tetrakis(triphenylphosphine)palladium (25 mg) and potassium
phosphate (250 mg)
in water (0.3 mL). The reaction was heated in a CEM Discovery microwave at 90
C for 3 hrs.
The crude reaction was loaded onto silica gel and columned using hexane/ethyl
acetate (0 ¨
30%) to afford tert-butyl N-[242-chloro-6-(diethoxymethyl)-5-(o-
tolyppyrrolo[2,3-d]pyrimidin-
7-yllethyl]carbamate (0.06 g). LCMS (ESI) 489 (M + H).
184
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 118
Synthesis of 7-[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-(o-
tolyppyrrolo[2,3-
d]pyrimidine-6-carboxylic acid, Compound 118
re,"7"----4,:µ,õOH
\
1 = 0
1 t
To tert-butyl N-[2- [2-chloro-6-(diethoxymethyl)-5 -(o-to lyl)pyrrolo [2,3 -d]
pyrimidin-7-
yflethylicarbamate (0.85 g, 1.74 mmole) in AcOH (10 mL) was added water (1.5
mL). The
reation was stirred at room tempreature for 16 hrs. The crude reaction was
then concentrated
under vacuum. After the addition of ethyl acetate (50 mL), the organic layer
was washed with
satd. NaHC01. The organic layer was dried with magnesium sulfate and then
concentrated under
vacuum to afford the crude intermediate, tert-butyl N-[242-chloro-6-formy1-5-
(o-
tolyppyrrolo[2,3-d]pyrimidin-7-yl]ethyl]carbamate. To this crude intermediate
in DMF (5 nit)
was added oxone (1.3 g). After stirring for 2.5 hrs, water (20 mL) and ethyl
acetate (100 mL)
were added. The organic layer was separated, dried and then concentrated under
vacuum to
afford the crude product which was columned over silica gel using hexane/ethyl
acetate (0 ¨
50%) to afford
7[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-(o-tolyppyrrolo [2,3 -
d]pyrimidine-6-carboxylic acid (0.112 g). LCMS (ESI) 431 (M + H).
185
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 119
Synthesis of Compoound 119
\
I \
N H
To 7-[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-(o-tolyl)pyrrolo[2,3-
d]pyrimidine-
6-carboxylic acid (0.1 g, 0.261 mmol) in DCM (4.1 mL) was added DMAP (20 mg)
followed by
the addition of N,N'-diisopropylcarbodiimide (0.081 mL, 2eq). After stirring
for 3 hrs, TFA
(0.723 mL) was added. Stirring was then continued for another 30 minutes. The
reaction
mixture was neutralized with satd. NaHCO3. DCM (20 mL) was then added and the
organic
layer separated, dried with magnesium sulfate and then concentrated under
vacuum to afford the
crude product which was columned using hcxanelethylacetate (0-100%) to afford
chloro
tricyclic amide Compound 119 (0.65 g). LCMS (ES1) 313 (M + H).
Example 120
Synthesis of Compound 120
N
N
To the chloro tricyclic amide (0.040 g, 0.128 mmole) (Compound 119) in dioxane
(2.5
mL) under nitrogen was added Pd2(dba)3 (12 mg), sodium tert-butoxide (16 mg),
131NAP (16
mg) and 4-morpholinoanilinc (22.7 mg, 1 eq). The reaction mixture was heated
at 90 C in a
CEM Discovery microwave for 3.0 hrs. The crude reaction was loaded onto a
silica gel column
and the contents eluted with DCM/Me0H (0-6%) to afford the product (10 mg).
LCMS (EST)
186
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
455 (M + H). IHNMR (600 MHz, DMSO-d6) 6 ppm 2.14 (s, 3 H) 3.23 - 3.50 (m, 2 H)
3.57 -
3.73 (m, 2 H), 3.81 - 3.92 (m, 8H), 7.11 -7.31 (m, 4 H) 7.31 -7.48 (m, 1 H)
7.58 - 7.73 (m, 1 H)
7.77 - 7.95 (m, 2 H) 8.05 - 8.21 (m, 1 H) 8.44 (s, 1 H) 9.85 - 10.01 (m, 1 H).
Example 121
Synthesis of Compound 121
N
I \
To the chloro tricyclic amide (0.024 g) (Compound 119) in N-methyl-2-
pyrrolidone
(NMP) (1.5 mL) was added trans-4-aminocyclohexanol (0.0768 mmol, 26.54 mg, 3
eq) and
Hunig's base (0.4 mL). The reaction was heated in a CEM Discovery microwave
vessel at 150
C for 1.2 hrs. The crude reaction was loaded onto a silica gel column and the
contents eluted
with DCM/Me0H (0 - 10%) to afford the product (21 mg). LCMS (ESI) 392 (M + H).
IHNMR
(600 MHz, DMSO-d6) 6 ppm 1.23 (d, J=8.78 Hz, 4 H) 1.84 (br. s., 4 H) 2.11 (s,
3 H) 3.34 - 3.43
(m, 1 H) 3.55 (br. s., 2 H) 3.72 (br. s., 1 H) 4.13 (br. s., 2 H) 4.50 (br.
s., 1 H) 7.03 (br. s., 1 H)
7.12 - 7.28 (m, 4 H) 7.96 (br. s., 1 H) 8.18 (br. s., 1 H).
187
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 122
Synthesis of 7-[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid, Compound 122
0
...---- ------ra
-"IN1`
\---.'A OH
a
0
......." HN
OA/
7[2-(tert-butoxycarbonylamino)ethy11-2-chloro-pyrrolo[2,3-d]pyrimidine-6-
carboxylic
acid was synthesized using a similar experimental procedure as that described
for the synthesis
of 742-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-(o-
tolyl)pyrrolo[2,3-d]pyrimidine-6-
carboxylic acid. LCMS (ESI) 341 (M + H).
Example 123
Synthesis of Compound 123
-,
Cr N
Chloro tricyclic amide, Compound 123, was synthesized using a similar
experimental
procedure as that described for the synthesis of chloro tricyclic amide
(Compound 119). LCMS
(ESI) 223 (M + H).
Example 124
Synthesis of Compound 124
HO.
,......õ.N7 \
N N NH
H \--/
.188
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
To the chloro tricyclic amide, Compound 123 (0.035 g, 0.00157 mole) in NMP
(1.5 mL)
was added Hunig's base (0.3 mL) followed by the addition of the trans-4-
aminocyclohexanol
(54.2 mg). The reaction mixture was heated at 150 C for 1.5 hrs. The crude
reaction was
loaded onto a silica gel column and the column was eluted with DCM/Me0H (0 -
10%) to afford
the product (5 mg). LCMS (ESI) 302 (M + H).
Example 125
Synthesis of tert-butyl N-12-1(5-bromo-2-chloro-pyrimidin-4-Aamino]-2-methyl-
propyl]carbamate, Compound 125
C,f 1,1 r,1
0
tert-butyl N-[2- [(5-bromo -2-c hloro -pyrimidin-4-y0amino] -2-methyl-propyl]
carbamate
was synthesized by treating 5-bromo-2,4-dichloropyrimidine with tert-butyl N-
(2-amino-2-
methyl-propyl)carbamate using similar experimental conditions as described for
the synthesis of
tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-yl)amino]ethyl]carbamate. LCMS
(ESI) (M+H)
379.
Example 126
Synthesis of tert-butyl N-12-112-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yljamino]-2-
methyl-propylicarbamate, Compound 126
CE
tert-butyl N-[2- [ [2-chloro -5-(3 ,3 -diethoxyprop -1 -ynyl)pyrimidin-4-yl]
amino] -2-methyl-
propyl]earbamate was synthesized by treating tert-butyl N-[2-[(5-bromo-2-
chloro-pyrimidin-4-
189
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
yl)amino]-2-methyl-propyl]carbamate with 3,3-diethoxyprop-1-yne in the
presence of a catalyst
such as Pddba using similar experimental conditions as described for the
synthesis of tert-butyl
N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4
yl]amino]ethyl]carbamate.
LCMS (ESI) (M+H) 427.
Example 127
Synthesis of tert-butyl N-1242-chloro-6-(diethoxymethyl)pyrrolo[2,3-
d]pyrimidin-7-y1]-2-
methyl-propylicarbamate, Compound 127
CEN
0 ________________________
tert-butyl N42-[2-chloro-6-(diethoxymethyppyrrolo[2,3-d]pyrimidin-7-y1]-2-
methyl-
propyl]carbamate was synthesized by treating tert-butyl N-[24[2-chloro-5-(3,3-
diethoxyprop-1-
ynyl)pyrimidin-4-yl]amino]-2-methyl-propyl]carbamate with TBAF using similar
experimental
conditions as described for the synthesis tert-butyl N-[242-chloro-6-
(diethoxymethyppyrrolo[2,3- d]pyrimidin-7-yl]ethyl]carbamate. LCMS (ESI) (M+H)
427.
190
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 128
Synthesis of 742-(tert-butoxycarbonylamino)-1,1-dimethyl-ethyl]-2-chloro-
pyrrolo [2,3-
d]pyrimidine-6-carboxylic acid, Compound 128
0
CI N 011
0
7-[2-(tert-butoxycarbonylamino)-1,1-dimethyl-ethyl]-2-chloro-pyrrolo [2,3-
d]pyrimidine-
6-carboxylic acid was synthesized using a similar experimental procedure as
that described for
the synthesis of 7[2-(tert-butoxycarbonylamino)ethy11-2-chloro-5-
(o-tolyppyrrolo [2,3-
d]pyrimidine-6-carboxylic acid. LCMS (ESI) 369 (M + H).
Example 129
Synthesis of Compound 129
0
N
\
CI
Chloro tricyclic amide, Compound 129, was synthesized using a similar
procedure as that
described for the synthesis of chloro tricyclic amide, Compound 119. LCMS
(ESI) 251 (M + H).
Example 130
Synthesis of Compound 130
,
0
1
,
191
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 130 was synthesized by treating chlorotricyclic amine Compound 129
with
trans-4-aminocyclohexanol using similar experimental conditions as for
compound 124. LCMS
(ESI) 330 (M + H). 1HNMR (600 MHz, DMSO-d6) 6 ppm 1.07 - 1.34 (m, 4 H) 1.47 -
2.05 (m,
H) 3.09 (m, 1H) 3.51 (d, J = 2.91 Hz, 2 H) 3.57 (m, 1H) 4.50 (br. s., 1 H)
6.89 (s, 1 H) 6.94 -
5 7.05 (m, 1 H) 8.04 (br. s., 1 H) 8.60 (s, 1 H) 9.00 (br. s., 1 H).
Example 131
Synthesis of benzyl N-11-[[(5-bromo-2-chloro-pyrimidin-4-
yl)amino]methyllpropyl]carbamate, Compound 131
N
11
0
10 Benzyl N- [1 [[(5-bromo-2-chl oro-pyrimi din -4-yl)amino]methyl jpropyl]
carbamate was
synthesized by treating 5-bromo-2,4-di chloropyrimidine
with benzyl N-[ -
(aminomethyl)propyl]carbamate using similar experimental conditions as
described for the
synthesis of tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-
yl)amino]ethyl]carbamate. LCMS
(ESI) (M+H) 413.
Example 132
Synthesis of benzyl N-11-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl] amino] methyl] propyl] carbamate, Compound 132
I
0
Benzyl N-[1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]methyl]propyl]carbamate was prepared by treating benzyl N41-[[(5-
bromo-2-chloro-
192
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
pyrimidin-4-y0amino]methyl]propyl]-carbamate with 3,3-diethoxyprop- 1 -yne in
the presence of
a catalyst such as Pddba using similar experimental conditions as described
for the synthesis of
tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]ethylicarbamate
LCMS (ESI) (M+H) 461.
Example 133
Synthesis of benzyl N-I1-[[2-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]pyrimidin-
7-yl]
methyl]propyl] carbamate, Compound 133
K"
..........<0
.,..j.õõ
a "\-=-,,,,----------
0-\
1
\L---..(-- \
0 ---õ,
FIN--____f \ ,...õ.
0õ
Benzyl N-E1-[[2-chloro-6-(diethoxymethyppyrrolo [2,3-d]pyrimi din-7-
yl]methyl]propyl]carbamate was synthesized by treating benzyl N-[1-[[[2-chloro-
5-(3,3-
diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]methyl]propyl]carbamate with TBAF
using similar
experimental conditions as described for the synthesis tert-butyl N-[2-[2-
chloro-6-
(diethoxymethyl)pyrrolo[2,3 dlpyrimidin-7-yl]ethylicarbamate. LCMS (ESI) (M+H)
461.
Example 134
Synthesis of 7-[2-(benzyloxycarbonylamino)buty1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid, Compound 134
0
Cle".1Nil Oh
0 O.
0
193
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
7[2-(benzyloxycarbonylamino)buty1]-2-chloro-pyrrolo[2,3-d]pyrimidine-6-
carboxylic
acid was synthesized using a similar experimental procedure as that described
for the synthesis
of 7-[2-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-(o-tolyppyrrolo[2,3-
d]pyrimidine-6-
carboxylic acid. LCMS (ESI) 403 (M + H).
Example 135
Synthesis of Compound 135
0
CI
To a solution of 7-[2-(benzyloxycarbonylamino)buty1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid in dichloromethane was added HBr, the reaction
was stirred at 45
degrees for 3 hrs. After concentration, 2N NaOH was added to basify (pH = 8.0)
the reaction
followed by the addition of THF (20 mL). Boc20 was then added (1.2 eq) and the
reacation was
stirred for 16 hrs. To the crude reaction mixture was then added ethyl acetate
(100 mL) and
water (50 mL) and the organic phase was separated, dried (magnesium sulfate)
and then
concentrated under vacuum. To the crude product was added dichloromethane (30
mL) followed
by DIC and DMAP. After stirring for 2 hrs, TFA was added and the contents
stirred for an hour.
The solvents were evaporated under vacuum and the residue basified with satd.
NaHCO3. Ethyl
acetate was then added and the organic layer separated, dried (magnesium
sulfate) and then
concentrared under vacuum. Colum chromatography with hexane/ethyl acetate (0 -
100%)
afforded the desired chlorotricyclic core, Compound 135. LCMS (ESI) 251 (M +
H).
Example 136
Synthesis of Compound 136
N
194
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compound 136 was synthesized by treating chlorotricyc lie amine, Compound 135,
with
trans-4-aminocyclohexanol using similar experimental conditions as for
compound 124. LCMS
(ESI) 330 (M + H). 1I-INMR (600 MHz, DMSO-d6) 6 ppm 0.80 - 0.95 (m, 3 H) 1.35
¨ 1.92 (m,
H) 3.66 (br. m., 3 H) 4.17 (br. s., 2 H) 4.47 (br. s., 1 H) 6.85 (s, 1 H) 6.96
(br. s., 1 H) 8.15
5 (br. s., 1 H) 8.62 (br. s., 1 H).
Example 137
Synthesis of tert-butyl N-11-[[(5-bromo-2-chloro-pyrimidin-4-
yl)amino] methyl] cyclopentyl] carbamate, Compound 137
.õ.c.........,.....e,..Bc
1 H
H
tert-butyl N- [1 - [ [(5-bromo-2-chloro-pyrimidin-4-y0amino]methyl]
cyclopentyl] carbamate
was synthesized by treating 5-bromo-2,4-dichloropyrimidine with tert-butyl N-
[1-
(aminomethyl)cyclopentyl]carbamate using similar experimental conditions as
described for the
synthesis of tert-butyl N-[2-[(5-bromo-2-chloro-pyrimidin-4-
yl)amino]ethyl]carbamate. LCMS
(ES!) 405 (M+H).
Example 138
Synthesis of tert-butyl N-11-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-
4-
yl] amino] methyl] cyclopentyl] carbamate, Compound 138
L.0
r4.----"
a-N--- ---N---"' N'''---õ,----v '--,,-""
o
195
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-butyl N-[1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyOpyrimidin-4-
yl]amino]methyl]cyclopentyl]carbamate was synthesized by treating tert-butyl N-
[1-[[(5-bromo-
2-chloro-pyrimidin-4-y0amino]methyl]cyclopentyl]carbamate with with 3,3-
diethoxyprop-1-yne
in the presence of a catalyst such as Pddba using similar experimental
conditions as described for
the synthesis of tert-butyl N-[2-[[2-chloro-5-(3,3-diethoxyprop-1-
ynyl)pyrimidin-4
yl]amino]ethyl]carbamate LCMS (ESI) 453 (M+H).
Example 139
Synthesis of tert-butyl N-114[2-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]
pyrimidin-7-
.. ylimethyl]cyclopentyl]earbamate, Compound 139
a
, 0 __________________ \
0
tert-butyl N-[1-[[2-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]pyrimidin-7-
yl]methyl]cyclopentyl]carbamate was synthesized by treating tert-butyl N-[2-
[[2-chloro-5-(3,3-
diethoxyprop-1-ynyOpyrimidin-4-yl]amino1-2-methyl-propylicarbamate with TBAF
using
similar experimental conditions as described for the synthesis tert-butyl N-[2-
[2-chloro-6-
(diethoxymethyl)pyrrolo[2,3 dipyrimidin-7-yl]ethyl]carbamate. LCMS (EST) 453
(M+H).
196
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 140
Synthesis of 7-[[1-(tert-butoxycarbonylamino)cyclopentyl]methyl]-2-chloro-
pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid, Compound 140
/0:( ,1
OH
Cl H
0
HN-
7-[[1-(tert-butoxycarbonylamino)cyclopentyl]methy1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-6-carboxylic acid was synthesized using a similar experimental
procedure as that
described for the synthesis of 742-(tert-butoxycarbonylamino)ethy1]-2-chloro-5-
(o-
tolyppyrrolo[2,3-d]pyrimidine-6-carboxylic acid. LCMS (ES1) 395 (M + H).
Example 141
Synthesis of Compound 141
I \
CI
Chlorotricyclic core Compound 141 was synthesized using a similar experimental
procedure as that described for the synthesis of chloro tricyclic amide
Compound 119. LCMS
(ESI) 277 (M + H).
197
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 142
Synthesis of Compound 142
H
a
.........õ............Jõ,õ
H \ o
Compound 142 was synthesized by treating chlorotricyclic amine, Compound 141,
with
trans-4-aminocyclohexanol using similar experimental conditions as for
Compound 124. LCMS
(ESI) 356 (M + H). itINMR (600 MHz, DMSO-d6) ö ppm 1.08 - 1.32 (m, 8 H) 1.60 -
2.09 (m, 8
H) 3.03 - 3.17 (m, 1 H) 3.35 (s, 2 H) 3.54 - 3.62 (m, 1 H) 4.51 (d, 1=4.39 Hz,
1 H) 6.88 (s, 1 H)
6.96 (Ur. s., 1 H) 8.07 (hr. s., 1 H) 8.58 (s, 1 H).
.. Example 143
Synthesis of tert-butyl N-R1-[(5-bromo-2-chloro-pyrimidin-4-
yl)amino] cyclopentyll methyl] carbamate, Compound 143
N ---------,----, 1:cs....
1 11
s--... ,....>r_
õ. IT
8
tert-butyl N- [[1-[(5-bromo-2-chloro-pyrimi di n -4-yl)ami no] cycl op entyl]m
ethyl ] c arb amate
was synthesized by treating 5-bromo-2,4-dichloropyrimidine with tert-butyl N-
[(1-
aminocyclopentyl)methyl]carbamate using similar experimental conditions as
described for the
synthesis of tert-butyl N42-[(5-bromo-2-chloro-pyrimidin-4-
y0amino]ethyl]carbamate. LCMS
(ESI) 405 (M+H).
198
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 144
Synthesis of tert-butyl N-12-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-
yl]amino]-2-
methyl-propyl] carbamate, Compound 144
CI
tert-butyl N-[[1-[[2-chloro-5-(3,3-diethoxyprop-1-ynyOpyrimidin-4-
yl]amino]cyclopentyl]methyl]carbamate was synthesized by treating tert-butyl
N42-[(5-bromo-
2-chloro-pyrimidin-4-yl)amino]-2-methyl-propyl]carbamate with 3,3-diethoxyprop-
1-yne in the
presence of a catalyst such as Pddba using similar experimental conditions as
described for the
synthesis of tert-butyl N-[24[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4
yflamino]ethyl]carbamate.
LCMS (ESI) 453 (M+H).
Example 145
Synthesis of tert-butyl N-I[142-chloro-6-(diethoxymethyl)pyrrolo [2,3-
d]pyrimidin-7-
yl]cyclopentyl]methyl]carbamate, Compound 145
CI N
H
199
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
tert-Butyl N-[[1-[2-chloro-6-(diethoxymethyl)pyrrolo[2,3-d]pyrimidin-7-
yl]cyclopentyl]methyl]carbamate was synthesized by treating tert-butyl N-[2-
[[2-chloro-5-(3,3-
diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]-2-methyl-propyl]carbamate with TBAF
using
similar experimental conditions as described for the synthesis tert-butyl N-[2-
[2-chloro-6-
(diethoxymethyl)pyrrolo [2,3 d]pyrimidin-7-yl]ethyl]carbamate. LCMS (ESI) 4534
(M+H).
Example 146
Synthesis of 742-(tert-butoxycarbonylamino)-1,1-dimethyl-ethyl]-2-chloro-
pyrrolo12,3-
d]pyrimidine-6carboxylic acid, Compound 146
0
N
\
0 ti
Cr N
c".
\
7-[2-(tert-Butoxycarbonylamino)-1,1-dimethyl-ethy1]-2-chloro-pyrrolo[2,3-
d]pyrimidine-
6-carboxylic acid was synthesized using a similar experimental procedure as
that described for
the synthesis of 7[2-(tert-butoxycarbonylamino)ethy11-2-chloro-5-(o-
tolyppyrrolo [2,3-
d]pyrimidine-6-carboxylic acid. LCMS (ESI) 395 (M + H).
200
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 147
Synthesis of Compound 147
N----7-"---,------).__(19
,..._ 1
õ...----......-:, õ..-------.N
01 -14- il H
F-
3
Chloro tricyclic amide, Compound 147 was synthesized using a similar
experimental
procedure as that described for the chloro tricyclic amide, Compound 119. LCMS
(ESI) 277 (M
+H).
Example 148
Synthesis of Compound 148
,õõ,=¨=õ%=-..., õõõ...----õ,.. tsi
H
6---j
Compound 148 was synthesized by treating chlorotricyclic amine, Compound 147,
with
trans-4-aminocyclohexanol using similar experimental conditions as for
Compound 124. LCMS
(ESI) 356 (M + H). 11-INMR (600 MHz, DMSO-d6) 6 ppm 1.06 - 1.35 (m, 8 H) 1.45 -
1.95 (m, 8
H) 3.10 (m, 1 H) 3.58 (br. s., 2 H) 3.95 (br. s., 1 H) 4.49 (br. s., 1 H) 6.84
(s, 1 H) 6.85 - 6.93 (m,
1 H) 8.29 (s, 1 H) 8.61 (br. s., 1 H).
Example 149
Synthesis of Compound 149
µIe.'µ) I\V" 1 \ O
N N.irk.. 1 m
i_v_. j''' NH
0
c)
201
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Step 1: Compound 59 is Boc protected according to the method of A. Sarkar et
at. (JOC, 2011,
76, 7132-7140).
Step 2:
Boc-protected Compound 59 is treated with 5 mol% NiC12(Ph3)2, 0.1 eq
triphenylphosphine, 3 eq Mn, 0.1 eq tetracthylammonium iodide, in DMI under
CO2 (1 atm) at
25 C for 20 hours to convert the aryl halide derivative into the carboxylic
acid.
Step 3: The carboxylic acid from Step 2 is converted to the corresponding acid
chloride using
standard conditions.
Step 4: The acid chloride from Step 3 is reacted with N-methyl piperazine to
generate the
corresponding amide.
.. Step 5: The amide from Step 4 is deprotected using trifluoroacetic acid in
methylene chloride to
generate the target compound. Compound 149 is purified by silica gel column
chromatography
eluting with a dichloromethane ¨ methanol gradient to provide Compound 149.
Each of Compounds 119 through 149 and corresponding compounds with various R8,
RI
and Z definitions may be reacted with sodium hydride and an alkyl halide or
other halide to
insert the desired R substitution prior to reaction with an amine, such as
described above for the
synthesis of Compound 120, to produce the desired product of Formulae I, 11,
111, IV, or V.
Example 150
CDK4/6 Inhibition In Vitro Assay
Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3
CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, CA) to
determine their
inhibitory effect on these CDKs. The assays were performed using microfluidic
kinase detection
technology (Caliper Assay Platform). The compounds were tested in 12-point
dose-response
format in singlicate at Km for ATP. Phosphoacceptor substrate peptide
concentration used was 1
1AM for all assays and Staurosporine was used as the reference compound for
all assays.
Specifics of each assay arc as described below:
CDK2/CyclinA: Enzyme concentration: 0.2 nM; ATP concentration: 50 [tM;
Incubation
time: 3 hr.
CDK2/CyclinE: Enzyme concentration: 0.28 nM; ATP concentration: 100 ittM;
Incubation time: 1 hr.
202
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CDK4/CyclinD1: Enzyme concentration: 1 nM; ATP concentration: 200 [iM;
Incubation
time: 10 hr.
CDK6/CyclinD3: Enzyme concentration: 1 nM; ATP concentration: 300 [iM;
Incubation
time: 3 hr.
The inhibitory IC50 values for the compounds in Table 1 for CDK4/CycD1,
CDK2/CycE,
CDK2/CycA, as well as fold selectivity are presented in Table 2.
Table 2: Selective Inhibition of CDK4
CDK4/ CDK2/
CycD1 ICso CycE ICso Fold Selectivity CDK2/CycA
Fold Selectivity
Structure [nM] [nM] (CDK2/CycE/CDK4) ICso [nM]
(CDK2/CycAlCDK4)
A 4.2 6350 1516 3160 754
B 0.4 3040 6862 1890 4266
C 1.4 1920 1333 616 428
D 0.9 3480 3779 1500 1629
E 1 695 688 204 202
F 1.5 628 419 190 127
G 1.5 2580 1767 646 442
H 1.5 1520 1013 377 251
I 2 2120 1065 1130 568
J 0.7 5110 7707 4340 6546
K 1 1070 1019 738 703
L 5.7 4530 789 1490
260
M 2.3 2280 1004 1410 621
N 1 1500 1500 ND ND
O 2.5 41410 1636 3150
1245
P 3.3 3560 1085 1010
308
Q 0.6 1080 1722 3030 4833
R 0.5 1920 3918 1360 2776
S 1.7 1250 718 342 197
T 0.8 1660 2022 1670 2034
U 0.7 1460 2229 857
1308
203
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CDK4/ CDK2/
CycD1 ICso CycE ICso Fold Selectivity CDK2/CycA Fold
Selectivity
Structure [nM] [nM] (CDK2/CycE/CDK4) 1050 [nM]
(CDK2/CycAlCDK4)
V 2.9 3500 1224 2130 745
W 2.7 3970 1481 539 201
X 0.9 11600 12975 1840 2058
Y 2.5 124 50 61 25
Z 3.2 3710 1174 647 205
AA 0.5 6100 13319 4630 10109
BB 0.8 1680 2017 502 603
CC 1.6 1250 791 755 478
DD 1.9 9620 5200 8360 4519
EE 3.8 1660 432 1110 289
FF 1.2 4620 3949 1400 1197
GG 1 3580 3377 1510 1425
HH 1.7 1280 766 265 159
II 2 367 184 239 120
JJ 1.4 288 204 ND ND
KK 2.3 1760 762 915 396
LL 2 202 103 108 55
MM 1.8 3390 1863 597 328
NN 3.7 4700 1274 1560 423
00 9 3980 442 570 63
PP 3.1 3600 1146 3090 984
QQ 4.1 3060 746 2570 627
RR 1.2 1580 1374 693 603
SS 0.8 1460 1865 1390 1775
TT 0.8 1260 1550 596 733
UU 7.3 3960 542 ND ND
VV 3.3 2630 809 789 243
WW 0.7 1350 204 ND ND
XX 1.3 7300 5615 6290 4838
YY 4.6 6900 1490 ND ND
204
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
CDK4/ CDK2/
CycD1 IC50 CycE IC50 Fold Selectivity CDK2/CycA Fold
Selectivity
Structure [nM] [nM] (CDK2/CycE/CDK4) IC50 [nM]
(CDK2/CycAlCDK4)
ZZ 10.5 9960 949 ND ND
AAA 2.3 6010 2591 2130 918
BBB 2.8 187 68 85 31
CCC 2 2170 1074 457 226
DDD 9.5 9350 986 ND ND
EEE 2.3 2950 1266 943 405
FFF 4.7 4540 966 1370 291
GGG 13.7 7610 555 ND ND
HHH 6.8 2840 419 ND ND
III 6 3770 626 ND ND
JJJ 3.2 5200 1620 2830 882
KKK 1.3 291 231 87.3 69
LLL 3.2 1620 509 4530 1425
MMM 3.2 1890 600 990 314
NNN 1.4 2930 2154 1010 743
000 2.4 393 164 203 85
PPP 0.8 16500 21263 2640 3402
QQQ 10.5 11100 1057 ND ND
RRR 2.6 4500 1758 ND ND
SSS 2 2280 1112 1880 917
TTT 3.4 3030 899 ND ND
UUU 18 16460 914 ND ND
VVV 7.4 4380 589 ND ND
WWW 18.5 2500 135 ND ND
XXX 11.4 6620 581 ND ND
To further characterize its kinase activity, Compound T was screened against
456 (395
non-mutant) kinases using DiscoveRx's KINOMEscanTm profiling service. The
compound was
screened using a single concentration of 1000 nM (> 1000 times the IC50 on
Cdk4). Results
from this screen confirmed the high potency against Cdk4 and high selectivity
versus Cdk2.
205
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Additionally, the kinome profiling showed that Compound T was relatively
selective for Cdk4
and Cdk6 compared to the other kinases tested. Specifically, when using an
inhibitory threshold
of 65%, 90%, or 99%, Compound T inhibited 92 (23.3%), 31(7.8%) or 6(1.5%) of
395 non-
mutant kinases respectively.
In addition to CDK4 kinase activity, several compounds were also tested
against CDK6
kinase activity. The results of the CDK6/CycD3 kinase assays, along with the
CDK4/cyclinD1,
CDK2/CycA and CDK2/cyclinE kinase assays, are shown for PD0332991 (Reference)
and the
compounds T, Q, GG, and U in Table 3. The IC50 of 10 nM for CDK4/cyclinD1 and
10uM for
CDK12/ CyclinE agrees well with previously published reports for PD0332991
(Fry et al.
Molecular Cancer Therapeutics (2004) 3(11)1427-1437; Toogood et al. Journal of
Medicinal
Chemistry (2005) 48, 2388-2406). Compounds T, Q, GG, and U are more potent
(lower IC50)
with respect to the reference compound (PD0332991) and demonstrate a higher
fold selectivity
with respect to the reference compound (CDK2/CycE IC50 divided by CDK4/CycD1
IC5o).
Table 3: Inhibition of CDK kinases by Compounds T, Q, GG, and U
Formula CDK4/CycD1 CDK2/CycE
Fold Selectivity CDK2/CycA CDK6/CycD3
IC50(nM) IC50(uM) CDK2/CDK4 IC50(uM) IC50(nM)
PD0332991 10 10 1000 Not Not
determined
Reference determined
Compound T 0.821 1.66 2022 1.67 5.64
Compound Q 0.627 1.08 1722 3.03 4.38
Compound GG 1.060 3.58 3377 1.51 4.70
C o mpound U 0.655 1.46 2229 .857 5.99
Example 151
GI Arrest (Cellular G1 and S-phase) Assay
For determination of cellular fractions in various stages of the cell cycle
following
various treatments, H568 cells (human skin fibroblast cell line (Rb-positive))
were stained with
propidium iodide staining solution and run on Dako Cyan Flow Cytometer. The
fraction of cells
206
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
in GO-G1 DNA cell cycle versus the fraction in S-phase DNA cell cycle was
determined using
FlowJo 7.2 .2 analysis.
The compounds listed in Table 1 were tested for their ability to arrest HS68
cells at the
GI phase of the cell cycle. From the results of the cellular GI arrest assay,
the range of the
inhibitory EC50 values necessary for G1 arrest of HS68 cells was from 22 nIV1
to 1500 nM (see
column titled "Cellular GI Arrest EC50" in Table 4).
Example 152
Cell cycle arrest by compound T in Cdk4/6-dependent cells
To test the ability of Cdk4/6 inhibitors to induce a clean Gl-arrest, a cell
based screening
method was used consisting of two Cdk4/6-dependent cell lines (tHS68 and
WM2664; Rb-
positive) and one Cdk4/6-independent (A2058; Rb-negative) cell line. Twenty-
four hours after
plating, each cell line was treated with Compound T in a dose dependent manner
for 24 hours.
At the conclusion of the experiment, cells were harvested, fixed, and stained
with propidium
iodide (a DNA intercalator), which fluoresces strongly red (emission maximum
637 nm) when
excited by 488nm light. Samples were run on Dako Cyan flow cytometer and >
10,000 events
were collected for each sample. Data were analyzed using FlowJo 2.2 software
developed by
TreeStar, Inc.
207
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
FIG. 2B is a graph of the number of tHS68 cells (CDK4/6-dependent cell line)
vs. the
DNA content of the cells (as measured by propidium iodide). Cells were treated
with DMSO for
24 hours, harvested, and analyzed for cell cycle distribution. FIG. 2C is a
graph of the number of
WM2664 cells (CDK4/6-dependent cell line) vs. the DNA content of the cells (as
measured by
.. propidium iodide). Cells were treated with DMSO for 24 hours, harvested,
and analyzed for cell
cycle distribution. FIG. 2D is a graph of the number of A2058 cells (CDK4/6-
independent cell
line) vs. the DNA content of the cells (as measured by propidium iodide).
Cells were treated
with DMSO for 24 hours, harvested, and analyzed for cell cycle distribution.
FIG. 2E is a graph
of the number of tHS68 cells (CDK4/6-dependent cell line) vs. the DNA content
of the cells (as
measured by propidium iodide) after treatment with Compound T. Cells were
treated with
Compound T (300 nM) for 24 hours, harvested, and analyzed for cell cycle
distribution. As
described in Example 152, treatment of tHS68 cells with Compound T causes a
loss of the S-
phase peak (indicated by arrow). FIG. 2F is a graph of the number of WM2664
cells (CDK4/6-
dependent cell line) vs. the DNA content of the cells (as measured by
propidium iodide) after
treatment with Compound T. Cells were treated with Compound T (300 nM) for 24
hours,
harvested, and analyzed for cell cycle distribution. As described in Example
152, treatment of
WM2664 cells with Compound T causes a loss of the S-phase peak (indicated by
arrow). FIG.
2G is a graph of the number of A2058 cells (CDK4/6-independent cell line) vs.
the DNA content
of the cells (as measured by propidium iodide) after treatment with Compound
T. Cells were
treated with Compound T (300 nM) for 24 hours, harvested, and analyzed for
cell cycle
distribution. As described in Example 152, treatment of A2058 cells with
Compound T does not
cause a loss of the S-phase peak (indicated by arrow).
Example 153
Compound T Inhibits Phosphorylation of RB
The Cdk4/6-cyclin D complex is essential for progression from G1 to the S-
phase of the
DNA cell cycle. This complex phosphorylates the retinoblastoma tumor
suppressor protein (Rb).
To demonstrate the impact of Cdk4/6 inhibition on Rb phosphorylation (pRb),
Compound T was
exposed to three cell lines, two Cdk4/6 dependent (tHS68, WM2664; Rb-positive)
and one
Cdk4/6 independent (A2058; Rb-negative). Twenty four hours after seeding,
cells were treated
with Compound T at 300nM final concentration for 4, 8, 16, and 24 hours.
Samples were lysed
208
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
and protein was assayed by western blot analysis. Rb phosphorylation was
measured at two sites
targeted by the Cdk4/6-cyclin D complex, Ser780 and Ser807/811 using species
specific
antibodies. Results demonstrate that Compound T blocks Rb phosphorylation in
Rb-dependent
cell lines by 16 hours post exposure, while having no effect on Rb-independent
cells (Figure 3).
Example 154
Small cell lung cancer (SCLC) Cells are Resistant to CDK4/6 Inhibitors
The retinoblastoma (RB) tumor suppressor is a major negative cell cycle
regulator that is
inactivated in approximately 11% of all human cancers. Functional loss of RB
is an obligate
event in small cell lung cancer (SCLC) development. In RB competent tumors,
activated
Cdk2/4/6 promote GI to S phase traversal by phosphorylating and inactivating
RB (and related
family members). Conversely, cancers with RB deletion or inactivation do not
require Cdk4/6
activity for cell cycle progression. Since inactivation of RB is an obligate
event in SCLC
development, this tumor type is highly resistant to Cdk4/6 inhibitors and co-
administration of
Cdk4/6 inhibitors with DNA damaging chemotherapeutic agents such as those used
in SCLC
should not antagonize the efficacy of such agents.
Several compounds (PD0332991, Compound GG, and Compound T) were tested for
their
ability to block cell proliferation in a panel of SCLC cell lines with known
genetic loss of RB.
SCLC cells were treated with DMSO or the indicated Cdk4/6 inhibitor for 24
hours. The effect
of Cdk4/6 inhibition on proliferation was measured by EdU incorporation. An RB-
intact,
Cdk4/6-dependent cell line (WM2664 or tHS68) and a panel of RB-negative SCLC
cell lines
(H69, H82, H209, H345, NCI417, or SHP-77) were analyzed for growth inhibition
by the
various CDK4/6 inhibitors.
As shown in Figure 4, Rb-negative SCLC cells are resistant to Cdk4/6
inhibition. In Figure
4A, PD0332991 inhibits the Rb-positive cell line (WM2664), but does not affect
the growth of
the Rb-negative small cell lung cancer cell lines (H345, H69, H209, SHP-77,
NCI4I7, and H82).
In Figure 4B, Compound GG inhibits the Rb-positive cell line (tHS68), but does
not affect the
growth of the Rb-negative cell lines (H345, H69, SHP-77, and H82). In Figure
4C, Compound T
inhibits the Rb-positive cell line (tHS68), but does not affect the growth of
the Rb-negative cell
lines (H69, SHP-77, and H209). This analysis demonstrated that RB-null SCLC
cell lines were
resistant to Cdk4/6 inhibition, as no change in the percent of cells in S-
phase were seen upon
209
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
treatment with any of the Cdk4/6 inhibitors tested, including Compound T and
Compound GG,
while the RB-proficient cell line in each experiment was highly sensitive to
Cdk4/6 inhibition
with almost no cells remaining in S-phase after 24 hours of treatment.
Example 155
Rb-Negative Cancer Cells are Resistant to CDK4/6 Inhibitors
Cellular proliferation assays were conducted using the following Rb-negative
cancer cell
lines: H69 (human small cell lung cancer - Rb-negative) cells or A2058 (human
metastatic
melanoma cells ¨ Rb-negative). These cells were seeded in Costar (Tewksbury,
Massachusetts)
3093 96 well tissue culture treated white walled/ clear bottom plates. Cells
were treated with the
compounds of Table 1 as nine point dose response dilution series from 10uM to
1nM. Cells
were exposed to compounds and then cell viability was determined after either
four (H69) or six
(A2058) days as indicated using the CellTiter-Glo0 luminescent cell viability
assay (CTG;
Promega, Madison, Wisconsin, United States of America) following the
manufacturer's
recommendations. Plates were read on BioTek (Winooski, Vermont) 5yngergy2
multi-mode
plate reader. The Relative Light Units (RLU) were plotted as a result of
variable molar
concentration and data was analyzed using Graphpad (LaJolla, Califomaia) Prism
5 statistical
software to determine the EC50 for each compound.
Select compounds disclosed herein were evaluated against a small cell lung
cancer cell
line (H69) and a human metastatic melanoma cell line (A2058), two Rb-deficient
(Rb-negative)
cell lines. The results of these cellular inhibition assays are shown in Table
4. The range of the
inhibitory EC50 values necessary for inhibition of H69 small cell lung cancer
cells was 2040 nM
to >3000 nM. The range of the inhibitory EC50 values necessary for inhibition
of A2058
malignant melanoma cell proliferation was 1313 nM to >3000 nM. In contrast to
the significant
inhibition seen on Rb-positive cell lines, it was found that the compounds
tested were not
significantly effective at inhibiting proliferation of the small cell lung
cancer or melanoma cells.
210
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Table 4: Resistance of Rb-Negative Cancer Cells to CDK4/6 Inhibitors
Cellular G1 A2058
Arrest EC50 H69 Cellular Cellular ECso
Structure (nM) EC50 [nM] [nM]
A 110 >3000 ND
B 90 ND ND
C 95 ND ND
D 50 2911 1670
E 75 2580 1371
F 175 ND ND
G 175 ND ND
H 85 2040 1313
1 80 2950 1062
J 110 >3000 >3000
K 28 >3000 1787
L 65 2161 >3000
M 100 ND ND
N 25 >3000 1444
O 40 >3000 2668
P 30 >3000 >3000
Q 100 >3000 2610
211
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Cellular G1 A2058
Arrest EC50 H69 Cellular Cellular EC50
Structure (nM) EC50 [nM] [nM]
R 70 >3000 2632
S 150 >3000 >3000
T 100 >3000 >3000
U 25 >3000 >3000
V 70 >3000 1353
W 160 >3000 >3000
X 65 >3000 >3000
Y 350 ND ND
Z 110 ND ND
AA 70 >3000 ND
BB 75 2943 1635
CC 90 >3000 >3000
DD 100 ND ND
EE 125 ND ND
FF 80 ND ND
GG 80 2920 2691
1-111 110 ND ND
II 40 >3000 >3000
212
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Cellular G1 A2058
Arrest EC50 H69 Cellular Cellular EC50
Structure (nM) EC50 [nM] [nM]
JJ 90 >3000 >3000
KK 22 2421 1379
LL 125 >3000 >3000
MM 100 >3000 >3000
NN 110 ND ND
00 95 >3000 >3000
PP 100 ND ND
QQ 120 >3000 >3000
RR 90 2888 1617
SS 80 2948 1658
TT 75 ND ND
UU 300 ND ND
VV 200 ND ND
WW 400 ND ND
)0( 225 ND ND
YY 175 ND ND
ZZ 500 ND ND
AAA 275 >3000 >3000
213
CA 02906156 2015-09-11
WO 2014/144326
PCT/US2014/028685
Cellular G1 A2058
Arrest EC50 H69 Cellular Cellular EC50
Structure (nM) EC50 [nM] [nM]
BBB 230 >3000 >3000
CCC 250 ND ND
DDD 350 ND ND
EEE 250 >3000 >3000
FFF 650 ND ND
GGG 350 ND ND
HHH 250 ND ND
III 250 ND ND
JJJ 240 ND ND
KKK 190 ND ND
LLL 250 ND ND
MMM 200 >3000 >3000
NNN 210 ND ND
000 200 >3000 >3000
PPP 275 ND ND
Q4Q 500 ND ND
RRR 400 ND ND
SSS 1500 ND ND
214
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Cellular G1 A2058
Arrest EC50 H69 Cellular Cellular EC50
Structure (nM) EC50 [nM] [nM]
TTT 350 ND ND
U U U 300 ND ND
VVV 300 ND ND
WWW 300 ND ND
XXX 300 ND ND
Example 156
HSPC Growth Suppression Studies
The effect of PD0332991 on HSPCs has been previously demonstrated. Figure 5
shows
the EdU incorporation of mice HSPC and myeloid progenitor cells following a
single dose of
150 mg/kg PD0332991 by oral gavage to assess the temporal effect of transient
CDK4/6
inhibition on bone marrow arrest as reported in Roberts et al. Multiple Roles
of Cyclin-
Dependent Kinase 4/6 Inhibitors in Cancer Therapy. JCNI 2012;104(6):476-487.
As can be
seen in Figure 5, a single oral dose of PD0332991 results in a sustained
reduction in HSPC
(LKS+) and myeloid progenitor cells (LKS-) for greater than 36 hours. Not
until 48 hours post
oral dosing do HSPC and myeloid progenitor cells return to baseline cell
division.
Example 157
Bone Marrow Proliferation as Evaluated Using EdU Incorporation and Flow
Cytometry
Analysis
For HSPC proliferation experiments, young adult female FVB/N mice were treated
with
a single dose as indicated of compound T, compound Q, compound GG or PD0332991
by oral
gavage. Mice were then sacrificed at the indicated times (0, 12, 24, 36, or 48
hours following
compound administration), and bone marrow was harvested (n = 3 mice per time
point), as
previously described (Johnson et al. J. Clin. Invest. (2010) 120(7), 2528-
2536). Four hours
215
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
before the bone marrow was harvested, mice were treated with 100 [tg of EdU by
intraperitoneal
injection (Invitrogen). Bone marrow mononuclear cells were harvested and
immunophenotyped
using previously described methods and percent EdU positive cells were then
determined
(Johnson et al. J. Clin. Invest. (2010) 120(7), 2528-2536). In brief, HSPCs
were identified by
expression of lineage markers (Lin-), Seal (S+), and c-Kit (K+).
Analysis in mice determined that Compound T, Compound Q, and Compound GO
demonstrated dose dependent, transient, and reversible Gl-arrest of bone
marrow stem cells
(HSPC) (Figure 6). Six mice per group were dosed by oral gavage at 150 mg/kg
of Compound
T, Compound Q, Compound GG, or vehicle only. Four hours before animals were
sacrificed and
the bone marrow was harvested, mice were treated with 100 rig of EdU by
intraperitoneal
injection. Three mice per group were sacrificed at 12 hours and the remaining
three animals per
group were sacrificed at 24 hours. Results are shown in Figure 6A as the ratio
of EdU positive
cells for treated animals at 12 or 24 hour time points compared to control.
Compound T and GG
demonstrated a reduction in EdU incorporation at 12 hours which was starting
to return to
normal at 24 hours. Compound Q also demonstrated some reduction at 12 hours
and started to
return to baseline at 24 hours despite the fact that oral bioavailability of
Compound Q is low.
Further experiments were completed with Compound T examining dose response and
longer periods of compound treatment. Compound T was dosed by oral gavage at
50, 100 or 150
mg/kg and EdU incorporation into bone marrow was determined at 12 and 24 hours
as described
above. Alternatively, Compound T was dosed by oral gavage at 150 mg/kg and EdU
incorporation into bone marrow was determined at 12, 24, 36 and 48 hours. As
can be seen in
Figures 6B and 5C, and similar to the cellular washout experiments, bone
marrow cells, and in
particular HSPCs were returning to normal cell division as determined by EdU
incorporation in
24 hours following oral gavage at a number of doses. The 150 mg/kg oral dose
of Compound T
in Figure 6C can be compared directly to the results of the same dose of
PD0332991 shown in
Figure 5 where cells were still non-dividing (as determined by low EdU
incorporation) at 24 and
36 hours, only returning to normal values at 48 hours.
216
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 158
HSPC Growth Suppression Studies Comparing Compound T and PD0332991
Figure 7 is a graph of the percentage of EdU positive HSPC cells for mice
treated with
either PD0332991 (triangles) or compound T (upside down triangles) v. time
after administration
(hours) of the compound. Both compounds were administered at 150 mg/kg by oral
gavage.
One hour prior to harvesting bone marrow, EdU was IP injected to label cycling
cells. Bone
marrow was harvested at 12, 24, 36, and 48 hours after compound treatment and
the percentage
of EdU positive HSPC cells was determined at each time point.
As seen in Figure 7, a single oral dose of PD0332991 results in a sustained
reduction in
HSPCs for greater than 36 hours. In contrast, a single oral dose of Compound T
results in an
initial reduction of HSPC proliferation at 12 hours, but proliferation of
HSPCs resumes by 24
hours after dosage of Compound T.
Example 159
Cellular Wash-Out Experiment
HS68 cells were seeded out at 40,000 cells/ well in 60mm dish on day 1 in DMEM
containing 10% fetal bovine serum, 100 U/m1 penicillin/ streptomycin and lx
Glutamax
(Invitrogen) as described (Brookes et al. EMBO J, 21(12)2936-2945 (2002) and
Ruas et al. Mol
Cell Biol, 27(12)4273-4282 (2007)). 24hrs post seeding, cells are treated with
compound T,
compound Q, compound GG, compound U, PD0332991, or DMSO vehicle alone at 300nM
final
concentration of test compounds. On day 3, one set of treated cell samples
were harvested in
triplicate (0 Hour sample). Remaining cells were washed two times in PBS-CMF
and returned to
culture media lacking test compound. Sets of samples were harvested in
triplicate at 24, 40, and
48 hours.
Alternatively, the same experiment was done using normal Renal Proximal Tubule
Epithelial Cells (Rb-positive) obtained from American Type Culture Collection
(ATCC,
Manassas, VA). Cells were grown in an incubator at 37 C in a humidified
atmosphere of 5%
CO2 in Renal Epithelial Cell Basal Media (ATCC) supplemented with Renal
Epithelial Cell
Growth Kit (ATCC) in 37 C humidified incubator.
217
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Upon harvesting cells, samples were stained with propidium iodide staining
solution and
samples run on Dako Cyan Flow Cytometer. The fraction of cells in GO-G1 DNA
cell cycle
versus the fraction in S-phase DNA cell cycle was determined using FlowJo 7.2
.2 analysis.
Figure 8 shows cellular wash-out experiments which demonstrate the inhibitor
compounds of the present invention have a short, transient G1 -arresting
effect in different cell
types. Compounds T, Q, GG, and U were compared to PD0332991 in either human
fibroblast
cells (Rb-positive) (FIGS. 8A & 8B) or human renal proximal tubule epithelial
cells (Rb-
positive) (FIGS. 8C & 8D) and the effect on cell cycle following washing out
of the compounds
was determined at 24, 36, 40, and 48 hours.
As shown in Figure 8 and similar to results in vivo as shown in Figure 5,
PD0332991
required greater than 48 hours post wash out for cells to return to normal
baseline cell division.
This is seen in Figure 8A and Figure 8B as values equivalent to those for the
DMSO control for
either the GO-G1 fraction or the S-phase of cell division, respectively, were
obtained. In
contrast, H568 cells treated with compounds of the present invention returned
to normal baseline
cell division in as little as 24 hours or 40 hours, distinct from PD0332991 at
these same time
points. The results using human renal proximal tubule epithelial cells (FIGS.
8C & 8D) also
show that PD0332991-treated cells took significantly longer to return to
baseline levels of cell
division as compared to cells treated with compounds T, Q, GG, or U.
.. Example 160
Pharmacokinetic and pharmacodynamic properties of CDK4/6 inhibitors
Compounds of the present invention demonstrate good pharmacokinetic and
pharmacodynamic properties. Compound T, Q, GG, and U were dosed to mice at 30
mg/kg by
oral gavage or 10 mg,/kg by intravenous injection. Blood samples were taken at
0, 0.25, 0.5, 1.0,
2.0, 4.0, and 8.0 hours post dosing and the plasma concentration of compound
T, Q, GG, or U
were determined by HPLC. Compound T, GG, and U were demonstrated to have
excellent oral
pharmacokinetic and pharmacodynamic properties as shown in Table 5. This
includes very high
oral bioavailability (F(%)) of 52% to 80% and a plasma half-life of 3 to 5
hours following oral
administration.
Compound T, Q, GG, and U were demonstrated to have excellent
pharmacokinetic and pharmacodynamic properties when delivered by intravenous
218
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
administration. Representative IV and oral PK curves for all four copounds are
shown in Figure
9.
Table 5: Pharmacokinetic and pharmacodynamic properties of CDK4/6 inhibitors
Mouse PK Compound T Compound Q Compound Compound U
GG
CL (mL/min/kg) 35 44 82 52
Vss (L/kg) 2.7 5.2 7.5 3.4
t1/2(11) 5 0.8 3.5 3
AUC 0 nif (uM*11) i.v. 1.3 0.95 1.1 0.76
AUC (uM*h) p.o. 2.9 0.15 1.9 3.3
C. (uM) p.o. 2.5 0.16 1.9 4.2
T111(h)p.o. 1 0.5 1 0.5
F (%) 80 2 52 67
Example 161
Metabolic Stability
The metabolic stability of Compound T in comparison to PD0332991 was
determined in
human, dog, rat, monkey, and mouse liver microsomes. Human, mouse, and dog
liver
microsomes were purchased from Xenotech, and Sprague-Dawlcy rat liver
microsomes were
prepared by Absorption Systems. The reaction mixture comprising 0.5 mg/mL of
liver
microsomes, 100 mM of potassium phosphate, pH 7.4, 5 mM of magnesium chloride,
and 1 uM
of test compound was prepared. The test compound was added into the reaction
mixture at a
final concentration of 1 uM. An aliquot of the reaction mixture (without
cofactor) was incubated
in shaking water bath at 37 deg. C for 3 minutes. The control compound,
testosterone, was run
simultaneously with the test compound in a separate reaction. The reaction was
initiated by the
addition of cofactor (NADPH), and the mixture was then incubated in a shaking
water bath at 37
219
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
deg. C. Aliquots (100 [tL) were withdrawn at 0, 10, 20, 30, and 60 minutes for
the test
compound and 0, 10, 30, and 60 minutes for testosterone. Test compound samples
were
immediately combined with 100 IAL of ice-cold acetonitrile containing internal
standard to
terminate the reaction. Testosterone samples were immediately combined with
800 [tI, of ice
cold 50/50 acetonitrile/dH20 containing 0.1% formic acid and internal standard
to terminate the
reaction The samples were assayed using a validated LC-MS/MS method. Test
compound
samples were analyzed using the Orbitrap high resolution mass spectrometer to
quantify the
disappearance of parent test compound and detect the appearance of
metabolites. The peak area
response ration (PARR) to internal standard was compared to the PARR at time 0
to determine
the percent of test compound or positive control remaining at time-point. Half-
lives were
calculated using GraphPad software, fitting to a single-phase exponential
decay equation.
Half-life was calculated based on t1/2 = 0.693k, where k is the elimination
rate constant
based on the slope plot of natural logarithm percent remaining versus
incubation time. When
calculated half-life was longer than the duration of the experiment, the half-
life was expressed as
> the longest incubation time. The calculated half-life is also listed in
parentheses. If the
calculated half-life is > 2x the duration of the experiment, no half-life was
reported. The timely
resumption of cellular proliferation is necessary for tissue repair, and
therefore an overly long
period of arrest is undesirable in healthy cells such as HSPCs. The
characteristics of a CDK4/6
inhibitor that dictate its arresting duration are its pharmacokinetic (PK) and
enzymatic half-lives.
Once initiated, a Gl-arrest in vivo will be maintained as long as circulating
compound remains at
an inhibitory level, and as long as the compound engages the enzyme. PD032991,
for example,
possesses an overall long PK half-life and a fairly slow enzymatic off-rate.
In humans,
PD0332991 exhibits a PK half-life of 27 hours (see Schwartz, GK et al. (2011)
BJC, 104:1862-
1868). In humans, a single administration of PD0332991 produces a cell cycle
arrest of HSPC
lasting approximately one week. This reflects the 6 days to clear the compound
(5 half-lives x
27 hour half-life), as well as an additional 1.5 to 2 days of inhibition of
enzymatic CDK4/6
function. This calculation suggests that it takes a total of 7+ days for
normal bone marrow
function to return, during which time new blood production is reduced. These
observations may
explain the severe granulocytopenia seen with PD0332991 in the clinic.
Further experiments were completed with Compound T and PD0332991 to compare
the
metabolic stability (half-life) in human, dog, rat, monkey, and mouse liver
microsomes. As
220
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
shown in Figure 10, when analyzing the stability of the compounds in liver
microsomes across
species, the determinable half-life of Compound T is shorter in each species
compared to that
reported for PD0332991. Furthermore, as previously described above and in
Figure 8, it appears
that PD0332991 also has an extended enzymatic half-life, as evidenced by the
production of a
pronounced cell cycle arrest in human cells lasting more than forty hours even
after compound is
removed from the cell culture media (i.e., in an in vitro wash-out
experiment). As further shown
in Figure 8, removal of the compounds described herein from the culture media
leads to a rapid
resumption of proliferation, consistent with a rapid enzymatic off rate. These
differences in
enzymatic off rates translate into a marked difference in pharmacodynamic (PD)
effect, as shown
in Figures 5, 6C, and 7. As shown, a single oral dose of PD0332991 produces a
36+ hour growth
arrest of hematopoietic stem and progenitor cells (HSPCs) in murine bone
marrow, which is
greater than would be explained by the 6 hour PK half-life of PD0332991 in
mice. In contrast,
the effect of Compound T is much shorter, allowing a rapid re-entry into the
cell cycle, providing
exquisite in vivo control of HSPC proliferation.
Example 162
Compound T prevents chemotherapy-induced cell death, DNA damage, and caspase
activation
In order to demonstrate that pharmacological quiescence induced by Compound T
treatment
affords resistance to chemotherapeutic agents with differing mechanisms of
action, an in vitro
model was developed using telomerized human diploid fibroblasts (tHDFs; a
human foreskin
fibroblast line immortalized with expression of human telomerase). These cells
are highly
Cdk4/6-dependent for proliferation as demonstrated by their complete G1 arrest
following
treatment with Cdk4/6 inhibitors (See Roberts PJ, et al. Multiple Roles of
Cyclin-Dependent
Kinase 4/6 Inhibitors in Cancer Therapy. J Natl Cancer Inst 2012;Mar
21;104(6): 476-87). Cell
survival was determined by Cell TiterGlo assay per manufacturer's
recommendations. For both
y-H2AX and caspase 3/7 assays, cells were plated and allowed to become
adherent for 24 hours.
Cells were then treated with Compound T (at indicated concentrations) or
vehicle control for 16
hours, at which time the indicated chemotherapy was added to the pretreated
cells. For y-H2AX,
cells were harvested for analysis 8 hours after chemotherapy exposure. For the
y-H2AX assay,
cells were fixed, permeabilized, and stained with anti¨y-H2AX as per the y-
H2AX Flow Kit
221
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
(Millipore) and quantitated by flow cytometry. Data was analyzed using FlowJo
2.2 software
developed by TreeStar, Inc. For the in vitro caspase 3/7 assay, cells were
harvested 24 hours
post chemotherapy treatment. Caspase 3/7 activation was measured using the
Caspase-Glo 3/7
Assay System (Promega) per manufacturer's recommendations.
As shown in Figure 11, Compound T provides selective protection from
carboplatin and
etoposide-induced cell death.
Treatment of tHS68 human fibroblasts with increasing
concentrations of Compound T in the presence of etoposide (5 iiiM; Figure 11A)
or carboplatin
(100 [iM; Figure 11B) selectively induces a dose dependent cell survival as
determined by Cell
TiterGlo.
Treatment with Compound T prior to treatment with several DNA damaging agents
(e.g.,
carboplatin, doxorubicin, etoposide, camptothecin) or an anti-mitotic
(paclitaxel) attenuated
DNA damage as measured by y-H2AX formation (Figure 12A). Additionally,
treatment of
tHDF cells with Compound T prior to carboplatin, doxorubicin, etoposide,
camptothecin, and
paclitaxel exposure elicited a robust decrease in caspase 3/7 activation in a
dose-dependent
manner (Figure 12B). These data show that a transient cell cycle arrest in G1,
induced by
Cd1c4/6 inhibition, decreases the toxicity of a variety of commonly used
cytotoxic chemotherapy
agents associated with myelosuppression in Cdk4/6-sensitive cells.
Example 163
Compound T inhibits proliferation of hematopoietic stem and/or progenitor
cells (HSPCs)
To characterize the effects of Compound T treatment on proliferation of the
different mouse
hematopoietic cells, 8-week-old female C57B1/6 mice were given a single dose
of vehicle alone
(20% Solutol) or Compound T (150 mg/kg) by oral gavage. Ten-hours later, all
mice were given
a single i.p. injection of 100 mcg EdU (5-ethyny1-2"-deoxyuridine) to label
cells in S-phase of
the cell cycle. All treated mice were euthanized 2 hours after EdU injection,
bone marrow cells
were harvested and processed for flow cytometric analysis of EdU-incorporation
(Figure 13).
In Figure 13, representative contour plots show proliferation in WBM (whole
bone marrow;
top) and HSPCs (hematopoietic stem and progenitor cells; LSK; bottom), as
measured by EdU
incorporation for cells with no treatment, EdU treatment only, or EdU plus
Compound T
treatment. Compound T was found to reduce proliferation of whole bone marrow
and
hematopoietic stem and progenitor cells.
222
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Compared to vehicle-treated mice, Compound T treated mice showed significantly
less EdU-
positive (EdU) cells in all hematopoietic lineages analyzed. The reduction in
EdU cell
frequency is most likely due to reduced S-phase entry, which is consistent
with the fact that
Compound T potently inhibits Cdk4/6 activity. Overall, Compound T treatment
caused ¨70%
reduction of EdU + cell frequency in unfractionated whole bone marrow cells
(Sec Figure 13 and
Figure 14). In the hematopoietic stem and progenitor cells (HSPC), Compound T
treatment
resulted in potent cell cycle arrest of hematopoietic stem cells (HSC, 74%
inhibition), the most
primitive cells in the entire hematopoietic lineage hierarchy, as well as
multipotent progenitors
(MPP, 90% inhibition), the immediate downstream progeny of HSCs (Figure 14A).
As shown in Figure 14B, further down the lineage differentiation hierarchy,
proliferation of
the lineage restricted myeloid (CMP, GMP and MEP) and lymphoid progenitors
(CLP) were also
significantly inhibited by Compound T, showing between a 76-92% reduction in
EdU cell
frequency.
.. Example 164
Compound T inhibits proliferation of differentiated hematopoietic cells
Using the same experimental protocol as discussed in Example X above and shown
in
Figures 13 and 14, the effects of Compound T on the proliferation of
differentiated
hematopoietic cells was investigated. The resulting effect of Compound T in
differentiated
hematopoietic cells was more variable than that seen in HSPCs. While T and B
cell progenitors
are highly sensitive to Compound T (>99% and > 80% reduction in EdU' cell
frequencies
respectively), proliferation of differentiated myeloerythroid cells are more
resistant to Compound
T, with Mac1+G1 myeloid cells showing 46% reduction in EdU cell frequency, and
Ter119
erythroid cells showing 58% reduction in EdU + cell frequency (Figure 15).
Together, these data
suggest that while all hematopoietic cells are sensitive to Compound T-induced
cell cycle arrest,
the degree of inhibition varies among different cell lineages, with myeloid
cells showing a
smaller effect of Compound T on cell proliferation than seen in the other cell
lineages.
223
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 165
Compound GG Protects Bone Marrow Progenitors
To assess the effect of transient CDK4/6 inhibition by Compound GG on
carboplatin-
induced cytotoxicity in the bone marrow, FVB/n mice (n=3 per group) were
treated with vehicle
control, 90 mg/kg carboplatin by intraperitoneal injection, or 150 mg/kg
Compound GG by oral
gavage plus 90 mg/kg carboplatin by intraperitoneal injection. 24 hours after
treatment bone
marrow was harvested and the percent of cycling bone marrow progenitors was
measured by
EdU incorporation as explained earlier. As shown in Figure 16, administration
of Compound
GG at the same time as carboplatin administration results in a significant
protection of bone
marrow progenitors. EdU incorporation in control animals was normalized to
100% and
compared to EdU incorporation for bone marrow from carboplatin treated animals
or carboplatin
and Compound GG treated animals.
Example 166
Compound T decreases 5FU-induced myelosuppression
To determine the ability of Compound T to modulate chemotherapy-induced
myelosuppression, a well characterized single-dose 5-fluorouracil (5FU)
regimen, known to be
highly myelosuppressive in mice, was utilized. FVB/n female mice were given
single oral doses
of vehicle or Compound T at 150 mg/kg, followed 30 minutes later by a single
intraperitoneal
dose of 5FU at 150 mg/kg. Complete blood cell counts were measured every two
days starting
on day six.
Co-administration of Compound T positively impacted recovery of all
hematopoietic
lineages from 5-FU induced myelosuppression. Figure 17 demonstrates the time
course of
recovery of different blood cell types in mice treated with Compound T or
vehicle control prior
to 5FU administration. It was determined that in each hematopoietic cell
lineage tested (whole
blood cells, neutrophils, lymphocytes, platelets, and red blood cells),
Compound T provided a
more rapid recovery of that cells treated only with 5FU. These data show that
Compound T
treatment likely decreases 5FU-induced DNA damage in HSPCs, leading to
accelerated blood
count recovery post-chemotherapy.
Figure 18 shows the data from day 14 of the myelosuppression studies described
above and
shown in Figure 17. Complete blood cell counts were analyzed on day 14. Figure
18 shows the
224
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
results for white blood cells (Figure 18A), neutrophils (Figure 18B),
lymphocytes (Figure 18C),
red blood cells (Figure 18D), and platelets (Figure 18E). In all cases,
Compound T when
administered with 5FU resulted in a significant protection of each cell type
at Day 14 as
compared to the myelosuppressive effect of 5FU treatment alone.
Example 167
Compound T decreases 5FU-induced myelosuppression through repeated cycles of
5FU
treatment
To determine the ability of Compound T to modulate chemotherapy-induced
myelosuppression, a well characterized 5-fluorouracil (5FU) regimen, known to
be highly
myelosuppressive in mice was utilized. 8-week-old female C57B1/6 mice were
given a single
oral dose of vehicle (20% Solutol) or Compound T at 150mg/kg followed 30
minutes later by an
intraperitoneal dose of 5FU at 150 mg/kg. This was repeated every 21 days for
3 cycles. Blood
samples were taken for hematology analysis on Day 10 of Cycles 1-3.
Co-administration of Compound T reduced the myelosuppression on Day 10 of the
third
cycle (Figure 19), as well as other cycles (data not shown). In accordance
with the single-dose
study described above, these data show that Compound T treatment likely
decreases 5FU-
induced DNA damage in HSPCs, leading to improved hematopoietic blood cell
counts.
Example 168
DNA cell cycle analysis in human renal proximal tubule cells
To test the ability of Cdk4/6 inhibitors to induce a clean Gl-arrest in non-
hematopoietic
cells, G1 arrest was examined in human renal proximal tubule cells. The cells
were treated with
Compound T in a dose dependent manner for 24 hours. At the conclusion of the
experiment,
cells were harvested, fixed, and stained with propidium iodide (a DNA
intercalator), which
fluoresces strongly red (emission maximum 637 nm) when excited by 488nm light.
Samples
were run on Dako Cyan flow cytometer. Data were analyzed using FlowJo 2.2
software
developed by TreeStar, Inc. Assays were run in triplicate, and error bars were
not detectable. As
seen in Figure 20, results show that Compound T induces a robust G1 cell cycle
arrest in human
renal proximal tubule cells, as nearly all cells are found in the GO-G1 phase
upon treatment with
increasing amounts of Compound T.
225
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Example 169
Compound T protects renal proximal tubule epithelial cells from chemotherapy-
induced
DNA damage
The ability of Cdk4/6 inhibitors to protect human renal proximal tubule cells
from
chemotherapy induced DNA damage was analyzed using etoposide and cisplatin.
The cells were
treated with Compound T in a dose dependent manner (10 nM, 30 nM, 100 nM, 300
nM, or 1000
nM). At the conclusion of the experiment, cells were harvested, fixed, and
stained with
propidium iodide (a DNA intercalator), which fluoresces strongly red (emission
maximum
637 nm) when excited by 488nm light. Samples were run on Dako Cyan flow
cytometer. Data
were analyzed using FlowJo 2.2 software developed by TreeStar, Inc. As seen in
Figure 21,
results show that Compound T protects renal proximal tubule epithelial cells
from chemotherapy
induced DNA damage, as increasing dosages of Compound T in combination with
etoposide or
cisplatin cause a decrease in the percentage of S-phase cells, with a
corresponding rise in the
percentage of cells in the GO-G1 phase.
Example 170
Compound T prevents chemotherapy-induced DNA damage and caspase activation in
human renal proximal tubule cells
In order to demonstrate that pharmacological quiescence induced by CDK4/6
inhibitor
treatment affords resistance to chemotherapeutic agents in non-hematopoietic
cells, the
protective effect of Compound T on human renal proximal tubule cells was
analyzed. Normal
renal proximal tubule epithelial cells were obtained from American Type
Culture Collection
(ATCC, Manassas, VA). Cells were grown in an incubator at 37 C in a humidified
atmosphere
of 5% CO2 in Renal Epithelial Cell Basal Media (ATCC) supplemented with Renal
Epithelial
Cell Growth Kit (ATCC) in 37 C humidified incubator. Cells were treated with
either DMSO or
10 nM, 30 nM, 100 nM, 300 nM or 1 uM Compound T in either the absence or
presence of 25
uM cisplatin. For the y-H2AX assay, cells were fixed, permeabilized, and
stained with anti¨y-
H2AX as per the y-H2AX Flow Kit (Millipore) and quantitated by flow cytometry.
Data was
analyzed using FlowJo 2.2 software developed by TreeStar, Inc. Caspase 3/7
activation was
-- measured using the Caspase-Glo 3/7 Assay System (Promega, Madison, WI) by
following the
manufacturer's instructions.
226
CA 02906156 2015-09-11
WO 2014/144326 PCT/US2014/028685
Treatment of renal proximal tubule cells with Compound T in combination with
cisplatin
attenuated DNA damage as measured by y-H2AX formation (Figure 22). As seen in
Figure 22,
DNA damage caused by cisplatin decreased in a dose-dependent manner after
treatment with
Compound T.
The ability of Compound T to protect renal proximal tubule epithelial cells
against
cisplatin induced apoptosis (caspase 3/7 activation) was also investigated. As
shown in Figure
23, Compound T demonstrated a dose-dependent reduction in caspase 3/7
activation in these
cells. This reduction in caspase 3/7 activity was seen at all three levels of
cisplatin tested (25
uM, 50 uM, or 100 uM). These data show that a transient cell cycle arrest in
G1 , induced by
Cdk4/6 inhibition, can protect renal proximal tubule cells from chemotherapy-
induced DNA
damage.
Example 171
Preparation of Drug Product
The active compounds of the present invention can be prepared for intravenous
administration using the following procedure. The excipients hydroxypropyl-
beta-cyclodextrin
and dextrose can be added to 90% of the batch volume of USP Sterile Water for
Injection or
Irrigation with stirring; stir until dissolved. The active compound in the
hydrochloride salt form
is added and stirred until it is dissolved. The pH is adjusted with 1N NaOH to
pH 4.3 + 0.1 and
1N HC1 can be used to back titrate if necessary. USP Sterile Water for
Injection or Irrigation can
be used to bring the solution to the final batch weight. The pH is next re-
checked to ensure that
the pH is pH 4.3 + 0.1. If the pH is outside of the range add IN HC1 or IN
NaOH as appropriate
to bring the pH to 4.3 + 0.1. The solution is next sterile filtered to fill 50
or 100 mL flint glass
vials, stopper, and crimped.
This specification has been described with reference to embodiments of the
invention.
The invention has been described with reference to assorted embodiments, which
are illustrated
by the accompanying Examples. The invention can, however, be embodied in
different forms
and should not be construed as limited to the embodiments set forth herein.
Given the teaching
herein, one of ordinary skill in the art will be able to modify the invention
for a desired purpose
and such variations are considered within the scope of the invention.
227
